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Advancements in our ability to obtain high quality bacterial whole genome 
sequences have increased the rate natural product biosynthetic gene clusters are identified, 
but these projects require computational methods for gene annotation which are limited by 
their reliance on comparison to previously annotated genes.  Thus, even in a well-defined 
cluster with a known product it may be difficult to predict how structural characteristics 
arise if they have no known precedent.  Without further work, such limitations will 
continue to impede the utility of sequenced bacterial genomes.  Biosyntheses of the 
peptidyl nucleoside antibiotics and atypical anthracyclines like nogalamycin are topics 
which exemplify these challenges.  
The peptidyl nucleoside antibiotics (PNAs) are a structurally complex group of 
natural products with diverse biological activities which could be useful for the 
development of novel antimicrobials.  Amipurimycin and the miharamycins are 
remarkably similar PNAs elaborated by the bacteria Streptomyces miharaensis ATCC 
19440 and Streptomyces novoguineensis CBS 199.78, respectively.  Their dissimilarity to 
other well-characterized groups of antibiotics has presented a challenge to the study of their 
unique structural features.  Herein, we describe the identification of the amipurimycin and 
miharamycins biosynthetic gene clusters though a comparative genomics approach.  
 vii 
Besides providing insight into the biosynthesis of the rare amino acids adorning these PNA, 
our analysis revealed a plausible biosynthetic route to the unique 2-aminopurine 
nucleobase and suggests the core saccharides are generated by a polyketide synthase.   
The anthracyclines are a mainstay of chemotherapy, but their use is limited by fatal 
cardiotoxicity and tumor resistance.  The structures of the anthracyclines are sensitive to 
modification, as even small changes can ablate their biological activity.  Nevertheless, the 
diversification of anthracyclines through semi- or total syntheses is an ongoing effort.  
Nogalamycin is rare amongst the anthracyclines because of its extended ring system and 
unusual glycosylation pattern.  It is hoped an understanding of the biosynthesis of 
nogalamycin could allow the incorporation of its uncommon structural features into other 
anthracyclines to develop novel compounds with improved actitivty.  Towards this end, we 
investigated the biosynthesis of the amino sugar found in nogalamycin, nogalamine, to 
clarify ambiguous steps in the reported biosynthetic pathway for this sugar.     
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Chapter 1: Biosynthesis of The Peptidyl Nucleoside Antibiotics and 
Glycosylation of Anthracyclines, Under-Explored Topics in the Study of 
Natural Products 
1.1.  INTRODUCTION 
Nature has been the source of bioactive compounds used by humans for medicinal 
purposes since prehistoric times.  Whereas these compounds were often used by direct 
ingestion of the plants, herbs, fungi, or other material they derive from or though crude 
extracts such as teas or broths, the first isolation of a plant derived natural product, 
morphine, in pure form was reported in the early 19th century.  The field of natural product 
isolation quickly flourished thereafter, and with it an increased understanding of the 
ecology of natural products.  Deemed “secondary metabolites” at the end of the 19th 
century, these compounds were differentiated from “primary metabolites,” the set of 
compounds necessary for life, such as amino acids, carbohydrates, and nucleosides.  The 
exact environmental roles which the secondary metabolites play are still not fully 
appreciated.  Yet, these compounds often increase the competitiveness of their producing 
organisms through a variety of mechanisms.  For example, some natural products directly 
inhibit the growth of other organisms, an activity known as antibiosis.1-3    The discovery 
of penicillin, an antibiotic substance produced by a strain of the fungus Penicillium notatum 
garnered much attention as the first antibiotic natural product isolated from a 
microorganism.  However, perhaps the greater legacy of penicillin is its establishment of 
microorganisms as an important source of bioactive molecules.  In particular, the 
subsequent decades revealed soil-dwelling bacteria of the order Actinomycetales to be 
prolific producers of natural products.  Thousands of antibiotic compounds had been 
discovered through intensive screening of many bacterial species, since it was thought that 
the diversity of bacteria drove the diversity of their natural products.1,4  The advent and 
 2 
development of molecular cloning techniques led to two key findings which have 
accelerated and greatly facilitated the discovery of new natural products.  First, bacterial 
natural product biosynthetic genes are now known to be clustered at discrete loci on the 
genome.4,5  For the first time, the biosynthetic pathway of natural products could be directly 
correlated with genes.  Cloning of natural product biosynthetic pathways also enabled the 
possibility of “engineering” the production of their products by relieving transcriptional 
repression, eliminating shunt pathways leading to less valuable compounds, or increasing 
the genetic dosage of key biosynthetic enzymes.  Secondly, biosynthetic gene clusters are 
recognized to be modular, where structurally similar natural products are biosynthesized 
similarly.5  Thus, since biosynthetic pathways are largely conserved, the ability of a 
bacterium to produce a given type of natural product could be “screened” genetically, 
rather than through time-consuming screening of growth and fermentation conditions.5-7   
Recent advances in genomic sequencing have revealed these bacteria often harbor 
many natural product gene clusters, suggesting they have an enormous and largely 
untapped biosynthetic capacity.  It is estimated that we have accessed only a fraction of 
this diversity, as major limitations to the study of bacterial natural products include the 
inability to culture most bacteria in the laboratory and the transcriptional “silence” of most 
biosynthetic gene clusters under laboratory conditions.5  The availability of a wealth of 
genomic data and our understanding of gene cluster organization combined with current 
technology have reduced the sometimes decade-long process of identifying gene clusters 
to a matter of days, increasingly independent of an axenic cultures of the bacteria harboring 
these gene clusters.8-10  While powerful, new algorithms can often predict the product of 
these clusters, these computational methods can be limited since accurate identification of 
gene clusters or prediction of their products relies on comparison with gene clusters and 
natural products already discovered.  On the other hand, even in a well-defined cluster with 
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a known product it is still difficult to predict how some structural characteristics are 
biosynthesized if they have no known precedent.5,6,11  Given the staggering number of 
identified but as of yet unclassified bacterial biosynthetic gene clusters, without further 
work to assign functions to uncharacterized genes, these limitations will continue to impede 
the full utility of the massive number of bacterial genomes sequenced.5,12,13 
1.2. BIOSYNTHESIS OF THE PEPTIDYL NUCLEOSIDE ANTIBIOTICS 
1.2.1. Introduction 
The peptidyl nucleoside antibiotics (PNA) comprise a subset of the nucleoside 
natural products whose study exemplifies the challenges associated with natural products 
lacking structural conservation with compounds from other mode widely studied groups of 
natural products.14  Minimally, the PNA are composed of a nucleoside with at least one 
pendant amino acid attached via a peptide bond.  However, given the diversity of PNA 
structures, this group of compounds can be best conceptualized as three components: the 
nucleobase, the “core” saccharide, and the appended amino acid(s).  Frequently, each of 
these components include structures rarely seen, e.g., hypermodified nucleobases, higher-
carbon sugars, and non-proteinogenic amino acids.14-17  Representative PNA are shown in 
Figure 1.1.  While the biological activities of the majority of the PNA discovered to date 
are unknown, several PNA have been more closely studied, and their activities include: 
prokaryotic and eukaryotic protein synthesis inhibition (puromycin18 (1) and blasticidin S19 
(3)), prokaryotic tRNA synthetase inhibition (albomycin20 (18), bacterial translocase 
inhibition (mureidomycins and pacidamycins21,22 (5)), and fungal chitin synthase inhibition 
(nikkomycins (15) and  
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Figure  1.1: Structures of some representative peptidyl nucleoside antibiotics 
polyoxins23,24 (2)).  No PNA are currently used clinically, but nikkomycin Z is under 
investigation as a first-in-class antifungal agent for the treatment of coccidioidomycosis 
(“valley fever”) in humans.25-29  Furthermore, puromycin and blasticidin S are heavily used 
in molecular biology both as selection agents19 and probes of ribosomal function18,19; 
polyoxin23 and mildiomycin30 (73) find use as agricultural fungicides; and ningnanmycin 
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(a stereoisomer of gougeroutin (4)) is used as an agricultural viricide.31  In light of the 
diverse biological activities exhibited by these “privileged” pharmacophores and unique 
constituent amino acids and nucleobases, further study of the PNA holds promise for both 
the development of novel therapeutics and the enrichment of natural product chemistry.     
The understanding of the modularity and conservation of gene clusters for many 
groups of compounds led to rapid discovery of new members of these classes, so a more 
complete understanding of PNA biosynthesis is expected to greatly aid in the identification 
of novel PNA gene clusters.5,12  The structural heterogeneity of the PNA confounds efforts 
to closely compare individual compounds.  However, recently discovered PNA 
biosynthetic gene clusters have begun to reveal some common biosynthetic motifs, 
warranting a more useful framework for classification of these compounds. Despite their 
lack of obviously comparable features, the PNA can be classified based on the nature of 
their components and the mechanisms employed in their assembly.  What follows is a 
thorough discussion of the biosynthesis of PNA, using only data from currently available 
biosynthetic gene clusters.   
1.2.2. Amino Acid Attachment 
In spite of having no uniform structural layout, all PNA have at least one pendant 
amino acid.  Investigation into the biosynthesis and attachment of these amino acids can 
provide a useful “handle” on the biosynthesis of the rest of the molecule.17,22  A thorough 
description of the biosyntheses of all unusual amino acids found in the structures of the 
PNA is beyond the scope of this work, but thus far, only five mechanisms for the 
establishment of peptide bonds in the PNA have been described.  These mechanisms are 
summarized in Figure 1.2 and can be further classified by whether or not ATP is involved. 
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Figure 1.2: An overview of peptide bond formation mechanisms utilized in PNA 
biosynthesis. A. Mechanism of ATP-grasp ligase-mediated peptide bond formation; B. 
Mechanism of NRPS-mediated peptide bond formation; C. Mechanism of tRNA-mediated 
peptide bond formation; D. Mechanism of methyltransferase-mediated peptide bond 
formation; E. Mechanism of coenzyme A-mediated peptide bond formation  
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1.2.2.1. ATP-dependent Peptide Bond Formation  
1.2.2.1.1. ATP-grasp Ligases 
The ATP-grasp ligases, so-called for their distinct ATP binding motif, comprise a 
family of enzymes capable of forming an amide bond through activation of a carboxylate 
via an acyl phosphate intermediate (Figure 1.2A).32-34  This mechanism is in contrast to 
activation of carboxylates through adenylation, as observed in adenylate-forming enzymes 
and non-ribosomal peptide synthetase (NRPS)-associated adenylation domains (Figure 
1.2B).35  Some ATP-grasp ligases make only one amide bond between two substrates, but 
others are capable of iteratively condensing substrates to create homopolymers.36-39  While 
ATP-grasp ligases can be found in primary metabolism, such as glycinamide 
ribonucleotide synthase (PurD), biotin carboxylase, and D-Ala:D-Ala ligase, many of these 
ligases have been implicated in various secondary metabolic pathways, either through 
direct investigation or speculation based on genetic context.  Indeed, ATP-grasp ligases are 
widespread, and their participation in natural product biosynthesis is probably 
underestimated.35,37,39 
A hallmark of NRPS-associated adenylation domains is the ability to predict the 
amino acids they activate a priori by extraction of primary sequence residues comprising 
a “specificity code.” This property has been employed in the prediction of the structures of 
NRPS-based natural products.40,41  The ATP-grasp ligases lack known indicators of 
specificity despite selectivity for their particular substrates.  The central ATP-binding 
portion of the ligases is the most well-conserved portion of these enzymes, while the N- 
and C-terminal sequences display considerable variety.35  Interestingly, at least one ligase 
has been demonstrated to be non-specific for the C-terminal residue utilized.36,42   
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Blasticidin S 
The blasticidin S biosynthetic gene cluster, bls, from Streptomyces 
griseochromogenes was found to encode an ATP-grasp ligase, BlsI.  Blasticidin S is a 
hexopyranosyl peptidyl cytosylglucuronic acid (CGA)-derived nucleoside formed through 
the glycosylation of cytosine with UDP-glucuronic acid with a single amino acid, N-
methyl-β-arginine, appended to the core saccharide (Figure 1.1).19  While blasticidin S has 
only one amide bond, the precise role of BlsI is not known. Methylation of β-arginine is 
the last step in the biosynthetic pathway of blasticidin S, and demethylblasticidin S is 
known to be an early intermediate in the biosynthetic pathway, formed through the 
condensation of β-arginine and cytosinine.  However, while BlsI could be responsible for 
the installation of β-arginine at this step, leucyldemethylblasticidin S is a known later 
intermediate.  Presently, it is not clear whether β-arginine is directly attached to cytosinine 
by BlsI or if this enzyme is responsible for the attachment of a leucyl-β-arginine dipeptide 
to cytosinine.19,43  These possible routes are shown in Figure 1.3.   Remarkably, the bls 
cluster includes another putative non-ATP-grasp ligase, BlsK, which will be discussed in 
section 1.2.3.3.  It is possible either a.) one ligase first attaches β-arginine, followed by 
leucine attachment by the other ligase, e.g., 9  10a  10b in Figure 1.3; or b.) one of the 
ligases forms the β-arginine-leucine dipeptide and the other attaches it to cytosinine,  e.g., 
13  10b.43  The biosynthesis of arginomycin, a remarkably similar PNA produced by 
Streptomyces arginensis NRRL 15941, likely involves a similar sequence of amino acid 
attachment, as it, too, is found as a leucyl derivative.44,45  Accordingly, the arginomycin 
gene cluster, arg, encodes two ligases, ArgJ and ArgK, which are homologs of BlsI and 
BlsK, respectively.45  To date, the timing of amino acid attachment in the biosynthesis of 
arginomycin is not clear.    
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Figure 1.3: Possible biosynthetic routes to formation of the leucyl-β-arginine dipeptide 
found in blasticidin S and arginomycin 
Polyoxins and Nikkomycins 
ATP-grasp ligases are also found in the biosynthetic gene clusters of the polyoxins 
in Streptomyces cacaoi var. asoensis, pol,23 and the nikkomycins in Streptomyces tendae 
and Streptomyces ansochromogenes, nik,24 and san,46 respectively.  The polyoxins and 
nikkomycins are groups of structurally similar peptidyl nucleosides of an unusual 
aminohexuronic acid derived from the condensation of phosphoenolpyruvate and a 
nucleoside monophospate, either UMP, or a derivative thereof (Figure 1.4).  The 
biosynthetic pathway of the polyoxins utilizes 5’-monophosphates of uridine (polyoxin  
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Figure 1.4: Comparison of the polyxins (left) and nikkomycins (right) structures 
K), 5-methyluridine (polyoxin H), 5-hydroxymethyluridine (polyoxin A), or 5-
carboxyuridine (polyoxin F) as a nucleoside substrate.23  In contrast, the nikkomycins are 
found as nucleosides of uracil (Z-nikkomycins) or 4-formyl-4-imidazolin-2-one (X-
nikkomycins).24  The biosynthesis of the core aminohexuronic acid saccharide will be 
discussed elsewhere.  The polyoxins have two unusual amino acids attached to the core 
saccharide, the azetidine-containing polyoximic acid (POIA) and carbamoylpolyoxamic 
acid (CPOAA), via the amino and carboxylate functionalities, respectively, of the core.23  
Similarly, while the most abundant nikkomycins (the O-type nikkomycins) in culture 
filtrates are found to have either hydroxypyridylhomothreonine (HPHT) or 2-amino-4-
hydroxy-4-(3’-hydroxy-6’-pyridyl) butanoic acid (AHPB) attached to the core via its 
amino functionality, the minor components nikkomycin I and nikkomycin J, X-type and 
Z-type nikkomycins, respectively, have an additional glutamate residue appended to the 
carboxylate of the core saccharide.24,47-49  While polyoxins and nikkomycins isolated with 
up to two amino acids appended to their core saccharides, the polyoxins cluster, pol, and 
the two nikkomycins clusters, nik and san, each encode only a single ATP-grasp ligase, 
PolG, NikS, and SanS, respectively.  The roles of these enzymes in the attachment of the 
amino acids in these compounds have been substantiated by the interruption of polG,23 
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nikS,24 and sanS50 in their respective gene clusters leading to the accumulation of only 
aminohexuronic acid nucleosides lacking the appended amino acids in the culture filtrates 
of mutant strains. Thus, unlike other ATP-grasp ligases studied to date, PolG, NikS, and 
SanS could be remarkably substrate flexible in terms of the their N- and C- terminal 
substrates. 
Albomycins 
The albomycins gene cluster, abm, from Streptomyces sp. ATCC 70094, was also 
found to contain a an ATP-grasp ligase-like protein (NCBI conserved protein domain 
family PRK000885: “phosphoribosylamine—glycine ligase; provisional”), AbmC.  The 
albomycins are complex PNA that are a conjugate of a ferrichrome siderophore and the 
unusual 4’-thioxylofuranosyl-based peptidyl nucleoside SB-217452 (16).   
 
 
Figure 1.5: Hypothetical biosynthetic route to assembly of the three albomycin structural 
components, the nucleoside (black), serine (blue), and the siderophore (red).  
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Accordingly, conserved siderophore biosynthetic enzymes are encoded in the abm cluster.  
However, the biosynthesis of the PNA portion is not completely understood.20,51  It is 
presently unknown which enzyme(s) are responsible for the attachment of the serine 
residue found in the structure of the nucleoside portion or for linking the PNA to the 
siderophore, but  given the possibility PolG, NikS, and SanS are able to catalyze the 
formation of two amide bonds in the biosynthesis of the polyoxins and the nikkomycins, 
AbmC seems to be a reasonable candidate for both of these reactions (Figure 1.5).    
The cloning of the abm cluster enabled the identification of a homologous gene 
cluster, ctj, in the publicly-available draft genome sequence of Streptomyces sp. C.  The 
product of the ctj cluster is not presently known, but, as this gene cluster encodes 
homologues of the enzymes believed to be responsible for the formation of both the 4’-
thioxylofuranosyl nucleoside core and siderophore of the albomycins, the encoded product 
is likely to have a structure similar to the albomycins.51  Curiously, the ctj cluster encodes 
an overt ATP-grasp ligase, CtjK, instead of an AbmC homolog. Elucidation of the exact 
roles AbmC and CtjK play will require further work.  It should also be noted there is 
speculation attachment of the serine residue to the nucleoside portion of SB-217452 and 
likely the Ctj-compound could involve a tRNA-mediated process.  In this way, a tRNA 
synthetase activates serine for another “transferase,” or as discussed later for the 
pacidamycins, the tRNA synthetase serves as the requisite ligase.   Indeed, both the abm 
and ctj gene clusters encode a seryl-tRNA synthetase, AbmK and CtjI, respectively.20,51  
AbmK was shown to be a mediator of resistance to the action of albomycin on the producer.  
However, this does not rule out an additional role for AbmK in the attachment of serine.20   
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A201A 
Recently, an A201A (21) biosynthetic gene cluster, mtd, was identified in the 
genome of the sea-dwelling bacterium Marinactinospora thermotolerans.52  A201A shares 
the N6,N6-dimethyl-3’-amino-3’-deoxyadenosine nucleoside core with the PNA 
puromycin.  However, instead of a tyrosine residue as is found in puromycin, the 3’-amino 
of the core saccharide is peptide linked to an α-methyl-p-coumeric acid disaccharide 
reminiscent of hygromycin A.53  The A201A biosynthetic gene cluster, ata, was originally 
found in Streptomyces capreolus NRRL 3817, but it was incompletely sequenced, leaving 
the means of establishing the peptide bond unknown.53  The mtd gene cluster includes the 
ATP-grasp ligase MtdC.  Although it is tempting to assign its role as the necessary peptide 
synthetase based on the involvement of ATP-grasp ligases in other PNA biosynthetic 
pathways and the fact MtdC is the only enzyme obviously capable of forming a peptide 
bond found in the mtd gene cluster (Figure 1.6), there are no data to support its role in the 
biosynthesis of A201A in M. thermotolerans.52 
 
 
Figure 1.6: Hypothetical peptide bond formation in the biosynthesis of A201A 
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1.2.2.1.2. Non-Ribosomal Peptide Synthetases 
Non-ribosomal peptide synthetases (NRPS) are renowned for their heavy 
involvement in the biosynthesis of secondary metabolites.  At the heart of NRPS-based 
peptide synthesis is the use of three basic domains to catalyze three key reactions: a 
thiolation domain (“T”-domain) which tethers an amino acid substrate via a 
phosphopantotheinyl prosthetic group, an adenylation domain (“A”-domain) which uses 
ATP to adenylate an amino acid substrate for loading onto a T-domain, and a condensation 
domain (“C”-domain) which catalyzes formation of a peptide bond (Figure 1.2B). NRPS 
enzymes are often found as large, multi-modular enzymes, with each module minimally 
composed of one of each of the three basic domains, i.e., one T-domain, one A-domain, 
and one C-domain.  Usually, after loading of an initial amino acid “starter unit,” each 
subsequent domain attaches another amino acid, and the lengthened substrate is “passed” 
to the next domain via a T-domain.13  As mentioned earlier, A-domain substrates can 
frequently be predicted on the basis of the domain’s primary amino acid sequence, so 
NRPS-based pathways are considered a form of “templated” biosynthesis.54,55  In addition 
to the basic domains, each module may also harbor “tailoring” domains (cis-acting 
domains), such as a methylation domain, cyclization domain, or reductase domain, which 
act to modify the most recently added amino acid.  NRPS systems can also be more 
complex with non-functional domains, iterative use of modules, and even trans-acting 
tailoring domains.54-58 
NRPS-based biosynthetic pathways are operative in several PNA, including the 
structurally similar muraymycins,59,60 pacidamycins,21 napsamycins,61,62 sansamycins,63 
and mureidomycins,63,64 as well as the streptothricins.65,66  Of the former group, the NRPS 
systems of the muraymycins and pacidamycins are the best studied.  Given their high 
structural similarity to the napsamycins, sansamycins, and mureidomycins, the available 
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data are likely paradigmatic for this class as a whole.  With the exception of the 
streptothricins, these PNA are inhibitors of MraY, the bacterial translocase catalyzing the 
transfer of phospho-MurNAc-pentapeptide from UDP-MurNAc-pentapeptide to 
undecaprenyl-phosphate in the biosynthesis of the cell wall component lipid I.22,67  In 
contrast, the streptothricins inhibit protein synthesis in both prokaryotes and eukaryotes.68-
71  Remarkably, these disparate biosynthetic pathways all rely on dissociated NRPS 
systems, where the typically large multi-modular NRPS is replaced with several separate 
enzymes, with each component comprising no more than three domains. 
Muraymycins 
The muraymycins are a group of PNA isolated from Streptomces sp. NRRL 30471.  
These compounds feature a higher carbon uridyl aminouronic acid nucleoside core 
common to the caprazamycins and liposidomycins, which are structurally similar 
liponucleosides.59  The biosynthesis of this moiety will be discussed in a later section.  
Because the muraymycins are also found to be acylated with long alkane side chains, they 
are often also referred to as nucleoside lipopeptides.  The core nucleoside of the 
muraymycins is further modified through N-acylation with a 3-amino-3-carboxypropyl 
side chain, a modification discussed in section 1.2.3.3, which serves as a “linker” between 
the core nucleoside and a tripeptide containing an unusual ureido bond.  This peptide is 
matured on the NRPS components and then coupled with the core nucleoside.59 
Biosynthesis of the peptide chain is expected to begin with the loading of the 
arginine-derived hexahydro-2-imino-4-pyrimidylglycyl moiety (epicapreomycidine, 22) 
onto Mur12, a C-, A-, T-tridomain NRPS module (Figure 1.7).  It is then predicted that the 
C-domain of Mur12 is responsible for establishment of the ureido bond found in the  
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Figure 1.7: Proposed NRPS-based biosynthetic pathway of muraymycins 
mature peptide by N-acylation of epicapreomycidine with bicarbonate.  The ureido bond is 
a unique feature amongst the PNA and is found only in the muraymycins59 and the 
pacidamycins.21,72  Next, Mur14, a standalone T-domain, is predicted to be loaded with 
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valine by Mur27, and then one of the standalone C-domains, Mur13 or Mur25, could ligate 
Mur14-tethered valine via its α-amino group to the N-carboxy group of Mur12-tethered 
epicapreomycidine, completing the ureido bond and resulting in a Mur12-tethered pseudo-
dipeptide (27).59  Two features make this proposed condensation unique.  First, the amide-
like ureido bond is formed between an α-amino group and a free carboxylate, unlike the 
typical NRPS-mediated condensation reactions which involve nucleophilic attack of an α-
amine from one amino acid to another amino acid substrate attached to an NRPS T-
domain.73  Secondly, because the new bond does not involve the thioester linkage of a T-
domain-tethered amino acid, the Mur12-tethered epicapreomycidine and Mur14-tethered 
valine would be expected to remain linked via the new ureido bond.54,55  Yet, the newly 
linked amino acids are expected to be bound to Mur12.  This prediction suggests either a 
cryptic hydrolytic release mechanism from Mur14 or the involvement of an as-of-yet 
unidentified hydrolase or thioesterase.  Maturation of the peptide chain would be completed 
through ligation of the Mur12-tethered pseudodipeptide to Mur21-tethered β-hydroxy 
valine by the remaining standalone C-domain, Mur13 or Mur25.  Coupling of the mature 
peptide (29) to the nucleoside core (28) is assumed to be accomplished by Mur30, a beta-
lactamase-like ligase discussed in another section.     
Pacidamycins 
The pacidamycins are a group of PNA produced by Streptomyces coeruleorubidus 
NRRL 18370 which superficially resemble the muraymycins but lack the acyl chains found 
in the latter.21,72  However, like the muraymycins, the pacidamycins feature a uridine-
derived core nucleoside, in this case 3’-deoxy-4’,5’-enaminouridine, the biosynthesis of 
which is discussed elsewhere.  The core nucleoside is modified through  
 
 18 
 
Figure 1.8: The NRPS-based pacidamycins biosynthetic pathway 
the attachment of a ureido bond-containing tetra- or pentapeptide chain biosynthesized 
through a dissociated NRPS system.  The peptide chain can be visualized as an Nβ-methyl 
2S, 3S-diaminoburytic acid (DABA) moiety extended in each direction from its two amino 
groups by the action of a diverse set of ligases and NRPS components.74 
Biosynthesis of the peptide chain has been thoroughly investigated through a series 
of in vitro experiments and begins with the auto-loading of PacP, an A-, T-, TE- tridomain 
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NRPS with desmethyl-DABA (36, Figure 1.8).74-76  Importantly, the TE-domain is 
expected to be non-functional based on sequence analysis.74  PacP serves as the scaffold 
for methylation of desmethyl-DABA by the methyltransferase PacV, and peptide chain 
extension commences with the transfer of DABA to PacH, a standalone T-domain.74  
Extension from the β-amino group of DABA is facilitated by the action of the standalone 
A-domains PacU or PacW, which activate alanine or m-tyrosine, respectively.75  
Apparently, DABA-tethered PacH and PacU or PacW are sufficient for the attachment of 
their respective amino acid substrates, suggesting these standalone adenylation domains 
possess latent peptide synthetase activity.  Extension of the DABA α-amino group begins 
with PacO, a standalone A-domain, loading alanine onto PacN, a C-,T-didomain NRPS 
module (32).  Analogously to the proposed role of Mur12 in the biosynthesis of the 
muraymycins,59 PacN facilitates the N-acylation of the tethered alanine with bicarbonate, 
ostensibly, but not definitively, through its C-domain (33).  The ureido bond is made 
between the new N-carboxylate and phenylalanine-tethered PacL, a C-, A-, T-tridomain 
NRPS module with a predicted non-functional C-domain, and the resultant 
pseudodipeptide remains linked to PacN (38).74  As with the formation of the ureido bond 
in the muraymycins, the fine details of the mechanism resulting in the ureido bond in the 
biosynthesis of the pacidamycins remain unclear.  Finally, the PacN-linked ureido 
dipeptide is condensed with the α-amino group of PacH-linked DABA through the action 
of the standalone C-domain PacD (37), and then the mature peptide is attached to the 
nucleoside core by the standalone C-domain PacI (42).74  The peptide chain can be further 
extended after coupling with the nucleoside by the action of PacB (43), an unusual ATP-
independent ligase which will be discussed later.75 
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Streptothricins 
The streptothricins have been isolated from at least four organisms: Streptomyces 
lavendulae NBRC 12789, Streptomyces rochei F20, Streptomyces rochei NBRC 12908, 
and Streptomyces noursei JA3890b.65,66,77  These PNA are characterized by a core 
nucleoside composed of a carbamoylated gulosamine-derived saccharide C-glycosidically 
linked to the purine-like heterocycle streptolidine.  The biosynthesis of the core is discussed 
later.78  The core nucleoside is decorated with an L-β-lysine oligopeptide chain of up to 
seven residues, and, while the assembly of this chain and its attachment to the core 
saccharide rely on a dissociated NRPS system like those discussed earlier, this system is 
different due to its use of a standalone adenylation domain to perform iterative 
condensation reactions, as summarized in Figure 1.9.65 
The streptothricins biosynthetic gene cluster was cloned from S. rochei NBRC 
12908 and sequenced, revealing the presence of genes encoding NRPS-like components: 
Orf5 (standalone A-domain), Orf13 (A-,T-didomain NRPS module), Orf18 (T-,C-
didomain NRPS module), and Orf19 (standalone A-domain).65  This finding was in accord 
with earlier studies in which the streptothricins biosynthetic gene clusters from S. rochei 
F20 and S. noursei JA3890b were partially sequenced.  In particular, Orf5 displayed 
significant homology to SttA and NpsA, the standalone A-domains previously found in the 
streptothricins gene clusters in S. rochei F20 and S. noursei JA3890b, respectively.66  
Interestingly, heterologous expression of the S. rochei NBRC 12908 gene cluster in which 
orf19 was inactivated resulted in the production of only streptothricin F, a streptothricin 
with only one pendant L-β-lysine residue.  The role of Orf19 in the production of longer 
L-β-lys oligopeptides was further substantiated by the finding that  
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Figure 1.9: Streptothricins biosynthetic pathway 
the streptothricin gene cluster from S. lavendulae NBRC 12789, a strain capable of 
producing only streptothricin F, lacks a homolog of orf19.  Furthermore, heterologous co-
expression of the S. lavendulae NBRC 12789 cluster with orf19 from the S. rochei NBRC 
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12908 cluster resulted in the production of streptothricins with longer L-β-lysine 
oligopeptide chains.65 
A combination of gene deletion experiments and in vitro assays led to the 
construction of a model for the attachment of the L-β-lysine residues to the streptothricin 
core.65  Overall, after the loading of the first L-β-lysine residue onto the T-domain of Orf18 
by Orf5 (46), the oligopeptide can be built on Orf18 through the iterative action of Orf19, 
i.e., 46  48.  Importantly, Orf5 and Orf19 are standalone A-domains with no predictable 
peptide synthetase activity.  The cryptic ability of these A-domains to function as ligases 
provides support for the role of PacU and PacW, standalone A-domains from pacidamycins 
biosynthetic pathway,74,75 to function as ligases as discussed earlier.  Orf18 can load a 
single L-β-lysine onto the streptothricin core to yield streptothricin F (46  7), or it can 
load longer polymers onto the streptothricin core (47  48).  Streptothricin F can also 
serve as a scaffold for the generation of longer L-β-lys polymers through the action of 
Orf19 (7  48). 
One remaining question is the role of Orf13, an A-,T-didomain NRPS module.  
Heterologous expression of the S. rochei NBRC 12908 gene cluster in which orf13 was 
inactivated resulted in the production no streptothricins, indicating a pivotal role for Orf13.  
However, none of the in vitro assays performed seemed to require Orf13, and the pathway 
leading to production of the L-β-lysine-appended streptothricins was reconstructed without 
the use of Orf13.65  This seeming contradiction was never addressed, perhaps indicating 
the in vivo biosynthesis of the streptothricins may differ from the model proposed. 
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1.2.2.2. ATP-independent Peptide Bond Formation 
1.2.2.2.1. N-acylation 
Amicetins 
Despite the wide use of ATP-dependent ligation mechanisms for the attachment of 
amino acids in the reported PNA biosyntheses, examples of apparently ATP-independent 
ligation mechanisms are also known (Figure 1.2E).  One such example is the biosynthesis 
of amicetin-type compounds, as described in Figure 1.10.  These PNA are produced by 
Streptomyces vinaceusdrappus and Streptomyces fasciculatis, and are composed of a 
deoxy sugar disaccharide nucleoside of cytosine with a dipeptide of p-aminobenzoic acid 
(PABA) and α-methylserine attached to the cytosine C4-amino group.79  Amongst the 
PNA, the site of amino acid attachment in the amicetins is rare, but it is also seen in the 
septacidin (49) and spicamycin (50).80  However, the amicetin group of PNA is the only 
example whose biosynthetic gene cluster is known.   
The amicetin biosynthetic gene cluster was identified in S. vinaceusdrappus.  
Sequence analysis suggested that AmiF, AmiR, and AmiT, which function as a GCN5-
related N-acetyltransferase, a malonyl CoA-acyl carrier protein transacylase, and an A-, T-
didomain NRPS module, respectively, are responsible for assembly of the dipeptide 
moiety.79  Deletion of amiF in S. vinaceusdrappus supported the role of AmiF in the 
attachment of PABA, as this mutant accumulated the amicetin disaccharide nucleoside 
lacking amino acids (53) and free PABA (51).  Similarly to the biosynthesis of 
gougerotin,31 PABA was expected to require activation with CoA prior to transacylation 
by AmiF, and AmiL was predicted to be the requisite acyl-CoA synthetase.  Accordingly, 
deletion of amiL resulted in accumulation of the same products as the amiF deletion 
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mutant, namely, amicetin nucleoside lacking amino acids and PABA.79  Unlike gougerotin, 
which uses CoA to activate both amino acids for attachment,31 AmiT, an A-,  
 
 
Figure 1.10: A. Structures of septacidin and spicamycin; B. Amicetins biosynthetic 
pathway. 
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T-didomain NRPS module was found to be encoded in the amicetin gene cluster.  AmiT 
was predicted to play a role in the activation of α-methylserine (54) for attachment, since 
the specificity signature of its A-domain indicated substrate preference for serine.  Because 
AmiT features a long N-terminal region with no predicted NRPS modules, the authors 
suggested this region could harbor some cryptic module, an “X-domain.”  However, no 
evidence for this suggestion was provided, and, notably, there seem to be no steps in the 
biosynthesis of the amicetins requiring unidentified enzymes.  The timing for methylation 
of serine is not known at this time, but it is predicted to occur before loading onto AmiT.  
Because no other typical ligases, such as those already discussed, appeared to be encoded 
in the amcetin gene cluster, AmiR, another GCN5-related N-acetyltransferase37 was 
suspected to serve as the second ligase.  This assertion was consistent with the results of 
the deletion of amiR, since amicetins lacking amino acids as well as amicetins bearing only 
the PABA moiety (56) were found to accumulate in this mutant.79   
 Gougerotin 
N-acylation is also used to attach the two amino acids found in gougerotin (4), as 
described in Figure 1.11.  This PNA is produced by several organisms,31 including 
Streptomyces graminaerus, Streptomyces gougerotii, Streptomyces toyocaensis var. 
aspiculamyceticus, and Streptomyces S-514.  It is structurally very similar to the 
bagougeramines.81  Gougerotin is a hexopyranosyl cytosyl nucleoside with an appended 
D-serine-sarcosine dipeptide.  The gougerotin biosynthetic gene cluster was cloned from 
S. graminaerus, and on the basis of gene deletions and bioinformatic analyses, GouK and 
GouJ, an acyl-CoA synthetase and an acyl-CoA N-acyltransferase, respectively, were 
proposed to be responsible for installation of the dipeptide chain found in this compound.31  
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GouK is predicted to activate both serine and glycine, the latter of which is N-methylated 
to give sarcosyl-CoA (66).   
Similarly to blasticidin S biosynthesis,43 the timing and order of attachment of the 
two amino acids was not clear.  It is not known if D-serine is used, or if L-serine is used 
and racemized at a later time.  For instance, GouJ could attach D- or L-seryl-CoA first  
 
 
Figure 1.11: A. Structures of the bagougeramines; B. Gougeroutin biosynthetic pathway. 
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and then sarcosyl-CoA, or GouJ could mediate the pre-assembly of the two amino acids 
and then transfer the resultant dipeptide to the nucleoside core structure, with racemization 
of serine as a “tailoring” step.  Evidence for the sequential attachment of serine and then 
sarcosine was garnered through the heterologous expression of the gougerotin gene cluster 
with the gene encoding GouN, the glycine N-methyltransferase, inactivated.  This 
experiment resulted in the accumulation of only seryl-gougerotin (66).  Surprisingly, 
structural analysis of purified gougerotin revealed the presence of ningnanmycin, a 
previously identified L-serine-containing steroisomer of gougerotin.  Thus, it is possible 
that an unidentified racemase is active in the gougerotin biosynthetic pathway, or GouJ 
naturally utilizes both isomers of serine.31  While a similar amino acid ligation mechanism 
may also be operational in the biosynthesis of the structurally related bagougeramines (58, 
59), their biosynthetic gene clusters have not yet been identified. 
1.2.2.2.2. Miscellaneous 
Pacidamycins 
The amino acid ligation methods discussed up to this point have relied on 
mechanisms to activate the carboxylic acids to facilitate nucleophilic attack by an amine 
commonly found in metabolic processes.  However, the biosynthesis of PNA also provides 
examples of unusual means to make peptide bonds.  First, PacB was recently shown to 
activate alanine as an aminoacyl-tRNA for attachment to the mature peptide chain of the 
pacidamycins as a post-coupling tailoring reaction (42  43 in Figure 1.8).75  PacB showed 
homology to FemX and FemB from Weissella viridescens and Staphylococcus aureus, 
respectively.  Since these enzymes utilize tRNA to activate amino acids in peptidoglycan 
biosynthesis, PacB was predicted to similarly activate alanine using tRNA.  Accordingly, 
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when commercially sourced tRNA and tRNA synthetase were included in reaction 
mixtures, alanine was efficiently added to the peptide chain of the pacidamycins. 
A-503083  
Another unusual means of peptide bond formation was found in the biosynthesis of 
the A-503083 group of antibiotics.  These natural products are capuramycin-type PNA 
isolated from Streptomyces sp. SANK62799 and Streptomyces griseus SANK60196 
featuring an amido hexuronyl-uridine nucleoside core.  A-503083 A (70) is decorated with 
L-aminocaprolactam (69), a cyclized form of L-lysine (Figure 1.12).82  Analysis of the A-
503083 gene cluster from S. sp. SANK62799, cap, revealed two genes, capU and capV, 
encoding a C-, A-, T-containing NRPS and a standalone C-domain, respectively. 
   
 
Figure 1.12: ATP-independent amide bond formation in the biosynthesis of A-503083 A. 
However, the A-domain specificity signature of CapU suggested utilization of L-lysine, 
which implicated the NRPS enzymes in the biosynthesis of the L-aminocaprolactam 
moiety.  Bordering genes encoding these enzymes is capW, an ORF encoding a class C β-
lactamase.  Because the A-50383A contains a lactam portion, it was believed that CapW 
could function as an amidase.  Since no other candidate exists in the cap cluster which 
could catalyze peptide bond formation, CapW was selected to test whether it can catalyze 
a peptide bond formation reaction.  It is worth mentioning that cultures of S. sp. 
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SANK62799 were found to also produce A-50383 E (68), the methyl ester of the core 
nucleoside, A-503083 F (67), which suggested that methylation could also be involved in 
the activation of the carboxylate group for ligation with L-aminocaprolactam.  To examine 
this possibility, CapW was incubated with the core nucleoside, L-aminocaprolactam, and 
each of the two methyltransferases found in the cap cluster, CapK and CapS.  Surprisingly, 
the reaction containing CapW, CapS, L-aminocaprolactam, and the core nucleoside 
resulted in attachment of L-aminocaprolactam to the core nucleoside.  Formation of the 
peptide bond was ostensibly accompanied by the elimination of methanol.35,82  Thus, CapW 
is the first example of ATP-independent peptide bond formation between a methyl-
activated carboxylate and an amine, catalyzed by a β-lactamase homolog.  A CapW 
homolog-encoding gene was also found in the biosynthetic gene cluster of the structurally 
similar A-500359 group of antibiotics from Streptomyces griseus SANK60196.83 
Muraymycins 
A β-lactamase may also play a role in the biosynthesis of the muraymycins (Figure 
1.7).  As discussed in section 1.2.2.1.2., the peptide chain of the muraymycins is matured 
separately from the nucleoside portion, and Mur30 is predicted to couple the two.59  Mur30 
is a class C β-lactamase of the penicillin binding protein (PBP) transpeptidase superfamily 
according to analysis using the NCBI Conserved Domain Database.  While the Mur30 
reaction mechanism is likely similar to that of CapW, the details remain obscure.  For 
example, the CapW catalyzed reaction requires methylation to activate an electrophilic 
carboxylate,82 but in muraymycin biosynthesis, the peptide chain is expected to be tethered 
through a thioester linkage to the T-domain of Mur21 for nucleophilic attack by the 
nucleoside.  To account for this disparity, a cryptic hydrolase may act first to free the 
peptide chain from Mur21, enabling activation of the free carboxylate by a 
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methyltransferase.  Interestingly, the methyltransferase Mur11 was predicted to play a role 
in the coupling of the nucleoside and the corresponding peptide chain, but no data have 
been reported to substantiate this prediction.59  
1.2.2.3. Unknown Mechanism 
The gene clusters of blasticidin S (bls),43 mildiomycin (mil),84 and puromycin 
(pur),18,85 encode putative ligases BlsK, MilH, and Pur6, respectively, which cannot be 
categorized due to a lack of similarity to any known ligases.  Few details regarding their 
function exist in the literature.   
Blasticidin S and Mildiomycin 
BlsK and MilH were reported to have homology to each other and to lysyl-tRNA 
ligases, but biochemical evidence for this conclusion based on sequence analysis is lacking, 
and no further information was available up to date.45,84  However, mildiomycin 
biosynthesis in Streptoverticillum remofaciens ZJU5119 offers insight into another unique 
mode of amino acid attachment.84  
 
 
Figure 1.13: Peptide bond formation in the biosynthesis of mildiomycin 
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Mildiomycin is a CGA-derived PNA closely related to blasticidin S,43 
arginomycin,45 and gougerotin.31  Similarly to these compounds, it has a 4’-amino group.  
The amino acid appended at the 4’-amino group is serine.  MilH, due to its homology to 
BlsK, was assigned to perform the ligation reaction.  Curiously, the mil cluster also includes 
MilI, a protein with no homology to any proteins in the NCBI database.  MilI contains a 
phosphopantotheinyl (PP) binding site near its N-terminus.84  The PP prosthetic group is a 
hallmark of thiolation domains and often acts to tether intermediates in NRPS or PKS 
pathways.13,55  Thus, it is predicted that MilI becomes acylated with serine (71) prior to the 
action of MilH.84  A major point of contention with this model is the mil cluster lacks any 
clear means for the activation of serine for loading onto MilI, such as a standalone 
adenylation protein or an adenylation domain, as is typical of NRPS enzymology.55,58  
Puromycin 
On the other hand, S. alboniger Pur6 from the puromycin (1) biosynthetic pathway 
lacks any known ATP-binding motifs, but in vitro reactions using cell lysates from 
recombinant E. coli and Streptomyces lividans overexpressing pur6 required ATP and Mg+ 
to ligate L-tyrosine (73) to 3’-amino-3’-deoxyadenosine or puromycin aminonucleoside 
(72, N6,N6-dimethyl 3’-amino-3’-deoxyadenosine).  The essential role of Pur6 in the 
biosynthesis of puromycin was also demonstrated by the deletion of pur6 in Streptomyces 
alboniger, the producing strain, which resulted in ablation of product formation.86      
Clearly more work is warranted to elucidate the mechanisms by which these enzymes 
catalyze peptide bond formation in their respective biosynthetic pathways.  
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Figure 1.14: Pur6-catalyzed peptide bond formation in the biosynthesis of puromycin 
1.2.3. Core Saccharide Origin: Beyond Hexoses Versus Pentoses 
 A key outcome of biosyntheses of the core saccharides found in PNA is the 
installation of functionality amenable to the attachment of pendant amino acids.  For the 
most part, previous surveys of the PNA focused on the number of carbons (e.g., pentose, 
hexose, or higher) comprising the core saccharide.15,16  However, this description does not 
offer significant biosynthetic insight, since analysis of recently elucidated PNA gene 
clusters indicates varying origins for the core saccharides, even for some with the same 
ring size.17,22  Thus, a more detailed classification scheme which considers more than ring 
size may help to identify similarities between apparently dissimilar PNAs and ultimately 
aid in the discovery of new PNA gene clusters.  We propose the core saccharides can be 
categorized as incidental, intact, or built up. 
1.2.3.1. Incidental 
The term incidental is used to describe core saccharides whose procurement results 
from incorporation of an intact nucleoside and whose carbon skeletons are not extended.  
Because the nucleosides themselves are of physiological origin, the pertinent saccharide is 
ribose.  Of the PNA with sequenced biosynthetic gene clusters, puromycin, A201A, and 
the pacidamycins are the only compounds in this group. 
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Puromycin and A201A 
Puromycin and A201A are products of S. alboniger18 and S. capreolus,53 
respectively.  They share an N6,N6-dimethyl-3’-amino-3’-deoxyadenosine nucleoside 
derived from adenosine, and the ribose skeleton is not extended any further.  Notably, 
puromycin and A201A are the only purine PNA to date whose biosynthetic gene clusters 
are known.  Even though the pur and ata clusters share some homologous enzymes, 
puromycin biosynthesis is the most studied of the two.  The biosynthesis of the N6,N6-
dimethyl-3’-amino-3’-deoxyadenosine nucleoside begins with oxidation of the 3’-
hydroxyl of adenosine triphosphate by Pur10 in S. alboniger or AtaP10 in S. capreolus.  
  
 
Figure 1.15: Biosynthesis of the aminonucleoside core of puromycin; homologous 
enzymes from the ata cluster are noted. 
This step is most likely followed by hydrolysis of adenosine triphosphate to adenosine 5’-
monophosphate by Pur7 or AtaP7, as 3’-keto adenosine has been shown to be toxic to 
DNA-dependent RNA polymerase in Gram-negative and Gram-positive bacteria, as well 
as Erlich acites cells.18  Then, 3’-transamination is carried out by aminotransferases Pur4 
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or AtaP4.18,53  Based on BLAST analyses, these aminotransferases belong to the 3-amino-
5-hydroxybenzoic acid synthase family (“AHBA_syn”) of fold I, pyridoxal phosphate 
(PLP)-dependent aspartate aminotransferases.  The timing of N-dimethylation of 3’-amino-
3’-deoxyadenosine has not been definitively established, but it is thought to occur after 
attachment of tyrosine and modification by an acetyltransferase, Pac.  The intermediacy of 
an acetylated species is supported by an inability of S. alboniger cell-free extracts to 
methylate tyrosyl 3’-amino-3’-deoxyadenosine.18   Finally, the monophosphatases Pur3 or 
AtaP3 act to remove the 5’- phosphate.  In the biosynthesis of puromycin, the removal of 
the 5’-phosphate is the penultimate step before export of the compound from the cell,18 but 
in the biosynthesis of A201A, the timing of the action of AtaP3 is not clear.53 
 Pacidamycins 
The pacidamycins from S. coeruleorubidus are built upon an unusual 3’-deoxy-
ribose-containing uridyl amino nucleoside with an exocyclic alkene.21,72,87  However, all 
of the carbon atoms of the core saccharide are contributed by the ribose of uridine, and the 
core is not further lengthened,87 characteristics warranting placement of the pacidamycins 
in the incidental group of PNA.  As mentioned earlier, although the sansamycins, 
napsamycins, and mureidomycins are structurally very similar to the pacidamycins, the 
pacidamycins are the most well-studied of these PNAs, so they are the PNA of focus here.   
The first point of contention regarding the origin of the uridine-derived core 
nucleoside is that uridine is usually found intracellularly as uridine nucleotide.21,72  Yet, 
unlike the puromycin18 or A201A biosynthetic gene clusters,52,53 the pacidamycins 
biosynthetic gene cluster contains no phosphatases.21,72  Given the presence of a 5’-amino 
group, oxidation of the ribose 5’-hydroxyl is an expected step in the biosynthesis of the  
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Figure 1.16: Biosynthesis of the enamino nucleoside core of the pacidamycins 
pacidamycins.  Indeed, the pac cluster encodes a putative flavoprotein, Pac11, that had 
been shown to be responsible for oxidizing the 5’-hydroxyl of uridine on the basis of gene 
deletion and feeding studies in the producing strain, as well as in vitro assays (Figure 
1.16).21,87  Oxidation of a ribose 5’-hydroxyl is actually a common step in the biosynthesis 
of several uridine-derived lipopeptidyl nucleosides, including the caprazamycins, A-
90289s, and the capuramycins, but these pathways rely on α-ketoglutarate, non-heme iron-
dependent oxygenases that convert uridine 5’-monophosphate to a uridine 5’-aldehyde.17,22   
The aminotransferase Pac5, a member of the acetylornithine family of the fold I 
aspartate aminotransferase superfamily, was predicted to perform the 5’-transamination, 
and this prediction was also borne out by gene deletions and in vitro assays.72,87  No 
enzymes encoded in the pac biosynthetic gene cluster could be assigned to participate in 
the formation of the unique exocyclic alkene or the 3’-deoxygenation.  However, one 
hypothesis is that spontaneous dehydration eliminates the 3’-hydroxyl, and subsequent 
tautomerization yields the exocyclic alkene.  Surprisingly, the cupin-family protein Pac13 
was shown to catalyze both alkene formation and elimination of the 3’-hydroxyl, although 
the exact mechanism has not been explored.  Since Pac13 was unable to generate the 
enamine nucleoside from 4’,5’-saturated pacidamycins, this transformation is expected to 
occur before coupling with the mature peptide chain.87 
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1.2.3.2. Intact 
The term intact is used to describe those PNA whose core saccharides result from 
the incorporation of some other non-ribose sugar which is not extended by any additional 
carbon atoms.  These sugars must be activated for condensation with their nucleobases, 
usually as nucleoside diphosphates.  Accordingly, PNA of this group are expected to 
include a glycosyltransferase gene in their biosynthetic gene clusters.17  Intact-type PNA 
with known biosynthetic gene clusters include the cytosylglucuronic acid derivatives 
blasticidin S, arginomycin, and gougerotin, as well as amicetin and the streptothricins. 
Blasticidin S, Arginomycin, and Gougerotin 
Blasticidin S,43 arginomycin,45 and gougerotin31 are PNA originating from 
cytosylglucuronic acid (CGA), the condensation product of cytosine and UDP-glucuronic 
acid.  As such, the biosyntheses of these PNAs rely on a glycosyltransferase known as a 
“CGA-synthase.”  Mildiomycin is also a CGA-derivative,84 but its particular biosynthetic 
pathway precludes designation as an intact-type PNA.  Although the abilities of BlsD88 and 
MilC,30,84 the blasticidin S and mildiomycin CGA-synthases, respectively, to glycosylate 
cytosine with UDP-glucuronic acid have been demonstrated, little work has been done to 
biochemically characterize CGA-synthases.  However, NCBI Conserved Domain Database 
(CDD) analyses do recognize a “CGA-synthase-like” domain amongst putative CGA-
synthases.  Another interesting feature of the biosyntheses of these PNAs is the necessity 
for a nucleoside 2’-deoxyribosyltransferase, because cytosine is rarely found as a free 
nucleobase intracellularly due to its biosynthesis from uridine.31,45,84  In support of the need 
for a nucleoside hydrolase in the biosynthesis of the CGA-derived PNA, supplementation 
of growing cultures of S. griseochromogenes with free cytosine increases the yield of CGA 
by almost 70-fold.43  The 2’-deoxyribosyltransferases encoded by the blasticidin S and 
mildiomycin gene clusters, BlsM43 and MilB,30 have been cloned, expressed, and 
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characterized as bona fide cytosine hydrolases.  As for typical 2’-deoxyribosyltransferases, 
these enzymes probably function through a covalent enzyme-deoxyribose intermediate.43  
 
 
Figure 1.17: Biosynthetic origins of the CGA-derivatives blasticidin S, arginomycin, and 
gougerotin. 
Despite sharing the common intermediate CGA with the gougerotin, the PNA 
blasticidin S,43 arginomycin,45 and mildiomycin84 are actually built upon cytosinine, an 
unusual unsaturated deoxy form of CGA.  The unsaturated glucuronic acid derivative of 
cytosinine is not well-represented in natural products, but it is reminiscent of an unsaturated 
hexuronide moiety found in A-503083-type PNA.82  The biosynthesis of cytosinine has not 
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been explored, but, in S. griseochromogenes, the biosynthesis of cytosinine is related to 
the production of pentopyranine C and pentopyramine D, which are saturated and are 
presumably shunt metabolites from the blasticidin S biosynthetic pathway.89  Comparison 
of the structures of pentopyranine C, pentopyramine D, and cytosinine led to a hypothetical 
cytosinine biosynthetic pathway presented by Zhang, et al (Figure 1.18).89  By analogy to 
other 3’-deoxy sugars such as CDP-D-ascarylose and GDP-D-colitose, which are cell-well 
components of several pathogenic Gram-negative bacteria, cytosinine could be derived 
from 4’-keto CGA.89,90  This intermediate is also mechanistically relevant considering that 
the installation of the 4’-amino group found in blasticidin S, arginomycin, mildiomycin, 
and even gougerotin would require a carbonyl substrate. BlsS, a GMC oxidoreductase 
homolog, was proposed to oxidize the 4’-position of CGA in the biosynthesis of blasticidin 
S.43  While the gougerotin biosynthetic gene cluster in S. graminareus includes a D-
arabinose dehydratase homolog, GouA,31 curiously, no homolog of BlsS or GouA is found 
in the arginomycin45 or mildiomycin84 biosynthetic gene clusters.   
As expected though, the gene clusters of all four CGA-derived PNA include an 
aminotransferase of the “AHBA_syn” family of fold I, pyridoxal phosphate (PLP)-
dependent aspartate aminotransferase superfamily.31,43,45,84  It was proposed the blasticidin 
S aminotransferase, BlsH, a so-called “cytosinine synthase” first generates a Schiff base at 
the 4’-position of CGA using a pyridoxamine monophosphate (PMP) cofactor instead of 
PLP,89 facilitating 4’-3’ dehydration via an unsaturated intermediate similar to the Δ3,4-
glucoseen intermediate proposed in the mechanism of 3’-deoxygenation of CDP-D-
ascarylose.90  Then, similarly to the 3’-deoxygenation of CDP- 
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Figure 1.18: Proposed PLP-dependent biosynthetic pathway to cytosinine, 
pentopyranine, and pentopyramine. 
D-ascarylose, two-electron reduction of the PMP-sugar adduct and subsequent hydrolysis 
of PMP could lead to pentopyranine-type products.  On the other hand, establishment of a 
BlsH internal aldimine with the PMP cofactor could result in pentopyramine-type products.  
Alternatively, reduction of the unsaturated sugar-PMP adduct could lead to elimination of 
the sugar 2’-hydroxyl, and subsequent establishment of the BlsH internal aldimine with the 
cofactor would result in cytosinine.89  Given the high homology between the putative 
aminotransferases of the CGA-derived PNA, the factors governing the outcome of their 
reaction with CGA are not clear, especially since gougerotin does not have an unsaturated 
saccharide.31 
Another possible biosynthetic route to cytosinine was suggested to involve a radical 
SAM enzyme by Feng, et al.91 in the biosynthesis of arginomycin (Figure 1.19).45  The 
biosynthetic gene clusters of blasticidin S,43 mildiomycin,84 and arginomycin45 all encode 
a putative radical SAM enzyme, BlsE, MilG, and ArgF, respectively.  BlsE was shown to 
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be able to decarboxylate CGA in vitro,91 a function now broadly ascribed to homologs of 
this enzyme, as the NCBI CDD recognizes an “rSAM_BlsE” domain in putative CGA-
decarboxylases.  Such a function for BlsE is reasonable, as the biosynthesis of 
pentopyranine C is predicted to involve decarboxylation of CGA.89,92  However, the 
conservation of a radical SAM protein in the gene clusters of blasticidin S, arginomycin, 
and mildiomycin is intriguing, since these PNA all share an unsaturated core saccharide.  
Furthermore, pentopyranine/pentopyramine-like products have only been isolated from the 
blasticidin S producing organism.89,92  The exact role of these radical SAM enzymes in the 
biosynthetic pathways of these PNAs remains unexplored to date, but may offer insight 
into the versatility of this class of enzymes. 
 
 
Figure 1.19: An alternative, radical-SAM-based biosynthetic route to cytosinine. 
 Streptothricins 
The core saccharide of the streptothricins, a carbamoylated gulosamine, was 
recently found to be derived from UDP-N-acetylgalactosamine (UDP-GalNAc).78  As an 
intact-type PNA whose biosynthesis involves the incorporation of a non-ribose core 
saccharide, some means of sugar activation for condensation with its nucleobase is 
required.  Because no NDP-transferase is found in any of the streptothricins gene clusters 
found to date, and the streptothricin biosynthetic gene cluster is expressed well in 
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heterologous hosts, a physiologically common sugar was implicated.  Previous labeled 
precursor feeding experiments demonstrated that N-acetylglucosamine (GlcNAc) is a 
precursor.  Since UDP-GlcNAc is a component of Gram-positive cell walls, it is, thus, a 
readily available substrate.  The involvement of UDP-GlcNAc in the biosynthesis of the 
streptothricins nicely reconciled these observations.  Unsurprisingly, the requisite 
glycosyltransferase, StnG (from the streptothricins gene cluster in Streptomyces sp. TP-
A0356), is distinct from the CGA synthases, and it belongs to glycosyltransferase family 
GT-2, fold GT-A.  While not an absolutely conserved motif amongst GT-A 
glycosyltransferases,93,94 StnG has a “DXD” motif which has been associated with the  
 
 
Figure 1.20: Origin of the galactosamine core saccharide of the streptothricins. 
potential to bind divalent cations.78  Purified StnG was indeed able to use UDP-GlcNAc to 
glycosylate the nucleobase streptolidine, but UDP-N-acetylgalactosamine (UDP-GalNAc) 
actually proved to be a better substrate.  Since UDP-GalNac is derived from epimerization 
of UDP-GlcNAc, this result still supported the earlier feeding studies.  Epimerization by 
StnJ and carbamoylation by StnQ complete the biosynthesis of the N-acetylgulosamine 
core saccharide.  Notably, the acetyl group appears to act as a “protecting group,” since 
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attachment and elaboration of the poly-β-lysine oligopeptide does not commence until it 
has been removed by the deacetylase StnI.78    
Amicetins 
The biosyntheses of ametcin-type PNA provide another striking example of intact-
type PNA, as its core disaccharide is composed of two deoxy sugars biosynthesized “de 
novo” from TDP-glucose.79  The deoxy sugars amosamine and amicetose are divergently 
generated from TDP-4’-keto-6’-deoxyglucose following the well-established biosynthetic 
logic of deoxy sugars,95,96 and the enzymes necessary for these reactions are all found in 
the amicetin gene cluster from S. vinaceusdrappus.   As  
 
 
Figure 1.21: Deoxy sugar pathway leading to the amicetin core saccharide. 
expected, since amicetin-type PNA bear a cytosine base, the amicetin gene cluster also 
includes a 2’-deoxyribosyltransferase and a CGA synthase, AmiI and AmiJ, respectively.  
After the coupling of amicetose and cytosine, amosamine is attached by the GT-1, fold GT-
B retaining glycosyltransferase AmiG.  This glycosyltransferase is apparently substrate 
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flexible towards the sugar donor, as amicetin derivatives with monomethylated amosamine 
moieties are also observed.  Furthermore, the precise placement of amosamine transfer by 
AmiG in the amicetin biosynthetic pathway is not known, which may indicate substrate 
flexibility towards the sugar acceptor.79 
1.2.3.3. Built-up 
The last group of PNA are the built-up type whose core saccharides may originate 
from ribose or another sugar through incidental- or intact-type biosynthetic pathways, 
respectively, but are lengthened or whose cores result from a “piecewise” assembly.  The 
PNA in this group include the polyoxins, nikkomycins, mildiomycin, muraymycin, 
albomycins, and A-503083s. 
Polyoxins and Nikkomycins 
The polyoxins and nikkomycins are aminohexuronic acids derived from octosyl 
acid, which, in turn, is known to be derived from phosphoenolpyruvate (PEP) and uridine 
5’-monophosphate (UMP).23,24  The condensation of PEP and UMP in the biosynthesis of 
the polyoxins and nikkomycins requires the pyruvyl transferases PolA and NikO, 
respectively.  The newly installed 3’-PEP is then transferred to the 5’-position in a reaction 
sequence that is not well-understood at this point, resulting in the formation of octosyl acid.  
Importantly, octosyl acid can exist in a “closed chain” perhydrofuropyran form or in an 
“open chain” form, and the two forms can interconvert, in an ostensibly non-enzymatic 
process.15,16  Since the polyoxins and nikkomycins are aminohexuronic acids derived from 
an octulosuronic acid, a net loss of two carbon atoms must occur at some point.  However, 
virtually nothing is known about how octosyl acid is converted to the hexuronic acid-based 
core nucleoside of the polyoxins and nikkomycins.  The product of this conversion is likely 
a keto acid, and PolI or NikK are the aminotransferases  
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Figure 1.22: Biosynthetic route to the built-up core saccharide of the polyoxins and 
nikkomycins. 
predicted to convert the keto hexuronic acid to an aminohexuronic acid.  Only the 
transaminase first half-reaction of NikK has been recently demonstrated.97  Interestingly, 
in the san cluster, the aminotransferase SanB appears to be fused to a phosphatase at its C-
terminus.46  Octosyl acid isolated from culture filtrates of the polyoxin producer S. cacaoi 
var. asoensis, octosyl acid lacks a phosphate group.15,16  The nik and pol clusters do encode 
the monophosphatases NikL24 and PolJ,23 respectively, but their placement in the 
biosynthetic pathways of the nikkomycins and polyoxins has not been established.  The 
composition of SanB may indicate that the phosphatases act after the construction of 
octosyl acid.  Further study of the polyoxin and nikkomycin biosynthetic pathways is 
expected to provide insight into the unusual chemistry represented therein. 
Mildiomycin 
Mildiomycin is a CGA derivative with a structure similar to those of blasticidin S 
and arginomycin.  Unlike these PNAs though, its cytosinine-based core is effectively 
lengthened through condensation with α-keto-L-arginine.84  Feeding studies of the 
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producing strain S. remofaciens demonstrated that all six carbon atoms of 13C6- L-arginine 
are incorporated into mildiomycin.  Based on analysis of the mildiomycin gene cluster, 
MilM and MilN were predicted to attach α-keto-L-arginine to the 4’-amino cytosinine core 
of this PNA.  MilM is an aminotransferase of the “enduracididine-MppP” family of the 
fold I aspartate aminotransferase superfamily, and this enzyme acts first to deaminate L-
arginine.  This is a reasonable assignment, as enduracididine is a non-proteinogenic amino 
acid derived from arginine that is found in several natural products.98,99  Then, MilN, a 
dihydropicolinate synthase homolog, could perform the actual condensation reaction.  
Since all six carbons of α-keto-L-arginine are incorporated into the structure of 
mildiomycin, the condensation reaction catalyzed by MilN, while not characterized, must 
proceed through decarboxylation of the 4’-amino cytosinine core nucleoside.84 
 
 
Figure 1.23: All six carbon atoms of 13C6-L-arginine are incorporated into the 
mildiomycin core saccharide. 
Albomycins 
The albomycins feature a rare C7-aminothiosugar-based nucleoside, the SB-217452 
portion, whose biosynthesis is not understood.  The albomycins are a good example of 
built-up-type PNA, as the aminothiosugar is predicted to be built up from cysteine or 
 46 
homocysteine and PEP and glycine.51  Analysis of the albomycins biosynthetic gene cluster 
led to the proposed roles of the 1-aminocyclopropane-1-carboxylate deaminase homolog 
AbmD, the radical SAM enzymes AbmM and AbmJ, and the serinehydroxymethyl 
transferase homolog AbmH in the biosynthesis of the aminothiosugar core saccharide.  The 
resultant 1-phosphate aminothiosugar is then hypothesized to be condensed with cytosine 
or uracil by AbmG, a deoxyribonucleoside kinase (DK) homolog.   
 
 
Figure 1.24: Overview of albomycin biosynthesis 
While DK in general acts to monophosphorylate deoxynucleosides at the 5’-position, 
human DK has apparently been observed to catalyze phosphorolysis of deoxynucleosides 
in vitro to generate free nucleobases and ribose-1-phosphate, so it was reasoned AbmG 
could perform the reverse reaction and transfer cytosine or uracil to the aminothiosugar.  
However, unlike the CGA-based PNA which require the action of a nucleosidase to provide 
free cytosine,17,43 the abm cluster does not include such an enzyme.  Thus, either AbmG 
can provide both nucleosidase and transfer activities, or a nucleosidase is recruited from 
elsewhere.  Finally, though the timing is not clear, albomycin bearing cytosine is predicted 
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to be methylated by AbmI to yield albomycin ε and then carbamoylated by AbmE to yield 
albomycin δ2.  There remain many issues to be resolved in the biosynthesis of the 
albomycins. 
A-503083s 
Very little is known regarding the biosynthesis of the capuramycinoid A-503083s, 
but the core saccharide is a six-carbon amide-containing sugar, suggesting a built-up-type 
biosynthetic pathway.82,83,100  Feeding studies have suggested that the core is derived from 
uridine and PEP, and the unsaturated hexuronic acid decorating the core saccharide 
originates from mannose-1-phosphate.  As such, the core saccharide is expected to be 
composed of eight carbon atoms.  Analogous to the polyoxins and nikkomycins, this 
saccharide is built-up and then partially degraded through an unknown mechanism.   
 
 
Figure 1.25: Putative biosynthetic precursors to A-50383 F 
Some insight into the biosynthesis of this core saccharide is afforded by the presence of a 
serinehydroxymethyltransferase (SHMT) homolog CapH and the non-heme iron(II)-
dependent oxygenases CapA and CapD in the A-503083 gene cluster in S. sp. SANK 
62799.  Similarly to the caprazamycins and liposidomycins,101 the extension of the uridine 
ribose could involve oxidation of the 5’-hydroxyl to an aldehyde and subsequent transfer 
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of PEP by the SHMT.  The next steps are not clear, and, unlike the gougerotin gene cluster 
which encodes the amidase GouB,31 no obvious candidates for formation of the A-503083 
amide are found in its gene cluster. 
Muraymycins 
Although the core nucleoside of the muraymycins is derived from an intact 
molecule of uridine, the ribose is extended through condensation with glycine.59  
Reminiscent of the strategy employed by the caprazamycins and liposidomycins,101 the 5’-
hydroxyl of the core ribose is proposed to be oxidized to an aldehyde by the NAD(P)H-
dependent acyl-CoA dehydrogenase homolog Mur22, and then the SHMT homolog Mur17 
mediates an aldol condensation with glycine.  Unlike the A-503083s, the glycine-modified 
ribose is not subject to the loss of any carbon atoms.  While not necessarily a core extension 
per se, the Mur17 product must modified by the attachment of a 3-amino-3-carboxypropyl 
linker to accept the amino acid chain of the mature product.  This linker is apparently 
derived from SAM by Mur24.  Since Mur24 is predicted to be an aminotransferase by 
BLAST homology analysis, perhaps the PLP-nucleoside adduct serves as a nucleophile to 
displace methylthioadenosine from SAM, and hydrolysis of the cofactor would lead to the 
modified nucleoside.  Then, Mur23, a type III PLP-dependent diaminopimelate 
decarboxylase, decarboxylates the 3-amino-3-carboxypropyl linker.  Finally, the core 
nucleoside is completed by the attachment of 5’-amino-deoxyribose, probably through the 
action of Mur18, Mur19, and Mur26, a pyrimidine-nucleoside phosphorylase, a GT-1, fold 
GT-B glycosyltransferase, and a nucleotidyltransferase, respectively.59 
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Figure 1.26: Proposed biosynthetic pathway of the muraymycins core saccharide.  
1.2.4. Conclusions and Outlook 
Clearly, the PNA offer tremendous opportunity for the study of unique or rarely 
encountered enzyme mechanisms, as little of the known pathways have been directly 
characterized.  However, deeper study of the PNA is hampered by the novelty of these 
pathways, since many have almost no enzymological precedent.  Currently, the increasing 
rates of antibiotic resistant pathogens around the world is troubling, and there is mounting 
pressure to develop novel medicines to stem the tide of infections due to resistant 
organisms.  In light of their diverse biological activities, the PNA are a group of natural 
products warranting further study.  While many of the PNA discovered to date are too toxic 
for human use, and the growing number of sequenced and annotated genomes will 
undoubtedly uncover many more PNA gene clusters, the challenges described in this work 
will likely continue to obfuscate the reliable identification of these clusters.  However, by 
leveraging what is known regarding the biosynthesis of the PNA to offer a more thorough 
classification of these compounds, it is hoped the field can benefit from the biosynthetic 
relationships between different pathways by increasing our understanding of PNA gene 
cluster composition and ultimately improving whole genome sequence-guided efforts to 
discover novel PNA.  
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1.3. ANTHRACYCLINE AMINO SUGARS 
1.3.1. Introduction 
Anthracyclines are a class of natural products which are a key component of 
treatment regimens for several cancers.102  These compounds are now known to be 
produced by several bacteria of family Streptomycetaceae, but the first anthracycline was 
discovered in the culture filtrate from a species of Streptomyces.  This compound was 
named rhodomycin probably as a result of its intense red color (rhodon= rose colored in 
Greek).  While the spectral characteristics of rhodomycin first suggested the presence of a 
polycyclic quinone, the structure of rhodomycin was only later found to be a tetracyclic 
anthraquinone.103-105  Shortly thereafter, researchers at Farmitalia and Rhone Poulenc 
Laboratories independently isolated another anthracycline called daunomycin and 
rubidomycin by each group, respectively.  Since daunomycin and rubidomycin were found 
to be the same compound, it was given a composite name, daunorubicin.106,107 
 
 
Figure 1.27: Structures of representative anthracyclines. 
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Like rhodomycin, daunorubicin contained a tetracyclic anthraquinone 
chromophore, but it was also found to be a glycoside, containing a single amino sugar.108  
Very soon after the isolation of the first anthracyclines, they were noted for their poor 
antimicrobial activity and very potent cytotoxic activity towards several cancer cell lines.  
The cytotoxicity of these compounds appeared to be related to their propensity to form 
complexes with nucleic acids, particularly DNA, and the glycoside daunorubicin was found 
to be much more potent than rhodomycin.  Surprisingly, removal of the amino sugar greatly 
diminished the cytotoxicity of daunorubicin.109,110  Clinical trials quickly commenced, and 
although daunorubicin and its derivative doxorubicin showed promising activity in a 
number of human cancers, they also displayed considerable and often fatal 
cardiotoxicity.107,111-113  Given the planar structure of the anthracyclines and their ability to 
tightly complex DNA, DNA intercalation is believed to be the main mechanism of action 
through which these compounds exert their biological activity.  However, the redox active 
nature of anthraquinones in general also lent credence to proposals that the anthracyclines 
generated free radical species in vivo.  Subsequent work demonstrated a clear correlation 
between the propensity of the anthracycline aglycons to undergo facile one-electron 
reduction and the fatal cardiotoxicity associated with anthracyclines.114-116  The 
anthracyclines are now understood to exert their biological activity through several 
mechanisms of action, including DNA intercalation and topoisomerase II inhibition, as 
well as other unidentified mechanisms.106,109,117   
The first X-ray crystal structures of daunorubicin and doxorubicin with 
oligonucleotides very clearly revealed the critical role of their amino sugars.  Daunosamine 
was found to mediate several minor groove interactions, which explained the need for this 
sugar for relevant biological activity.110,118  Given the importance of daunosamine to the 
tight DNA binding of daunorubicin and doxorubicin, this sugar is sensitive to structural 
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and conformational changes.  For example, the α-configuration of daunosamine leads to 
anthracyclines which bind DNA with much lower affinity than the typical β-configured 
daunosamine.119  More importantly, epimerization of the daunosamine 4’-hydroxyl in the 
anthracycline epirubicin dramatically reduces the cardiotoxicity of doxorubicin.  While the 
prototypical chemotherapeutic anthracycline doxorubicin has a maximum lifetime 
exposure limit of 550 mg/m2, epirubicin allows an increased maximum lifetime exposure 
limit of 900 mg/m2.120  Although over 1000 anthracycline analogs have been explored, to 
date epirubicin represents the most successful application of glycodiversification as a 
means to improve the activity profile of anthracyclines.121   
1.3.2. Amino Sugar Biosynthesis 
Glycosylated bacterial natural products are notable for the extensive representation 
of deoxy sugars.  These sugars are found to modulate the function of the compounds they 
are appended to, and often they are key to the biological activities of many natural products.  
Hundreds of different bacterial deoxy sugars have been found in nature, but, strikingly, 
these sugars are derived from only a handful of conserved precursors.95,96   
Beginning with glucose-1-phosphate, the first step in the biosynthesis of bacterial 
deoxy sugars is the creation of nucleoside diphosphate (NDP)-activated glucose.  All five 
physiological nucleosides are found to be used in the activation of glucose for deoxy sugar 
biosynthesis, but secondary metabolites frequently rely on a thymidine diphosphate group 
to activate glucose.  Activation as a nucleoside diphosphate serves two purposes.  Firstly, 
this activation step shunts primary metabolic sugars to deoxy sugar biosynthetic pathways.  
The enzymes of these pathways often rely on the NDP-portion of deoxy sugar 
intermediates for recognition.  Secondly, NDP activation prepares deoxy sugars for their 
ultimate purpose, the decoration of compounds through glycosylation.  The second step is 
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invariably the 4,6-dehydration of NDP-glucose.  The product of this reaction, NDP-4-keto-
6-deoxy glucose is shared 2-deoxy sugar biosynthetic pathways, as it can be further 
modified or attached to a substrate, or it can undergo 2,3-dehydration.  The product of the 
latter reaction is an unstable diketo sugar, so this step is coupled with another reaction like 
ketoreduction or transamination.  In some pathways, NDP-4-keto-6-deoxy glucose 
undergoes 3,4 ketoisomerization, which provides access to 3-keto-4-hydroxy sugars.95,96 
 
 
Figure 1.28: Deoxy sugar diversity can be generated from only a few conserved 
intermediates.  
Biosynthesis of amino sugars relies on the action of sugar transaminases.  These 
PLP-dependent enzymes catalyze the reversible interconversion of an amino acid and a 
ketosugar substrate.  In the biosynthesis of NDP-amino sugars, sugar transaminases can act 
at any position of the sugar ring, provided the position is first converted to a carbonyl.  
Phylogenetic analyses of sugar transaminases may enable a prediction of their sites of 
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action,  but a priori¸ such predictions are not possible given only the amino acid sequence 
of a particular enzyme.  After the installation of an amino group, it can be subject to further 
modifications as well, including acetylation, methylation, oxidation, carbamoylation, and 
even glycosylation.90 
Although daunosamine or epidaunosamine are important determinants of the action 
of the anthracyclines, very little work has been done to study the biosynthesis of amino 
sugars in other anthracycline pathways.  As a result, many of these amino sugar pathways 
are predicted but not characterized or validatated.122  The biosyntheses of amino sugars 
found in the structures of anthracyclines do not usually feature “exotic” or “unusual” 
enzyme mechanisms, but a better understanding of these pathways could further 
glycodiversification efforts in this very useful class of compounds. 
1.3.3. Conclusions and Outlook 
Semi-synthesis is the most commonly employed method to generate anthracycline 
analogs, but because these molecules are feature many reactive functional groups, synthetic 
schemes are often lengthy and time consuming.  In other cases, anthracyclines are built 
synthetically, also entailing complicated schemes.121  Despite the wide utility of the 
anthracyclines, this class of compounds suffers from dose-limiting, potentially fatal 
cardiotoxicity111-113 and the development of resistance in tumors.117,123  The critical roles 
played by the deoxy sugars appended to anthracyclines make them a prime target for 
optimization.  Bacterial deoxy sugar biosynthetic pathways are modular and rely on strictly 
conserved intermediates,95,96 so efforts to bioengineer the organisms producing these 
compounds by harnessing their ability to efficiently perform what would be difficult 
synthetic chemistry steps en route to the formation of these structurally complex molecules 
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could help to bypass long synthetic schemes and offer a novel approach to the improvement 
of anthracyclines.  
1.4. DISSERTATION STATEMENT 
This dissertation primarily aims to provide insight into the biosynthesis of complex 
peptidyl nucleoside antibiotics through investigation of the biosynthesis of the 
miharamycins and amipurimycin.  To a lesser degree, this work also aims to detail 
preliminary efforts towards the characterization of biosynthetic pathways of the deoxy 
sugars appended to the unusual anthracycline nogalamycin.   
The biosyntheses of the miharamycins, amipurimycin, and nogalamycin were 
selected as topics of study because they appear to represent substantial deviations from 
well-studied sugar biosynthetic logic and are, therefore, expected to expand our 
understanding of nature’s biosynthetic repertoire.  Chapter 1 furnishes a detailed but 
concise review of the available recent literature regarding the biosynthesis of peptidyl 
nucleoside antibiotics and addresses glycosylation of anthracyclines.  Chapter 2 describes 
a bioinformatics approach to the identification of the biosynthetic gene clusters of the 
complex PNA the miharamycins and amipurimycin and provides analysis of their content.  
Chapter 3 presents the results of efforts to characterize the biosynthesis of the 
miharamycins and amipurimycin.  Finally, Chapter 4 demonstrates the validation of the 
proposed biosynthetic pathway of TDP-nogalamine, the amino sugar found in 
nogalamycin, and offers an approach to the in vivo production of C1-hydroxylated 
anthracyclines. 
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Chapter 2: Identification of the Amipurimycin and Miharamycins Gene 
Clusters Through a Comparative Genomics Approach 
 
2.1. INTRODUCTION 
Recent advances in the capability to obtain high-quality genomic sequencing data 
inexpensively through next generation sequencing (NGS) technology have led to the 
widespread use of genome sequencing as a primary research tool in the study of natural 
products.  Whereas within the last decade the identification and cloning of biosynthetic 
gene clusters could be a tedious, years-long endeavor, today, identifying natural product 
biosynthetic gene clusters, from sequence data collection to data processing and annotation, 
has become a days- or weeks-long project.  NGS techniques allow not only very high 
throughput identification of biosynthetic gene clusters and, often, prediction of gene 
clusters’ products, but also the ability to study natural product gene clusters independent 
of axenic cultures of the organisms from which they originate.1-4    
The explosion in the number of available sequenced genomes is not without its 
challenges.  Because many aspects of data collection and processing can be automated, the 
rate at which newly sequenced genomes are made available has been exponential.1,2,5   
Since the annotation and, hence, prediction of the product of a gene relies on the collected 
validation information of the function of homologous gene products, the rate of generation 
of such massive quantities of genomic sequence data greatly outstrips our ability to directly 
elucidate the function of these genes, and the comparative functional assignment is 
complicated by mis-annotation of genes in the literature or an inability to annotate 
genes.2,3,5  Furthermore, because of the former difficulty in identifying biosynthetic gene 
clusters, the study of natural product biosynthesis required the collection of copious 
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biochemical data.  These data often yielded critical insight into the biosynthetic pathways 
in question, and frequently enabled the complete elucidation of a given biosynthetic 
pathway exclusive of a complete gene cluster sequence.3  Yet, because the identification 
of a putative gene cluster now often precedes detailed biochemical data, even with the 
sequenced gene cluster in hand, the biosynthetic route can still be unclear.  The practice of 
“genome mining,” is, thus, a more accurate descriptor of the use of genomic sequence data 
in the study of natural product biosynthesis.2,4,6  A key discovery in the biosynthesis of 
natural products was the observation of their modularity and conservation of their gene 
clusters, such that structurally similar compounds tend to have similarly composed gene 
clusters.  These conserved gene cluster characteristics are typically shared for a given class 
of compounds and facilitate the rapid identification of additional gene clusters of class 
members.  This logic relies on the previous successful identification of similar gene 
clusters, so it is often harder to identify the biosynthetic gene clusters for compounds with 
poorly conserved biosynthetic gene clusters, such as the peptidyl nucleoside antibiotics 
(PNAs).3,7-11 
The PNAs comprise a subset of the nucleoside natural products whose study 
exemplifies the challenges associated with natural products lacking structural conservation 
with compounds from other more widely studied groups of natural products.12  Minimally, 
the PNAs are composed of a nucleoside with at least one pendant amino acid attached via 
a peptide bond.  However, given the diversity of PNA structures, this group of compounds 
can be best conceptualized as three components: the nucleobase, the “core” saccharide, and 
the appended amino acid(s).  Frequently, each of these components include structures 
rarely seen, e.g., hypermodified nucleobases, higher-carbon sugars, and non-proteinogenic 
amino acids.9,12-14  Representative PNAs are shown in Figure 2.1. 
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Figure 2.1: Structures of representative peptidyl nucleoside antibiotics. 
While the biological activities of the majority of the PNAs discovered to date are 
unknown, several PNAs have been more closely studied, and their activities include: 
prokaryotic and eukaryotic protein synthesis inhibition,7,8 prokaryotic tRNA synthetase 
inhibition,9 bacterial translocase inhibition,11,15 and fungal chitin synthase inhibition.16,17  
No PNA are currently clinically used, but nikkomycin Z  (7) is under investigation as a 
first-in-class antifungal for the treatment of coccidioidomycosis (“valley fever”) in 
humans.18-22  Furthermore, puromycin (4) and blasticidin S (5) are heavily used in 
molecular biology both as selection agents23 and probes of ribosomal function;23,24 and 
mildiomycin (6) finds use as an agricultural fungicide.19  In light of the diverse biological 
activities exhibited by these “privileged” pharmacophores and unique constituent amino 
acids and nucleobases, further study of the PNAs holds promise for both the development 
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of novel therapeutics and the enrichment of natural product chemistry.  Because the 
structural heterogeneity of PNAs confounds efforts to readily identify their biosynthetic 
gene clusters, a more complete understanding of PNA biosynthesis is expected to greatly 
aid in the identification of novel PNA gene clusters.25,26   
The miharamycins (1-2) and amipurimycin (3) are PNAs elaborated by the soil-
dwelling actinomycetes Streptomyces miharaensis ATCC 19440 and Streptomyces 
novoguineensis CBS 199.78, respectively, which exemplify the difficulty in finding PNA 
biosynthetic gene clusters.  Despite their discovery over 40 years ago, the structures of 
these compounds were not elucidated until the 1980s, when they were found to be 
nucleosides of the rare nucleobase 2-aminopurine.27,28  Among the PNA, these are the only 
compounds bearing the 2-aminopurine base. The core saccharides are strikingly similar 
branched amino nonulosuronic acids, with the fused bicyclic core of the miharamycins 
resembling a cyclized C4-hydroxy form of the amipurimycin core.  The absolute 
stereochemistry of the molecules was not established in earlier studies, but recently an 
exhaustive NMR study showed the C6 stereochemistry of miharamycin A is S.  While this 
is probably the same for miharamycin B,29 the C6 stereochemistry of amipurimycin 
remains undetermined.27 Similarly, the arginine moiety of miharamycin B was determined 
to be L-configured; this is probably the case as well for the modified arginine found in 
miharamycin A, but its configuration has not yet been confirmed.28  These PNAs also 
feature the unique amino acids N5-hydroxyarginine and (1R,2S)-2-aminocyclopentane-1-
carboxylic acid, also known as cispentacin (Figure 2.2).  Although the biosyntheses of 
these amino acids have not been studied, they have been isolated from other organisms.  
N5-hydroxyarginine is known to be produced as a free amino acid by the dermatophytic 
fungus Nannizzia gypsea30 and two species of Bacillus,31,32 and is a component of the 
antibiotics argolaphos A and argolaphos B,3 as well as asterobactin.33   
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Figure 2.2: Biological precedent for N5-hydroxyarginine/ hydroxyguanidine-containing 
natural products and source organisms. 
A similarly hydroxylated guanidine is also found as a component of the marine natural 
product urupocidin A34 and the antifungal natural products octacosamicins A and B.35,36  
Cispentacin was found to be produced by a strain of Bacillus cereus37,38 and by 
Streptomyces setonii.39  
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The mechanisms of activity of the miharamycins and amipurimycin are not known, 
but these PNAs are notable for their potent and specific activity against the 
phytopathogenic fungus Magnaporthe grisea (also known as Pyricularia oryzae), the 
causative agent of rice blast disease,40,41 as well as activity against a wide variety of 
phytopathogenic fungi.  However, miharamycin A was found to exhibit antiviral activity 
against tobacco mosaic virus, cucumber mosaic virus, and potato virus X, and the 
mechanism was suggested to be inhibition of DNA-dependent RNA synthesis.42,43  The 
miharamycins are further distinguished from amipurimycin by their strong inhibitory 
activity in vitro against the Gram negative phytopathogenic bacteria Pseudomonas 
aeruginosa, Pseudomonas tabaci, and Pseudomonas fluorescens.40,41,44  Finally, the 
miharamycins and amipurimycin are considerably toxic to mice when administered 
intravenously.40-42   
While the determinants of these biological activities are not known, N5-
hydroxyarginine and cispentacin alone exhibit antifungal activity,30,35,38 and 2-aminopurine 
has been used as a molecular biology tool for over 50 years in structural studies due to its 
strong fluorescence and, since it can base-pair with cytosine and thymine, as a bacterial 
mutagen.45-48  Despite their potential use in the treatment of rice blast disease and their lack 
of toxicity to newly emergent leaves, these antibiotics had been shown to damage mature 
leaves of the plants they were applied to.  Nevertheless, the miharamycins and 
amipurimycin currently have not been used agriculturally or otherwise. 
Our interest in the miharamycins and amipurimycin lies in learning the biosynthesis 
of these compounds’ unique structural features, specifically their apparently higher-carbon 
core saccharides and the rare 2-aminopurine base.  The features of these PNA have inspired 
synthetic efforts over the last almost 30 years, but, surprisingly, neither the miharamycins 
nor amipurimycin have been successfully totally synthesized.29,49  In 2008, Marcelo and 
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co-workers reported the total synthesis of a completely protected form of miharamycin A, 
but unfortunately attempts to deprotect the molecule resulted in its decomposition.29  More 
recently, the same group revealed a novel approach to the bicyclic core of the 
miharamycins through Wittig olefination of 2-O-acyl-D-ribo-hexopyran-3-uloses with 
[(ethoxycarbonyl)methylene]triphenylphosphorane, but the product was still fully 
protected.50  Considerably more progress has been made in the synthesis of amipurimycin, 
as the total synthesis of a thymine analog was reported in 2008 by Stauffer and Datta.49  
Yet, given the rarity of their structures, the miharamycins and amipurimycin remain 
attractive synthetic targets.   
The activity of the miharamycins against P. aeruginosa, an important opportunistic 
human pathogen, is intriguing since the miharamycins do not resemble any 
antipseudomonal antibiotics in current use.51,52  Furthermore, the lack of antipseudomonal 
activity of amipurimycin despite equipotent antifungal activity to the miharamycins 
suggests distinct structural features underlie these activities.  Thus, it is hoped that insight 
into the biosyntheses of these unique compounds may enable the construction of their 
synthetically challenging scaffolds which can be used in the development of novel human 
antimicrobials or chemotherapeutics with improved toxicity profiles.  Herein, we describe 
the identification of the putative amipurimycin and miharamycins biosynthetic gene 
clusters through a comparative genomics approach.  Surprisingly, analysis of these gene 
clusters suggests the biosyntheses of these compounds rely on enzymes typical of 
polyketide synthase (PKS) based gene clusters.  Furthermore, amipurimycin and 
miharamycin are proposed to be the first members of a newly discovered group of PNAs.  
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Figure 2.3: Antipseudomonal antibiotics in current clinical use and their therapeutic 
classes. 
 
2.2. MATERIALS AND METHODS     
2.2.1. General 
All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
or Fisher Scientific (Pittsburg, PA) and used without further purification unless otherwise 
noted.  Laboratory disposables such as microcentrifuge tubes, petri dishes, and conical 
tubes were obtained from Fisher Scientific or VWR (Radnor, PA).  With exceptions as 
noted, techniques relating to the manipulation of recombinant DNA were performed 
according to standard protocols;53 similarly, all Streptomyces methods and media were 
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performed and made according to standard protocols unless otherwise noted.54  DNeasy 
Blood and Tissue kits were from QIAgen (Valencia, CA).   
 
2.2.2. Bacterial Strains: Procurement, Preservation, and Growth 
Streptomyces miharaensis Niida ATCC 19440 was purchased from American Type 
and Tissue Culture (Manassas, VA), and Streptomyces novoguineensis Iwasa CBS 199.78 
was obtained from the CBS-KNAW Fungal Biodiversity Centre (Utrecht, The 
Netherlands).  Both strains were maintained as mycelial suspensions in 20% glycerol and 
stored at -80 °C in 2 mL Corning® cryo-tubes from Sigma-Aldrich.   Strains were routinely 
grown as 10 mL cultures in sterile seed medium (pH 7.0),55 composed of 2% glucose, 1% 
Bacto® peptone from BD (Franklin Lakes, NJ) or peptone from Fisher Scientific, 0.5% 
meat extract from BD, 0.5% NaCl, and deionized (di) H2O, in test tubes (25 x 150 mm) 
containing several acid-washed glass beads.  Cultures were aseptically inoculated with 0.2 
mL mycelial suspension of either S. miharaensis or S. novoguineensis and capped with 
Kimble KIM-KAP® culture tube caps from Fisher Scientific.  These cultures were then 
grown at 28 °C with rotary shaking at 220 RPM in an Innova® 4200 Incubator-Shaker from 
New Brunswick Scientific (Edison, NJ) or a MaxQ® 6000 Incubator-Shaker from Thermo 
Scientific (Waltham, MA). 
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2.2.3. Isolation of Genomic DNA 
For the isolation of genomic DNA, 2-3 day old S. miharaensis or S. novoguineensis 
liquid cultures grown as above were gently vortexed with a Standard Mini Vortex from 
VWR, and then the mycelia from 1 mL culture aliquots were collected by centrifugation at 
14,000 x g in a 5415R refrigerated tabletop microcentrifuge from Eppendorf (Hamburg, 
Germany).  After carefully removing the supernatants by aspiration, genomic DNA was 
extracted from the mycelial pellets using the QIAgen DNeasy Blood and Tissue kit 
following the manufacturer’s instructions and using the suggested pretreatment for Gram 
positive bacteria.  
2.2.4. Whole Genome Sequencing 
 
Samples of S. miharaensis and S. novoguineensis genomic DNA (~250 ng/µL) in 
QIAgen buffer AE (10 mM Tris-HCl and 0.5 mM EDTA, pH 9.0) were submitted to the 
Genomic Sequencing and Analysis Facility (GSAF) of the Institute of Cell and Molecular 
Biology (ICMB) at the University of Texas at Austin.  The genomic DNA libraries for each 
strain were prepared by the GSAF and sequenced using Illumina MiSeq® technology.  
Paired-end (PE) and mate-pair (MP) libraries were generated for both strains with target 
sizes of 2 x 300 + 50 base-pairs (bp) and 3-4 kbp, respectively, and 2 million reads were 
targeted for each strain. 
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2.2.5. Data Analysis 
The PE and MP read data for each strain were processed separately using cutadapt 
v. 1.7.156 to remove sequencing adapters and isolate reverse-forward reads, respectively.  
The sequences of the adapters utilized are presented in Table 1.  For the PE read data, 
processing was limited to removal of the Illumina TruSeq® sequencing adapter from the 
5’-ends of the PE reads using the following commands:  
 
cutadapt -a TS -o PE_Read1_trim.fastq PE_Read1.fastq 
and  
cutadapt -a TS -o PE_Read2_trim.fastq PE_Read2.fastq 
 
where the input files were “PE_Read1.fastq” and “PE_Read2.fastq,” and the output files 
were  “PE_Read1_trim.fastq” and “PE_Read2_trim.fastq.” 
 
Name Sequence (5’ to 3’) Note Ref 
TruSeq V3 Y adapter 
(“TS”) 
GATCGGAAGC PE Data 57 
Nextera Read 1 External 
Adapter (“EXT1”) 
GATCGGAAGAGCACACGTCTGAACTCCAG
TCAC 
MP Data 58 
Nextera Read 2 External 
Adapter (“EXT2”) 
GATCGGAAGAGCGTCGTGTAGGGAAAGA
GTGT 
MP Data 58 
Circularized Single Junction 
Adapter (“SJA”) 
CTGTCTCTTATACACATCT MP Data 58 
Circularized Single Junction 
Adapter, Reverse 
Complement (“rcSJA”) 
AGATGTGTATAAGAGACAG MP Data 58 
Table 2.1: Adapter sequences utilized in whole-genome sequencing. 
MP data were processed in four steps.  First, reads containing the Illumina Nextera® 
Mate-Pair adapters EXT1 and EXT2 were removed from the dataset.  In order to keep the 
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read tables aligned, removal of EXT1- and EXT2-containing reads was accomplished using 
the following command sequence recommended in the cutadapt documentation: 
  
a. cutadapt -b EXT1 -O10 -m100 --discard --paired-output tmp.2.fastq -o 
tmp.1.fastq MP_Read1.fastq MP_Read2.fastq  
b. cutadapt -b EXT2 -O10 -m100 --discard --paired-output 
Trim_MP_Read1.fastq -o Trim_MP_Read2.fastq tmp.2.fastq tmp.1.fastq 
c. rm tmp.1.fastq tmp.2.fastq 
 
where “-O10” specified at least 10 bp matching, “-m100” removed reads shorter than 100 
bp, and “MP_Read1.fastq” and “MP_Read2.fastq” were the input files.  After removal of 
the EXT1- and EXT2-containing reads, the remaining reads are represented by the files 
“Trim_MP_Read1.fastq” and “Trim_MP_Read2.fastq.”  The last step was used to delete 
the temporary files “tmp.1.fastq” and “tmp.2.fastq.”  Next, to obtain reverse-forward 
oriented MP reads, the reads lacking the Illumina Nextera® Single Junction Adapter (SJA) 
and its reverse complement (cSJA) were discarded.  To keep the two file tables aligned, 
similarly to the last step, the following command sequence was used: 
  
a. cutadapt -b SJA --trimmed-only --paired-output tmp.2.fastq -o tmp.1.fastq 
Trim_MP_Read1.fastq Trim_MP_Read2.fastq 
b. cutadapt -b cSJA --trimmed-only --paired-output MP_RF_Read1.fastq -o 
MP_RF_Read2.fastq tmp.2.fastq tmp.1.fastq 
c. rm tmp.1.fastq tmp.2.fastq 
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The final, reverse-forward oriented reads are represented by the files 
“MP_RF_Read1.fastq” and “MP_RF_Read2.fastq.”  Finally, the processed MP reads were 
reverse complemented using the program fastx59with the following commands: 
 
fastx_reverse_complement -i MP_RF_Read1.fastq -o MP_RF_Read1rc.fastq -Q 
33 
and  
fastx_reverse_complement -i MP_RF_Read2.fastq -o MP_RF_Read2rc.fastq -Q 
33 
 The “-Q33” modifier is used to indicate Illumina data are being used since the 
quality scores from this platform are offset by a value of 33, i.e., quality (Q)= Phred 
score+33.60   The final MP read data files ready for assembly are represented by the files 
“MP_RF_Read1rc.fastq” and “MP_RF_Read2rc.fastq.” 
 
2.2.6. Assembly 
 
To generate the draft genome sequences for S. miharaensis and S. novoguineensis, 
the strains’ respective 5’-adapter trimmed-PE reads and reverse complemented, reverse-
forward oriented-MP reads were assembled with velvet, v. 1.2.10 in two steps, as directed 
by the manual.61-63 The dataset for assembly for each strain was created using velveth with 
following command:  
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velveth STRAIN_NAMEdir 73 -shortPaired -separate -fastq dir/ 
PE_Read1_trim.fastq dir/ PE_Read2_trim.fastq -shortPaired2 -separate –fastq 
dir/MP_RF_Read1rc.fastq dir/MP_RF_Read2rc.fastq 
 
where the kmer length is specified by “73,” and the file names are as described above.  
Once complete, the datasets were stored in directories named for each strain 
(“STRAIN_NAMEdir”), and assembly was carried out using velvetg with the following 
command: 
 
velvetg STRAIN_NAMEdir -exp_cov auto -cov_cutoff auto -shortMatePaired yes 
 
where the “-exp_cov” and “-cov_cutoff” parameters were left as their defaults (“auto”), “-
shortMatePaired yes” was used to indicate the use of mate-paired data in the dataset, and 
the final assembly file was saved to the STRAIN_NAME directory. 
 
2.2.7. Annotation and gene cluster analysis 
 
The assembled genomic data for each strain in fastq format were uploaded to Rapid 
Annotation Using Subsystem Technology (RAST) for annotation.64,65  The annotated 
genomes were analyzed using RAST tools and antiSMASH 2.066 and by whole-genome 
alignment using Mauve.67-69 
For comparative studies, the draft genome sequence data of Streptomyces sp. S-
1868, Streptomyces varsoviensis NRRL B-3589, Streptomyces canus str. 299MFChir4.1, 
and Actinoplanes sp. N902-109, and  Streptomyces monomycini NRRL B-24309 were 
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downloaded from NCBI in fastq format via their respective RefSeq FTP sites.  These data 
were uploaded to RAST for annotation and analyzed using the RAST tools. 
 
2.3. RESULTS AND DISCUSSION 
2.3.1. Gene Cluster Identification 
As discussed earlier, the high structural conservation between amipurimycin and 
the miharamycins, led us to believe they derived from similar or the same components.  
Thus, the content of their biosynthetic gene clusters was expected to be highly conserved 
as well.  Therefore, comparing the genomes of both producing organisms would allow the 
identification of conserved gene clusters and facilitate the co-discovery of the 
amipurimycin and miharamycins gene clusters. The availability of Illumina technology at 
the GSAF made it possible to quickly sequence with high quality the genomes of both S. 
miharaensis and S. novoguineensis, an option previously unavailable to our lab.  However, 
the amount of data this service provided required a strategic approach to analysis.   
The applications of next generation genomic sequencing technology are manifold, 
so unavailability of standard strategies to assemble the data is unsurprising.70-72  However, 
given the average size of actinomycete biosynthetic gene clusters of 30-50 kbp,54 we 
reasoned identification of the amipurimycin and miharamycins gene clusters would require 
a final assembly which, even if fragmentary, contained contiguous sequences of at least 50 
kbp.  Thus, our strategy involved the use of MP read data to generate scaffolds spanning 
long distances that could be complemented with shorter PE read data.70-72 To provide a 
reasonable depth of coverage and, hence, reliability of sequence data, based on a typical 
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actinomycete genome size of 12 Mbp,54 we estimated 2 million reads to be sufficient.  
Processing of the collected data was carried out as summarized in Figure 2.3.  
While the removal of the PE sequencing adapter was straightforward, processing of the 
MP read data to obtain the most useful fraction of the total reads was more difficult.  
According to the Illumina Nextera® mate-pair library documentation, the MP data are 
generated from circularized DNA fragments whose ends are linked by the annealing of two 
junction adapters.  These circularized fragments are then digested to provide, besides DNA 
lacking adapters, the desired reverse-forward (RF) mapping fragments composed of duplex 
junction adapters flanked by “arms” of DNA.  The RF mapping duplexed junction 
fragments are then fitted with external adapters for sequencing.58  However, in practice, 
the MP data contain reads from many other types of fragment-adapter combinations, so it 
was necessary to: 1) exclude reads containing the external adapter sequence, since these 
reads are expected to be derived from very short DNA fragments; and 2) keep only reads 
derived from the ideal DNA flanked duplex junction adapters, since these reads should 
contain the most useful sequencing data.  Finally, due to the RF orientation of the MP read 
data, these data were reverse complemented.58   
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Figure 2.3: De novo whole genome sequencing data assembly strategy overview. 
 
Trial assemblies with velveth showed a kmer length of 73 provided a good balance 
of specificity and coverage,73 and the best quality assembly was obtained when velvetg 
was allowed to optimize the parameters “exp_cov” and “cov_cutoff,” so they were left as 
their defaults, which were both “auto.”  After assembly of the PE and MP read data for 
each strain, the S. miharaensis genome was estimated to be 9.88 Mbp, and the assembly 
was composed of 223 nodes with an N50 of 1,067824 bp; the S. novoguineensis genome 
was estimated to be 8.32 Mbp, and the assembly was composed of 410 nodes with an N50 
of 84,005 bp.  After uploading the assemblies to the RAST server, the nodes were converted 
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to contigs, and 607 contigs were made for S. novoguineensis, and 864 contigs were made 
for S. miharaensis.  These characteristics indicated sequencing did provide adequate 
coverage, and there would be a high probability of finding the expected biosynthetic gene 
clusters on one contig. 
The next challenge was the identification of the correct amipurimycin and 
miharamycins biosynthetic gene clusters.  Gene cluster prediction by antiSMASH 2.0 
identified over 50 putative biosynthetic gene clusters for each strain, but only one cluster 
was found to be conserved between both S. miharaensis and S. novoguineensis.  Mauve67 
was used to confirm the presence of the shared cluster and localize it to a 30-40 kbp locus 
in each genome.  BLASTP analysis of the predicted products of the predicted ORFs found 
in these regions using the NCBI Non-Redundant (NR) Protein database suggested these 
putative clusters were not conserved in all bacteria, further supporting their uniqueness.  
Annotation by RAST predicted 28 ORFs in the 33.77 kbp conserved region found in S. 
novoguineensis (the putative snv cluster) and 27 ORFs in the 30.1 kbp conserved region 
found in S. miharaenesis (the putative smh cluster).  The clusters are shown in Figure 2.4, 
and ORFs from both putative gene clusters are listed in Table 2, along with their predicted 
products based on NCBI BLAST Conserved Domain Database (CDD) and BLASTP 
analyses.  PNAs are conceptually tripartite structures consisting of a core saccharide, a 
nucleobase, and at least one amino acid.9,11  Thus, a PNA biosynthetic gene cluster would 
be expected to encode a means to generate or procure a core saccharide, attach a nucleobase 
to the core, and attach an amino acid to the core nucleoside. Additionally, PNA clusters 
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frequently include the enzymes necessary to create any unusual amino acids and 
nucleobases attached to the core.  
 
Figure 2.4: Organization of the identified putative biosynthetic gene clusters snv and 
smh.   
Preliminary investigation of the newly identified snv and smh gene clusters revealed 
each encoded enzymes typical of polyketide biosynthesis including a monomodular type I 
PKS, Snv8 and Smh10, and a subcluster of enzymes implicated in the biosynthesis of the 
unusual PKS extender unit hydroxymalonylate (as its acyl carrier protein thioester), Snv9-
12 and Smh11-14.  This finding cast doubt on the role of these clusters in the biosynthesis 
of amipurimycin and the miharamycins.  Subsequent analysis of the S. novoguineensis 
cluster, snv, offered support for the role of this gene cluster in the biosynthesis of 
amipurimycin.   
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  Shared  S. miharaensis-specific  S. novoguineensis-specific  
SMH SNV Proposed Function SMH Proposed Function SNV Proposed Function 
4 1 inositol 2-dehydrogenase 2 extradiol dioxygenase α 0 
pathway activator 
(SARP) 
1 2 
branched chain 
aminotransferase 3 extradiol dioxygenase β A 3-oxo-ACP reductase 
5a 3a 
transketolase N-terminal 
domain 19 PP-transferase  (“Sfp”) B ACP 
5b 3b 
transketolase C-terminal 
domain 21 UbiE methyltransferase C Orn aminotransferase 
6 4 CGA synthase homolog 22 Phe-tRNA synthetase α D thioesterase 
7 5 aminoglycoside kinase 23 Phe-tRNA synthetase β E 3-oxo-ACP dehydr. 
8 6 flavin-dept. oxidoreductase 24 YqcI/YcgG F 3-oxoacyl-ACP synth. 
9 7 
PKS loading module, A-T-
type 25 TetR regulator G Dieckmann cyclase 
10 8 
PKS, type I (iterative?), AT-
KS-T 26 aldolase H acyl-CoA ligase 
11 9 
3-hydroxybutyryl-CoA 
dehydr. 27 ribose kinase 16 
pathway activator 
(SARP) 
12 10 ACP     
13 11 
short chain acyl-CoA 
dehydr.     
14 12 FkbH-like     
15 13 UbiE methyltransferase     
16 14 gluconate 5-reductase     
17 15 LOG-1 homologue     
20 18 ATP-grasp ligase     
18 19 MFS-1 efflux protein     
Table 2.2: ORFs in the snv and smh gene clusters and their predicted products. 
 
We found the majority of  the snv ORFs appeared to be inserted into a small gene 
cluster encoding homologs of Cfa1-5, comprising the  biosynthetic pathway of 2-carboxy-
2-cyclopentanone (CPC).  The polyketide-derived compound CPC is a precursor of 
coronafacic acid in the biosynthesis of coronatine, a virulence factor produced by several 
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pathovars of Pseudomonas syringae.74-76  The remarkable similarity between CPC and 
cispentacin suggested the latter could be derived from reduction and transamination of the 
former.  Indeed, an enoyl reductase, SnvA, and an ornithine aminotransferase, SnvC, not 
found in any other annotated CPC gene clusters in the NCBI database were encoded in the 
same genetic locus, which provided the first support for the correct identification of the 
amipurimycin gene cluster.  This pathway will be discussed in depth in a later section. 
 
 
Figure 2.5: Structures of coronatine and intermediates.   
To ensure the completeness of the snv and smh clusters, we performed comparison 
with other genomes in the RAST database in an effort to delineate the snv and smh gene 
cluster boundaries.  Surprisingly, the snv cluster appears to lie within a conserved locus in 
Streptomyces coelicolor A3(2)77 corresponding to sco6992 to sco7000 which supports the 
identified cluster boundaries.  The smh cluster boundaries are not as obvious upon 
comparison with other genome sequences in the RAST database, but its high conservation 
to the snv cluster supports the identified cluster boundaries. 
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Figure 2.6: Proposed snv gene cluster boundaries deduced from comparison with the S. 
coelicolor A3(2) genome. 
2.3.2. Gene Cluster Analysis 
Overall, the clusters are notable for their organization as three shared major 
portions: a three gene cassette putatively encoding a glycosyltransferase (Snv4 and Smh6), 
an aminoglycoside resistance kinase (Snv5 and Smh7), and flavin-dependent 
oxidoreductase of unknown function (Snv6 and Smh7); a monomodular minimal type I 
polyketide synthase (PKS) composed of single ketosynthase (KS), acetyltransferase (AT) 
and phosphopantetheinyl binding/ thiolation (T) domains immediately preceded an unusual 
putative adenylation/thiolation didomain loading module (Snv7 and Snv8; Smh9 and 
Smh10); and a conserved subcluster for the biosynthesis of hydroxymalonyl-ACP (Snv9-
12 and Smh11-14).  An ATP-grasp ligase (Snv18 and Smh20), a branched-chain 
aminotransferase (BCAT; Snv2 and Smh1), a two-component transketolase (Snv3a/b and 
Smh5a/b), a UbiE methyltransferase (Snv13 and Smh15), a putative LOG-1 homolog 
(Snv15 and Smh17), and two oxidoreductases, an inositol 2-dehydrogenase (Snv1 and 
Smh4) and a gluconate 5-reductase (Snv14 and Smh16), and a putative resistance efflux 
protein (Snv19 and Smh18) are also shared. 
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Inspection of the putative biosynthetic gene clusters identified in S. miharaensis 
and S. novoguineensis revealed their content varied from any previously published PNA 
gene clusters, making comparison difficult.  However, the smh and snv clusters do contain 
a weak CGA synthase homolog (Smh6, Snv4), a hallmark of several cytosyl-PNA gene 
clusters, but they lack the nucleoside hydrolase found in the known cytosyl-PNA gene 
clusters.9  This is not unexpected, since unlike these PNAs, the miharamycins and 
amipurimycin bear a purine base instead of cytosine, which is found in very low abundance 
as a free base physiologically.78  Nevertheless, the presence of the glycosyltransferases in 
the snv and smh  clusters suggests, as is the case for the cytosyl-PNAs,9 amipurimycin and 
the miharamycins are derived from glycosylation of a nucleobase with a sugar and not from 
modifications to a preformed nucleoside or nucleotide, a strategy employed in the 
biosyntheses of some PNAs, such as puromycin,24 the nikkomycins,17 and the 
pacidamycins.79   
2.3.2.1. Core Saccharide Biosynthesis 
2.3.2.1.1. Involvement of PKS enzymes 
Based on the biosynthetic gene clusters of blasticidin S,23 mildiomycin,80 and the 
other cytosyl-PNAs,81,82  one pathway envisioned for the biosynthesis of amipurimycin and 
the miharamycins involves the glycosylation of a purine base with an NDP-activated 
hexose, followed by elaboration via the PKS/ transketolase and amino acid attachment by 
the ATP-grasp ligase, but the origin of the requisite NDP-sugar is not clear.  The nine 
carbon core saccharides of the miharamycins and amipurimycin are rare amongst the 
PNAs, as the highest carbon sugars identified are sedoheptoloses, such as spicamycin and 
septacidin83 or octuloses, like ezomycin A1.13,14  More importantly, the miharamycins and 
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amipurimycin include both amino and carboxylate functionalities, a characteristic shared 
only by a handful of PNAs,16,17,84,85 as well as some liponucleosides.86-88  With the 
exception of the octosyl acid derivatives, the dual amino and carboxylate functionalities in 
these compounds arise from condensation of a nucleoside with glycine though the action 
of a serine hydroxymethyltransferase (SHMT) which functions as a pyridoxal 
monophosphate (PLP)-dependent aldolase.83  Octosyl acid-derived PNAs are generated 
from the condensation of uridine-5’-monophosphate and phosphoenol pyruvate, and then 
this product can be subject to tailoring reactions such as carbon atom elimination and 
transamination, albeit via poorly characterized mechanisms.13,14,16  Because the snv and 
smh gene clusters contain neither SHMTs nor enzymes indicative of the intermediacy of 
octosyl acid, we considered the role of the PKS enzymes encoded in these cluster. 
Intriguingly, the clusters are dominated by enzymes characteristic of polyketide 
natural product biosynthetic gene clusters, raising the possibility the branched core 
“saccharides” of amipurimycin and the miharamycins could be functionalized polyketide 
products.  However, there is no precedent for the formation of a sugar by a PKS per se, and 
the potential involvement of such an enzyme is complicated by the uncommonly simple 
architecture of the PKS enzymes in these clusters, as well as the branched  
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Figure 2.7: Known methods to install dual amino and carboxylic acid functionalities in 
PNAs and related natural products.   
 
structure of the saccharides, since, according to standard PKS logic, the nascent products 
of such a basic PKS system would be linear.7,8  Typically, type I PKS enzymes are very 
large and composed of several modules. Each module is minimally composed of 
ketosynthase (KS), acyltransferase (AT), and thiolation (T) domains, and each module is 
responsible for activating malonyl- or acetyl-CoA for the extension of a starter unit 
supplied by the initial or loading module and then the product of the preceding module by 
two carbon units.89-91  Although several mechanisms for PKS product release have been 
observed and proposed, the nascent polyketide chain is then typically released by a 
thioesterase (TE) domain usually found situated in the terminal module, and cyclization 
frequently ensues, generating a lactone product.92  Therefore, the length of a polyketide 
product can generally be predicted based on the number of modules composing the PKS.7,8  
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Following this biosynthetic logic and since the core saccharides of the 
miharamycins and amipurimycin are branched and contain nine carbon atoms, the PKS 
should contain at least a loading module, more than one extension module, and some means 
of branching.  Furthermore, because each extension module adds only two carbon atoms, 
an unusual three- or five-carbon starter unit would be necessary. However, as mentioned 
earlier, the PKS enzyme found in the miharamycins and amipurimycin biosynthetic gene 
clusters is composed of a single minimal module lacking a TE, and, in contrast to the PKSs 
involved in the biosynthesis of branched polyketides, no PKS branching domains or other 
previously described branching enzymes are present.93-96 Curiously, the smh and snv 
clusters each include a two-component transketolase encoded by Smh5a/5b and Snv3a/3b, 
respectively,  which could be utilized to effect branching as a post-PKS tailoring reaction.   
Some of these peculiarities can be reconciled by recent examples of deviations from 
standard PKS logic.97,98  Most importantly, it is now well-known that the co-linearity 
suggested by the multi-modular arrangement of PKS enzymes cannot be taken as a given.  
Frequently, one or more modules are used more than once in the generation of a linear 
polyketide.  This so-called “stuttering” activity is difficult to predict a priori and is usually 
only apparent upon inspection of the final product.7,8,99 Thus, it is not unreasonable to 
propose the PKS enzymes found in the SMH and SNV clusters are used iteratively.  
Although originally thought to be limited to fungi, iterative type I PKSs are also found in 
the biosynthetic gene clusters of several aromatic bacterial metabolites.  However, recently 
several examples of bacterial iterative PKSs involved in the biosynthesis of non-aromatic 
reduced metabolites were described.  Notably, the enediynes utilize an unusually composed 
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monomodular type I PKS lacking an obvious C domain to generate an octaketide precursor 
to their 9- or 10-membered aceytlenic “warhead” portions.98         
Also, while malonyl-CoA and acetyl-CoA are the most common PKS starter and 
extender units, the biosynthesis of polyketides can employ a wide spectrum of unusual 
“ketide” units.89,90  Hydroxymalonate and methoxymalonate are unique among the 
alternative ketide units as  PKS biosynthetic pathways that utilize these units include a 
biosynthetic subcluster of a conserved set of four genes to generate hydroxymalonyl-ACP 
or methoxymalonyl-ACP from 1,3-bisphosphoglycerate.100-102 
 
Figure 2.8: Methoxymalonyl-ACP/ hydroxymalonyl-ACP biosynthesis via the “Fkb” 
subcluster and occurrence of hydroxymalonate in zwittermicin. 
 
First found in the FK506 gene cluster, the so-called Fkb subcluster includes FkbH, 
which encodes an unusual phosphatase responsible for loading 1,3-bisphosphoglycerate 
onto a specific ACP encoded by FkbJ, and  FkbK and FkbI, which successively oxidize the 
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free primary alcohol to a carboxylic acid to give ACP-linked hydroxymalonate.  The cluster 
can also include an O-methyltransferase, FkbG, which methylates the secondary alcohol 
of hydroxymalonyl-ACP to yield methoxymalonyl-ACP.  A notable Fkb-like subcluster 
lacking an FkbG homolog is found in the zma gene cluster involved in the biosynthesis of 
zwittermicin.1,2   
Strikingly, the smh and snv clusters each have an Fkb subcluster found immediately 
downstream of the PKS-encoding gene, suggesting hydroxymalonyl-ACP may serve as a 
potential PKS starter and/ or extender unit.  The potential use of an uncommon starter unit 
is supported by the putative alternative didomain adenylation/ thiolase-type PKS loading 
module (Snv7 and Smh9) encoded immediately upstream of the PKS-encoding ORFs in 
each cluster.  These modules have been recognized to load “unusual” PKS starter units, 
and, in contrast to other types of loading modules, appear able accept free acid substrates.3 
The exact role  the monomodular PKS enzymes found in the snv and smh gene clusters 
play in the formation of these pyranoses remains to be established, but the substantial 
deviations from canonical PKS enzymology described above provide the basis for a 
biosynthetic model. 
2.3.2.1.2. PKS-centric Biosynthetic Model 
The presence of PKS enzymes in the snv and smh clusters can be rationalized by a 
biosynthetic model in which a rare three-carbon starter unit is iteratively elongated, and, as 
suggested by the Fkb cassettes in these gene clusters, one or more molecules of 
hydroxymalonyl-ACP are used in the biosynthesis of amipurimycin and the miharamycins.  
However, a key difference between the core saccharides of the miharamycins and 
amipurimycin is the C4’-hydroxyl in the former and its absence in the latter.  
Deoxygenation is a sugar modification that has been observed to require a PLP-dependent 
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aminotransferase-like enzyme, but no such enzymes are found in the snv and smh gene 
clusters besides the single branched-chain aminotransferase these clusters share.  
Alternatively, we propose that the miharamycins and amipurimycin share 
hydroxymalonate as a PKS starter unit, but the former are further composed of at least two 
additional hydroxymalonyl ketide units, whereas the latter is further composed of one 
additional hydroxymalonyl ketide unit and one malonyl ketide unit.   
 
 
Figure 2.9: PKS-centric model for the biosynthesis of the miharamycins and 
amipurimycin.  
Thus, biosynthesis of the miharamycins and amipurimycin commences when Smh9 
or Snv7 loads the starter unit to the KS domain of Smh10 or Snv8, respectively.  Because 
hydroxymalonate is produced as its ACP-thioester, its use by an adenylating PKS loading 
module would require some means to release the free acid from the ACP.  A suitable 
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hydrolase or thioesterase is not immediately obvious based on analyses of the snv and smh 
gene clusters’ content, but both clusters encode a small enzyme, Snv15 and Smh17, 
respectively, annotated as a “lysine decarboxylase.” by NCBI.  The basis for this predicted 
function is not clear because Snv15 and Smh17 are much smaller than authentic lysine 
decarboxylases.  However, these enzymes do have putative Rossmann motifs, indicating 
binding of a cofactor such as NAD(P)H, and may therefore possess latent function as 
oxidoreductases.   
Homologues of Snv15 and Smh17 have been implicated as molybdenum cofactor 
(MoCo) carrier proteins105 or as “Lonely Guy-1” (LOG-1) proteins involved in the 
maturation of cytokinin plant hormones.106,107  The function of Snv15 and Smh17 as MoCo 
loading proteins is doubtful given the absence of MoCo-utilizing enzymes in their 
respective clusters.  On the other hand, LOG-1 proteins putatively function as riboside 5’-
phosphoribohydrolases, hydrolyzing cytokinin nucleotides to yield mature cytokinin free 
bases and ribose 5’-monophosphate.  In the latter capacity, it is plausible Snv15 and Smh17 
could act to release hydroxymalonate from its ACP as shown in Figure 2.8, either 
hydrolytically or, in consideration of their predicted Rossmann motifs, perhaps as a 
reductase type of thioesterase.92  As is common for type I PKSs, Snv8 and Smh10 are 
expected to harbor pre-loaded T-domains.7  In the case of the miharamycins, the pre-loaded 
ketide unit is predicted to be hydroxymalonate, and to account for the C4-deoxy pyranose 
core of amipurimycin, as discussed earlier, we believe the T-domain of Snv 8 could be pre-
loaded with malonate. After the initial condensation, the five-carbon product is transferred 
back to the KS domain for one more round of elongation by another molecule of 
hydroxymalonate to yield a seven carbon linear triketide.  
The ensuing release and cyclization steps are unclear, since Smh10 and Snv8 lack 
a TE domain, and no stand-alone TE is encoded elsewhere in the clusters.  Furthermore, 
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no other means of product release, such as a PKS reductase or cyclase domains, can be 
readily identified in the smh and snv clusters,92 although it is possible this is a role fulfilled 
by the putative hydrolases Snv15 and Smh17.  In vitro experiments using cloned truncated 
PKS enzymes or individual modules demonstrate spontaneous cyclization and off-loading 
of nascent products is facile, but the full-length PKS enzymes they derive from usually rely 
on a distinct thioesterase, whether as a PKS domain or a stand-alone enzyme, for off-
loading and cyclization in vivo.8  Alternatively, while no pyran cyclase/ cyclase domains 
can be identified in Smh10 or Snv8, it could be argued that the product of the smh and snv 
PKSs are branched pyrans hydrolytically released.  Several mechanisms for pyran 
formation have been reported, and though the cyclization is effected through different 
modalities, the conserved mechanism is an oxa-1,4-conjugate addition that occurs on a 
PKS-tethered intermediate and requires an unsaturated substrate.93-96  The strongest 
argument against this possibility is the lack of a mechanism to desaturate the requisite 
substrate, such as a dehydratase or dehydratase PKS domain.   
However, both clusters encode methyltransferases downstream from their Fkb 
subclusters (Smh15 and Snv13) distinct from FkbG, and whose closest annotated homologs 
are each other.  The function of these enzymes is not clear because observation of the 
structures of amipurimycin and the miharamycins does not reveal evidence of methylation, 
but these methyltransferases could methylate the carboxylate of their respective free PKS 
products, encouraging cyclization.  There are no examples of this mechanism from PKS 
biosynthesis, but in biosynthesis of the capuramycins, methylation is used to activate a 
carboxylate for amide bond formation, resulting in expulsion of methanol.108,109 The 
possibility these methyltransferases function as unusual pyran forming cyclases cannot be 
ruled out at this point.  By analogy to other full-length PKS and NRPS pathways lacking 
an obvious means to off-load products,92 and in consideration of the above, we propose 
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cryptic product release and cyclization by one of at least three sequences (Figure 2.10): a) 
the triketide product is spontaneously tautomerized while still tethered to the PKS, enabling 
lactonization and product release; or b) the PKS-bound product is cyclized by a trans-
acting cylclase, leading to product release; or c.) the PKS product is hydrolytically released, 
and subsequent tautomerization enables spontaneous or enzyme-catalyzed lactonization.  
Importantly, tautomerization of the PKS product yields a carbonyl at C6 which is expected 
to be aminated by the BCAT homologs Snv2 and Smh1 to allow attachment of the amino 
acids found in amipurimycin and the miharamycins by their respective ATP-grasp ligases, 
Snv18 and Smh20. 
As mentioned earlier, the smh and snv clusters each encode a two component 
transketolase (Snv3a/3b and Smh5a/5b).  In light of the branched core saccharides of the 
miharamycins and amipurimycin, two roles for the transketolases can be envisioned: the 
transketolases could interact with the PKS enzymes to generate or load an unusual 
branched PKS extender unit; or the transketolases are responsible for the addition of the 
two carbon branch clearly observed in the structure of amipurimycin and, in cyclized form, 
probably the miharamycins.  The juxtaposition of PKS machinery and transketolases is 
apparently rare, as only two examples of the former case have been reported. 
In the first example, the two component transketolase Azi C5/C6 is putatively 
involved in the formation of a unique aziridine-containing amino acid in the biosynthetic 
pathway of azinomycin B, an NRPS-derived natural product.110  In the other example, the 
products of a conserved three-gene cassette including an unusual transketolase were shown 
to procure the precursor to a two-carbon branch found in the tetrahydroisoquinoline 
antibiotics quinocarcin (QNC cluster) and ecteinascidin 743 (NDM cluster).111  Similarly 
to Smh5a/b and Snv3a/b, the TPP-binding domain of the transketolases in these clusters is 
divided between NapB and NapD or Qnc N and QncL, but NapD and Qnc N feature an 
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additional C-terminal domain reminiscent of pyruvate dehydrogenase component E2.  
These transketolases were shown to transfer a two-carbon unit from ketose phosphates to 
the third products of the cassette, the ACPs Nap C and 
 
Figure 2.10: Hypothetical PKS release mechanisms in the biosynthesis of the 
miharamycins and amipurimycin. 
Qnc M.  Once acylated, Nap C and Qnc M interact with the respective NRPS machinery 
to deliver the two-carbon unit.  Given the lack of an E2 domain in the transketolases found 
in the snv and smh gene clusters, they are not expected to act on a PKS/ ACP-associated 
substrate.  
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Figure 2.11: Examples of thiamine-dependent enzymes in PKS biosynthetic pathways. 
As mentioned earlier, two-carbon branching is a well-known tailoring reaction in 
deoxy sugar biosynthetic pathways.112  The archetypical transketolase is found in the 
pentose phosphate pathway, where this TPP-dependent enzyme acts in the interconversion 
of ketose phosphates.  However, transketolase-like enzymes are found in the biosynthetic 
gene clusters of several natural products containing two-carbon branched deoxy sugars.83  
By analogy to the biosyntheses of hydroxyethyl-branched sugars, we predict Smh5a/b and 
Snv3a/b, the transketolases found in the snv and smh gene clusters, contribute a two-carbon 
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fragment to the core heterocycle of the miharamycins and amipurimycin, generating the 
branched nine-carbon scaffold of these compounds.  
 
 
Figure 2.12: Transketolase-mediated two-carbon branching and subsequent reduction in 
the biosynthesis of the miharamycins and amipurimycin compared to a similar pathway 
from yersiniose biosynthesis.  
Although these sugars usually feature α-oxoethyl or α-hydroxyethyl branches 
derived from pyruvate,83 we felt the 1,2-dihydroxyethyl branch could probably derive from 
a reduced glycoaldehyde shunted from primary metabolism.  The proposed reduction of 
the Snv3a/b or Smh5a/b-derived two-carbon branch has precedent in the biosynthesis of 
CDP-yersiniose in Yersinia pseudotuberculosis VI.113  As encountered in nature, yersiniose 
features a hydroxyethyl branch, yet the pyruvate-derived two-carbon unit installed by YerE 
features a carbonyl.  While the required reductase was not identified, the yersiniose 
biosynthetic gene cluster also encodes a putative short-chain dehydratase/reductase 
(SDR).113  This arrangement is mirrored in the snv and smh clusters, which contain the 
gluconate 5-reductase (SDR) homologues Snv14 and Smh16.  Thus, we predict the 
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installation of the two-carbon branch to be a tailoring step shared in the amipurimycin and 
miharamycins biosynthetic pathways.  After this branch is installed, the reductases Snv14 
or Smh16 may act to generate the observed 1,2-dihydroxyethyl appendage found in open-
chain form in amipurimycin and, likely, in closed-chain form in the miharamycins.  
2.3.2.1.3. Perhydrofuropyran Formation  
The bicyclic perhydrofuropyran core of the miharamycins is not well represented 
in natural products.  While octosyl acid16 and the structurally similar core saccharides of 
the ezomycins and malayamycin,114-116 which appear to be octosyl acid derivatives, are also 
perhydrofuropyrans, the ether oxygens of their structures are on opposite sides of the ring 
system, as opposed to the analogous oxygen atoms on the miharamycin core, which are 
found on the same side of the ring system, indicating a likely divergent biosynthetic 
pathway from octosyl acid and the like.  
Furthermore, the nucleobase of the octosyl acids is found attached to the furan ring, 
unlike the miharamycins, where the nucleobase is found on the pyran portion.  Indeed, only 
the biosynthesis of octosyl acid has been studied, and this compound was found to be 
derived from the condensation of phosphoenolpyruvate and uridine 5’-monophosphate by 
the action of a unique transferase.13,14,16,117  While not a PNA, the natural product SB-
219383 is a bicyclic iminosugar which bears some similarity to the core saccharide of the 
miharamycins, but its biosynthetic gene cluster has not been identified.118  
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Figure 2.13: Natural occurrence of the perhydrofuropyran structural motif and a similar 
[3.2.1] aza-bicycle. 
Early in our studies, we believed the perhydrofuropyran of the miharamycins could 
be formed similarly to octosyl acid, but the content of the newly identified smh gene cluster 
does not support this pathway.  Instead, it was assumed the unique bicyclic core saccharide 
of the miharamycins would be derived from cyclization of a dihydroxyethyl or 
glycoaldehyde branch installed at C3.  Our inspection of the smh cluster revealed two genes 
unique to this cluster, smh26 and smh27, which encode an L-fuculose phosphate class II 
aldolase and a ribokinase, respectively.  Considering that aldolases are capable of carbon-
carbon bond formation and scission,119,120 and phosphorylation can increase the 
nucleofugality of leaving groups,121 these enzymes are good candidates for the cyclization 
the two-carbon branch installed by the smh transketolase, and three hypothetical pathways 
were envisioned (Figure 2.14).   
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Figure 2.14: Hypothetical biosynthetic routes to the formation of the miharamycin A 
perhydrofuropyran.  
In the first route, the terminal alcohol of C9 is phosphorylated by Smh27, 
facilitating Smh26-mediated nucleophilic attack on C9 by the C2-OH, resulting in 
expulsion of phosphate and formation of the furan ring (Figure 2.14, red route).  In the 
second route, the C9 alcohol is also phosphorylated by Smh27, but then deprotonation at 
C8 eliminates phosphate and generates an electrophilic methylene which can be attacked 
 105 
by the C2-OH in an Smh26-mediated process, likewise generating the furan ring (Figure 
2.14, blue route).  This pathway is complicated by the anticipated high pKa of the C8 
protons, but in light of our proposal the methyltransferases Snv13 and Smh15 participate 
in the cyclization of the core triketide as unusual cyclases, this cyclization could require a 
third enzyme to fulfill a similar role.  Supporting this possibility, the smh cluster encodes 
a second methyltransferase that is not shared with the snv cluster, Smh21, which could 
deprotonate C8 to yield the methylene intermediate, and Smh26 catalyzes the nucleophilic 
attack on this intermediate by the C2-OH.  Finally, in the third hypothetical pathway, the 
glycoaldehyde branch could tautomerize to give an electrophilic alkene.  Then, Smh26 
mediates nucleophilic attack by the C2-OH on C8 (Figure 2.14, green route).  
Phosphorylation of the C9-OH by Smh27 could facilitate its elimination to yield a 
dihydrofuran, and then Smh16, the SDR, could reduce this intermediate to complete 
formation of the furan.      
2.3.2.2. Glycosylation/ Nucleobase Attachment 
If amipurimycin and the miharamycins are derived from a PKS, the nascent 
products of these enzymes would be lactones and, thus, incapable of glycosylation to yield 
nucleosides.  Intriguingly, the smh and snv clusters contain the myo-inositol 2-
dehydrogenases Smh4 and Snv1, respectively.  Myo-inositol 2-dehydrogenase acts 
physiologically to oxidize myo-inositol, generating 2,4,6/3,5-
pentahydroxycyclohexanone.122  The similarity between the cyclohexanone product of 
myo-inositol 2-dehydrogenase and the proposed PKS precursors of amipurimycin and the 
miharamycins led us to believe Snv1 and Smh4 reduce the nascent triketide lactones to 
yield the hexopyranoside-containing core saccharides of these PNAs, which would then be 
capable of glycosylation.    
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As mentioned earlier, the smh and snv clusters both contain a three gene cassette 
composed of a CGA-synthase-like glycosyltransferase, an aminoglycoside resistance 
kinase, and a flavoprotein.  While not always the case, the co-localization of these three 
genes in their respective clusters suggests they act in temporal proximity in the biosynthesis 
of amipurimycin and the miharamycins.  This assertion is supported by the overlapping 
start and stop codons of these cassettes, which would be expected to lead to their 
transcription as polycistronic mRNAs.123,124  Given the presence of the glycosyltransferase, 
we assumed these three genes are involved in the glycosylation of the core saccharides of 
the miharamycins and amipurimycin.  The cytosyl-PNAs all rely on NDP-activated sugars 
for glycosylation,9 but if the miharamycins and amipurimycin are PKS-derived, they would 
need to be activated.  Because the cytosyl-PNAs usually rely on UDP-glucuronic acid, a 
physiological sugar, these pathways have no need for the inclusion of “activating” enzymes 
such as NDP-transferases.  Supporting this logic, the biosynthetic gene cluster of amicetin, 
the one cytosyl-PNA not derived from UDP-glucuronic acid, includes a thymididyl 
transferase to activate its precursor, glucose-1-phosphate.82   
The snv and smh clusters lack NDP-transferases, so one possibility is the core 
saccharides are activated by NDP-transferases recruited from elsewhere.  However, the 
presence of the aminoglycoside resistance kinases Smh7 and Snv5 in close proximity to 
glycosyltransferases suggests these kinases play a role in the activation of a sugar substrate 
for glycosylation.  The “true” glycosyltransferases typically require activation of their 
substrates by a high-energy substituted phosphate, e.g., pyrophosphate, acyl phosphate, 
triphosphate, but some types of glycosyltransferases are known to utilize 
monophosphorylated sugar substrates.125 Thus, it is not unreasonable to suggest the kinases 
Snv5 and Smh7 phosphorylate the “anomeric” hydroxyls of the reduced amipurimycin and 
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miharamycins PKS-derived sugars to facilitate their attachment to 2-aminopurine or a 
precursor of this rare nucleobase. 
 
 
Figure 2.15: Myo-inositol 2-dehydrogenase reaction  compared to reduction of a nascent 
PKS-derived pyran; putative glycosylation reaction sequence.  
2.3.2.3. 2-aminopurine Biosynthesis 
The biosynthetic origin of the 2-aminopurine base is not clear, but as mentioned 
earlier, the lack of a nucleoside hydrolase found in the biosynthetic gene clusters of other 
cytosyl-PNAs indicates the base could originate from a free purine precursor.  Furthermore, 
neither the smh or snv clusters nor their genomes contain paralogous purine biosynthetic 
enzymes, a finding which does not support a parallel alternative de novo purine 
biosynthetic pathway.  On the other hand, it is possible 2-aminopurine is derived from a 
physiological base.  Purines lacking a C6 substituent are exceedingly rare in nature because 
the physiologically relevant purines are made from inosine, which has a C6 carbonyl.126 
One example of a naturally-occurring purine lacking a C6 substituent is nebularine, also 
known as purine ribonucleoside.13  This natural product is produced by the fungus Lepista 
nebularis and the bacteria Streptomyces yokosukanensis127 and Microbiospora sp. 
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SCC1779.128  While the detailed mechanism has yet to be established, isotope-labeled 
precursor feeding studies [8-14C]inosine, [8-14C]adenosine, and [8-3H]guanosine in S. 
yokosukanensis established adenosine as the precursor to nebularine, and that adenosine is 
incorporated without prior catabolism.  The reaction of adenosine with partially purified 
enzyme from S. yokosukanensis was found to produce nebularine with concomitant 
production of hydroxylamine.  Surprisingly, the partially purified protein seemed to contain 
no chromophoric cofactor, such as heme or a flavin, and the addition of exogenous 
cofactors or metal ions or EDTA had no effect on the production of nebularine.127   
The flavoprotein found in the smh and snv clusters in the glycosylation cassette, 
Smh8 and Snv6, respectively, is a predicted flavin-dependent oxidoreductase of unknown 
function.  The only common purine also featuring a C2-amino functional group is guanine, 
which makes it or one of its derivatives a reasonable hypothetical precursor to the unusual 
2-aminopurine base found in the miharamycins and amipurimycin.  As expected based on 
analyses using the NCBI Conserved Domain Database (CDD), Smh8 and Snv6 feature an 
extended Rossmann fold which is indicative of flavin or NAD(P)H binding.   
Surprisingly, although not detected by BLASTP homology or CDD analyses, Smh8 
and Snv6 also contain a derivative of the CXXCXXXC motif, which is indicative of iron-
sulfur cluster binding.129  If, indeed, 2-aminopurine is derived from guanine, the  
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Figure 2.16: The biosynthesis of nebularine juxtaposed on de novo purine biosynthesis. 
removal of the C6-carbonyl resembles the reverse reaction of xanthine oxidase.126  
However, these analyses alone provide no insight into the timing of the Smh8 or Snv6 
reaction, and further investigation is needed to characterize the function of these 
oxidoreductases.   
 
 
Figure 2.17: A hypothetical origin of 2-aminopurine from 5’-GMP. 
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2.3.2.4. Amino Acids 
Similarly to other hPNAs, the smh and snv clusters encode ATP-grasp ligases (Smh 
20 and Snv18) which can be reasonably assigned as the ligases attaching the pendant amino 
acids to their respective cores, as no other means of peptide bond formation can be found 
in the clusters.10,109  Because the amino acids found in the structures of the miharamycin A 
and amipurimycin are non-proteinogenic, it was predicted that the smh and snv  gene 
clusters would encode the enzymes necessary for their biosynthesis of their unique amino 
acids.  This prediction seems to hold true for the cispentacin biosynthetic genes.   
Flanking the core set of genes shared with the smh cluster, the snv cluster includes 
a set of genes, snvA-H, encoding a full set of close homologues of enzymes comprising 
the highly conserved type II PKS biosynthetic pathway of 2-carboxy-2-cyclopentanone 
(CPC), a precursor of coronafacic acid in the biosynthesis of coronatine.74,130  Coronafacic 
acid is a virulence factor produced by several pathovars of Pseudomonas syringae, but the 
coronatine biosynthetic gene cluster from Pseudomonas syringae glycinea PG4180 is the 
most extensively studied.74,76  Recently, a coronafacic acid-like biosynthetic gene cluster 
was also identified in Streptomyces scabies, the causative agent of common potato scab.131   
Coronafacic acid is composed of the unusual amino acid coronamic acid and coronafacic 
acid, a polyketide.74,76,130  The dissociated PKS system composed of Cfa1-5 generates CPC, 
which serves as a starter unit for the multi-modular type I PKS system comprised of Cfa6 
and Cfa7.  While the biosynthesis of coronafacic acid has been investigated starting from 
CPC, very little work has been done regarding the biosynthesis of CPC itself.76   
On the basis of labeled precursor feeding studies, 2-ketoglutarate semialdehyde is proposed 
to contribute four of the six carbon atoms of CPC, and malonate provides the remaining 
two carbon atoms.  Interestingly, it is believed α-ketoglutarate semialdehyde originates 
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from primary metabolism or at least from an enzyme outside of the coronatine biosynthetic 
gene cluster, since no decarboxylase was identified in the cluster.74   
 
 
Figure 2.18: Proposed biosynthetic pathway with hypothetical route to cispentacin. 
The biosynthesis of CPC begins with the conversion of 2-ketoglutarate semialdehyde into 
succinic semialdehyde CoA thioester by Cfa5, a fatty acid-CoA ligase, resulting in the loss 
of one equivalent of carbon dioxide.  This activated substrate is then condensed with 
Cfa1(ACP)-linked malonate by the ketosynthase Cfa3.  The resultant linear Cfa1-bound 
product is then proposed to undergo a Diekmann cyclization catalyzed by Cfa4.  Cfa4 was 
originally assigned as the requisite cyclase even though its product has no homology to 
known cyclases because no other cyclase could be identified.  Finally, the cyclized product 
is dehydrated by Cfa2, a dehydratase, yielding CPC.74  This pathway is summarized in 
Figure 14, which includes the homologs found in the snv cluster. ACP-linked CPC is then 
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shuttled to Cfa6 for further elaboration into coronafacic acid.  Interestingly, hypothetical 
reduction and transamination of CPC would yield cispentacin.  In support of this 
hypothesis, the snv CPC sub-cluster was found to encode an enoyl reductase, SnvA, and 
an L-ornithine aminotransferase homolog, SnvC, enzymes not found in other identified 
CPC clusters.  In addition, a unique thioesterase (SnvD) is included in the subcluster.  
Therefore, SnvA may represent the entry point to the cispentacin biosynthetic pathway, the 
reduced CPC can be transaminated by SnvC, and then cispentacin is released from its ACP 
by SnvD. 
The biosynthesis of the N5-hydroxyarginine found in the structure of miharamycin 
A is not as straightforward.  Though the hydroxylated guanidine resembles a key 
intermediate in the reaction of nitric oxide synthase,132 no nitric oxide synthases or similar 
enzymes could be clearly identified in the smh cluster.  However, N5-hydroxyarginine was 
also recently found as a component of argolaphos, a phosphonate natural product produced 
by Streptomyces monomycini NRRL B-24309.3  Surprisingly, the reported argolaphos 
biosynthetic gene cluster encodes a homologue of Smh24, and these proteins are predicted 
YqcI/YcgG homoloues.  Two lines of evidence suggest these enzymes may play a role in 
the biosynthesis of N5-hydroxyarginine.  First, our analysis using the RAST server suggests 
YqcI/YcgG is a conserved enzyme found in several species of Bacillus, and two different 
species of Bacillus have been reported to produce N5-hydroxyarginine.31,32  Secondly, our 
bioinformatic analysis of Bacillus strains in the RAST database shows YqcI/YcgG lies in 
a three gene cassette also containing an amino acid permease and an arginine deiminase 
shared between Oceanobacillus iheyensis HTE831 and Bacillus B-14905, Bacillus 
vietnamensis, and many other species of Bacillus.  The O. iheyensis HTE831 cluster also 
includes a homolog of LysE, an efflux protein for basic amino acids, and Bacillus cereus 
VD131 and Bacillus anthracis have YqcI/YcgG homologs adjacent to a LysE homolog (B. 
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anthracis has two sets at different genomic loci).  Although Smh24 lacks recognizable 
cofactor binding motifs, it may be an unusual monooxygenase.  Furthermore, the weak 
homology between Agp12 and Smh24 (24.7% similarity, 17.7% identity) may reflect the 
structural dissimilarity between argolaphos and miharamycin A, suggesting the 
modification of arginine occurs after arginine is incorporated into these compounds. 
2.3.2.4. A Paradigm of Novel PNAs? 
The PKS machinery encoded in the smh and snv clusters is not found in any other 
known PNA gene clusters, but through the course of analysis, four additional highly similar 
putative biosynthetic gene clusters were identified in unannotated data in the NCBI 
database in the organisms Streptomyces sp. S-1868 (ses cluster), Streptomyces varsoviensis 
NRRL B-3589 (svs cluster), Streptomyces canus str. 299MFChir4.1 (sca cluster), and 
Actinoplanes sp. N902-109 (apn cluster).  The products of these four “orphan” gene 
clusters are not known, but because they all share the same major subparts of the snv and 
smh clusters, we speculate these products are structurally similar.   
The most surprising aspect of these clusters is their modularity and synteny, which 
suggests they are capable of producing compounds similar to amipurimycin and the 
miharmycins.  Specifically, these clusters feature close homologues of the PKS and loading 
modules found in the snv and smh gene clusters, and three of the four gene clusters have 
an intact Fkb subcluster. 
Interestingly, these clusters all have homologues of the smh and snv 
methyltransferases of unknown function, which indicates they play an important role in the 
biosynthesis of amipurimycin- and miharamycins-like compounds.   The S.  
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Figure 2.19: Organization of putative amipurimycin/ miharamycins-like PNA gene 
clusters 
varsoviensis cluster appears to be the most divergent cluster. While it seems to have the 
core components shared by the other clusters, like the transketolase and Fkb subcluster, the 
monomodular PKS is fused with the putative loading module observed in the other clusters, 
and this locus also has a partial queosine cluster composed of QueC-E and GTP 
cyclohydrolase I homologs.  Interestingly, the cluster lacks the branched-chain 
aminotransferase found in the other five clusters.  Unlike the amino acid portion of 
amipurimycin, the probable product may have an α-hydroxy acid moiety instead of the 
amino acid-like portion of amipurimycin and the miharamycins.  This is supported by the 
lack of an ATP-grasp ligase in the cluster.  The divergent modular PKS subclusters seem 
to produce two different saturated fatty acids, which could be appended to the alpha-
hydroxyl group.  In all, the S. varsoviensis cluster may be capable of producing several 
products. 
Streptomyces sp. NRRL S-1868
(29140 bp)
Actinoplanes sp. N902-109 
(35471 bp)
Streptomyces varsoviensis
(87261 bp)
Streptomyces canus
(21106 bp)
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2.4. CONCLUSIONS 
Sequencing of the S. miharaensis and S. novoguineensis genomes and comparative 
genomic analysis afforded identification of the putative miharamycins and amipurimycin 
biosynthetic gene clusters, smh and snv, respectively.  The content of these clusters is 
remarkably conserved between the two producing organisms.  Unexpectedly, the clusters 
contain enzymes typically associated with the biosynthesis of PKS-derived natural 
products.  It is tantalizing to implicate this PKS machinery in the biosyntheses of the 
miharamycins and amipurimycin, but there is no precedent for such a pathway in the 
biosynthesis of carbohydrates. Additionally, the possibility these compounds are derived 
from enzymes typical of polyketide biosynthesis holds promise for the greater 
understanding of the versatility of PKS enzymology.  Nevertheless, the data enabled the 
creation of a reasonable biosynthetic model, laying the groundwork for further 
investigation into the biosyntheses of these unusual PNAs.  Finally, the smh and snv 
clusters may potentially be paradigmatic of a new class of PKS-derived carbohydrates, as 
four highly conserved gene clusters in four distinct bacterial species were newly identified.  
Several issues remain to be explored regarding the biosynthesis of amipurimycin and the 
miharamycins, but given the rarity of these compounds and their components, it is expected 
they will continue to fuel both future synthetic efforts and chemical biology studies. 
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Chapter 3: Initial Characterization of Amipurimycin and 
Miharamycins Biosynthesis 
 
3.1. INTRODUCTION 
In the last chapter, the putative miharamycins and amipurimycin biosynthetic gene 
clusters, smh and snv, from the genomes of Streptomyces miharaensis and Streptomyces 
novoguineensis, respectively, were identified through a bioinformatics approach.  As is 
typical for the majority of natural product biosynthesis studies lately,1-3 the obtainment of 
the smh and snv gene clusters preceded the collection of any significant biochemical data 
regarding the biosyntheses of the miharamycins and ampurimycins. To guide our 
investigations into the functions of the smh and snv clusters, we turned to the literature 
regarding the biosynthesis of peptidyl nucleoside antibiotics (PNAs). 
While the miharamycins and amipurimycin are PNAs, they are best considered as 
part of a smaller subset of PNAs, the hexopyranosyl PNAs (hPNAs).  The hPNAs are built 
upon a pyran-containing core saccharide resembling a hexose, and, based on the 
classification scheme presented in Chapter 1, the known hPNAs generally belong to the 
“intact” group of PNAs whose core saccharides derived from an intact sugar other than 
ribose which is not lengthened by the addition of any more carbon atoms.  The hPNAs 
whose biosynthetic gene clusters had been sequenced include the cytosyl nucleosides 
blasticidin S,4 mildiomycin,5 arginomycin,6 gougerotin,7 and amicetin.8  As discussed 
earlier, these compounds result from the condensation UDP-glucuronic acid and cytosine; 
with the exception of amicetin, which results from the condensation of a deoxysugar, TDP-
amicetose, and cytosine.  Thus, besides a glycosyltransferase to mediate this condensation, 
the gene clusters also include a nucleoside hydrolase to provide free cytosine.8,9  
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Figure 3.1: Structures of hexopyranosyl peptidyl nucleoside antibiotics. 
 
Superficially, the miharamycins and amipurimycin seem to be members of hPNA, 
likely utilizing an intact-type biosynthetic route.  However, as presented in Chapter 2, the 
content of the smh and snv clusters belies these designations.  While the absence of the 
hydrolase is not too surprising considering the miharamycins and amipurimycin are not 
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cytosyl nucleosides, the lack of homologs of the glycosyltransferases in their putative gene 
clusters was unexpected.   
 
 
Figure 3.2:  Overview of hexopyranosyl nucleoside formation pathways 
Furthermore, unlike any of the hPNA gene clusters—or of any PNA gene clusters 
identified to date7,10—the smh and snv clusters are dominated by a type I polyketide 
synthease (PKS) as well as subclusters required for the biosynthesis of hydroxymalonate-
based PKS extender units.  These findings, along with the absence of enzymes involved in 
deoxy sugar biosynthesis, cast doubt on the involvement of these clusters in the 
biosynthesis of the miharamycins and amipurimycin.  In this chapter, protocols for the 
production and isolation of miharamycins and amipurimycin as well as evidence for the 
involvement of the snv cluster in the production of amipurimycin are presented, and the 
results of initial attempts to observe the function of Snv4 and Snv6 are detailed.    
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Figure 3.3:  Organization of the snv and smh gene clusters. 
3.2. MATERIALS AND METHODS 
3.2.1. General 
All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
or Fisher Scientific (Pittsburg, PA) and used without further purification unless otherwise 
noted.  Laboratory disposables such as microcentrifuge tubes, petri dishes, and conical 
tubes were obtained from Fisher Scientific or VWR (Radnor, PA).  With exceptions as 
noted, E. coli cloning and culture techniques as well as techniques relating to the 
manipulation of recombinant DNA were performed according to standard protocols.11  
Similarly, all Streptomyces manipulation methods and fermentations were performed 
according to standard protocols unless otherwise noted.12  Restriction endonucleases 
(REN), T4 DNA ligase kit, and calf intestinal alkaline phosphatase (CIAP) were obtained 
from New England Biolabs (NEB) (Ipswich, MA), E. coli DH5α was obtained from 
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Bethesda Research Laboratories (Bethesda, MD), E. coli S17-1 ATCC 47055 was acquired 
from American Type and Culture Collection (Manassas, VA), and E. coli XL-1 Blue MRF’ 
and E. coli BL21-Gold(DE3) were purchased from Stratagene (now Agilent, Santa Clara, 
CA).  Sequencing vector pCRBlunt and 1 KB Plus DNA Ladder were products of 
Invitrogen (Carlsbad, CA).  pET28b(+) vector DNA was obtained from Novagen 
(Madison, WI).  EconoSpin® Mini Spin columns and buffers from Epoch Life Science 
(Sugar Land, TX) were used for mini-scale DNA isolation, DNA gel extraction, and PCR/ 
REN digestion reaction clean-up procedures according to the QIAgen Miniprep Handbook, 
Fourth Edition.13  DNeasy Blood and Tissue kits and Ni-NTA resin were from QIAgen 
(Valencia, CA).  All reagents and apparatus for SDS-PAGE were obtained from Bio-Rad 
(Hercules, CA). 
3.2.2. Growth and Production of Compounds and Feeding 
Streptomyces miharaensis Niida ATCC 19440 was obtained from American Type 
and Tissue Culture (Manassas, VA), and Streptomyces novoguineensis Iwasa CBS 199.78 
was obtained from the CBS-KNAW Fungal Biodiversity Centre (Utrecht, The 
Netherlands).  Both strains were maintained as described in Chapter 2.  For the production 
of amipurimycin and miharamycins, 10 mL cultures of sterile seed medium (pH 7.0),14 
composed of 2% glucose, 1% Bacto® peptone from BD (Franklin Lakes, NJ) or peptone 
from Fisher Scientific, 0.5% meat extract from BD, 0.5% NaCl, and deionized (DI) H2O, 
in capped test tubes (25 x 150 mm) containing glass beads were inoculated with 0.2 mL 
mycelial suspension of either S. miharaensis or S. novoguineensis, and these cultures were 
grown at 28 °C with rotary shaking at 220 RPM in an Innova® 4200 Incubator-Shaker from 
New Brunswick Scientific (Edison, NJ) or a MaxQ® 6000 Incubator-Shaker from Thermo 
Scientific (Waltham, MA) for 2-3 days.  Then, 1 mL of seed culture was used to inoculate 
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50 mL of sterile production medium,15 composed of 4% sucrose, 3% soybean meal from 
Callahan’s General Store (Austin, TX) or Choripdong® soybean flour (plain or roasted 
type, as available) from Seoul Trading, Inc. (Englewood, NJ), 2% Bacto® malt extract from 
BD or AMRESCO® malt extract from VWR, 0.6% NaCl, and DI H2O, sterilized by 
autoclave in a 1 L baffled flask covered with two milk filter discs from KenAG (Ashland, 
OH).  This culture was grown for 4-5 days at 28 °C, with rotary shaking at 220 RPM, in 
the same incubator used for the seed cultures.  Culture conditions were designed to 
approximate the effects of sparged oxygen.16,17  
For culture feeding studies, 2-day-old production cultures were aseptically 
supplemented at 2 mM or other concentrations as needed using 0.2 µm-filter sterilized 
(cellulose acetate syringe filter from VWR) concentrated additive stock solutions and 
allowed to grow as before for an additional 2-3 days.  The stocks were made fresh 
immediately before use.  Additives were obtained from Sigma-Aldrich and included: L-
arginine, L-ornithine, L-lysine, L-norleucine, 2-aminopurine, guanine, guanosine, 5’-
guanosine monophosphate, 2-deoxy 5’-guanosine monophosphate, adenine, adenosine, 
thiamine, O-(carboxymethyl)-hydroxylamine, 6-diazo-5-oxo-L-norleucine, 1-
aminobenzotriazole, and oxythiamine. 
3.2.3. Isolation of Compounds 
The protocol for isolation of miharamycins was based on published protocols for 
its isolation14,15 and incorporated some elements from protocol for the isolation of 
nebularine.18 Production cultures of S. miharaensis were harvested after 4-5 days of growth 
by transferring the culture medium into a sterile 50 mL conical tube from VWR and 
centrifugation at 5,000 x g in an Avanti® J-E centrifuge and JS-5.3 swinging bucket rotor 
from Beckman Coulter (Brea, CA) for 20 min at 4 °C.  The supernatant was transferred to 
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a new sterile 50 mL conical tube containing 6 g pre-swollen Dowex® (H+ form) MAC3 
resin from Sigma-Aldrich, and this tube was spun in a Tube Rotator 60448 from Scientific 
Equipment Products (Aston, PA) at 4 °C overnight.  Then, the supernatant was poured off, 
and the resin was rinsed with copious DI H2O.  The resin was transferred to a 500 mL 
Erlenmeyer flask containing a magnetic stir bar, and 100 mL 0.5 N aqueous HCl were 
added.  The resin was stirred in HCl on a magnetic stir plate overnight at 4 °C, and then 
the supernatant was collected and adjusted to pH 3.0-4.0 using NaOH.  The pH-adjusted 
extract was then stirred with 0.5 g DARCO® -100 mesh activated charcoal powder from 
Sigma-Aldrich at 4 °C overnight.  The charcoal was collected by centrifugation at 5,000 x 
g in a sterile 50 mL conical tube and rinsed three times with DI H2O.  The charcoal pellet 
was then extracted with 50% aqueous acetone by stirring in a 500 mL Erlenmeyer flask at 
4 °C overnight.  The charcoal slurry was then filtered through a pad of Celite® 545 from 
Sigma-Aldrich in a sintered glass fritted funnel under vacuum.  The filtrate was 
concentrated to dryness by rotary evaporation under reduced pressure in an R-114 Rotary 
Evaporator from Büchi Labortechnik AG (Flawil, Switzerland).  The resultant residue was 
dissolved in <10 mL DI H2O and lyophilized in a sterile 50 mL conical tube.  The crude 
powder was dissolved in 1 mL DI H2O for immediate use or stored at -80 °C until later 
use. 
A “mini” scale isolation procedure was also developed to isolate miharamycins.  To 
do so, 0.5 mL production culture supernatant was vortexed with 60 mg moist Dowex® 
MAC3 resin (H+ form) in a 1.65 mL microcentrifuge tube from VWR, and then the 
supernatant was discarded.  The resin was vortexed twice with 1 mL DI H2O, and then 
washed by vortexing with 1 mL 0.5 N HCl.  The acidic eluate was transferred to a new 
microcentrifuge tube containing 10 mg activated charcoal.  After vortexing, the supernatant 
was removed by centrifugation in a 5415R tabletop microcentrifuge from Eppendorf 
 134 
(Hamburg, Germany).  The charcoal pellet was washed twice with 1 mL DI H2O by 
vortexing and centrifugation, and then the pellet was eluted with 1 mL 50% aqueous 
acetone by vortexing.  The supernatant was collected in a new microcentrifuge tube and 
evaporated to dryness at ~55 °C using a SpeedVac® SC-100 from Savant (now Thermo 
Scientific).  The residues were then stored at -80 °C until use. 
Alternatively, miharamycins could be collected though open column 
chromatography with Dowex® MAC3 resin (6 g per 50 mL original culture volume) using 
isocratic elution with 0.5 N aqueous HCl.  Miharamycin-containing fractions were detected 
with the Sakaguchi reaction which was performed as published before,19,20 except 30% 
NaOH was used to obviate the need for neutralizing column fractions.  Briefly, a 10 µL 
sample was first mixed with 2 µL ice cold 30% NaOH, then 2 µL ice cold 0.02% ethanolic 
α-naphthol were added, and the sample was mixed well by trituration.  Color development 
was accomplished by the addition of 1 µL ice cold 0.2% sodium hypobromite in 5% NaOH.  
The appearance of an intense red or pink color indicated a positive reaction.  The pooled 
fractions were then neutralized with NaOH and lyophilized in a 50 mL conical tube.  The 
resultant residue was dissolved in 1 mL DI H2O and further purified using an Oasis MCX 
1 mL SPE cartridge from Waters (Milford, MA) as follows.  After conditioning the column 
with 1 mL each of MeOH and DI H2O by gravity flow, 1 mL sample composed of 0.5 mL 
lyophilate and 0.5 mL 3.4% H3PO4 was applied to the column.  Then, the column was 
rinsed with 1 mL each of 0.1 N HCl and MeOH, and it was eluted with 5% NH4OH in 
MeOH. 
For the isolation of amipurimycin, the culture supernatant was collected as for the 
miharamycins and transferred to a new 50 mL conical tube containing 0.5 g activated 
charcoal.  This tube was spun in a Tube Rotator 60448 from Scientific Equipment 
Company (Aston, PA) overnight at 4 °C.  Then, the charcoal was collected, rinsed, and 
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eluted as for the miharamycins.  The elution was also concentrated, lyophilized, and stored 
as for the miharamycins. 
3.2.4. HPLC Analysis of Culture Extracts 
Extracts from cultures of S. miharaensis or S. novoguineensis were analyzed by 
HPLC using a Beckman Coulter System Gold® 125 Solvent Module and 166 UV Detector 
Module with 32 Karat HPLC Workstation Software from Beckman Coulter at ambient 
temperature and 314 nm or 223 nm.  The samples were chromatographed on a Microsorb® 
MV 100-5 (250 x 4.6 mm) C18 column from Varian (now Agilent) or ChromSep cartridge 
system with a Microsorb® MV 100-5 (250 x 4.6 mm) C18 cartridge and ChromSep C18 
guard column (10 x 3 mm) by Varian from Agilent (Santa Clara, CA) as well as a Zorbax 
ODS 5 µm semi-preparative column (9.4 x 250 mm) from Agilent.  Prior to analysis, 
samples were filtered through a 0.2 µm syringe filter.  The binary mobile phase was 
composed of 0.1% (v/v) trifluoroacetic acid (TFA) from Chem-Impex International, Inc. 
(Wood Dale, IL) in DI H2O (solvent A) and 0.095% (v/v) TFA in acetonitrile (solvent B).  
Solvents were filtered through a 0.2 µm cellulose acetate filter (solvent A) or a PTFE 0.2 
µm filter (solvent B) from EMDMillipore (Billerica, MA) prior to the addition of TFA.  
The elution program began with 0% solvent B and was carried out with a flow rate of 1 
mL/min for analytical scale or 3 mL/min for semi-preparative scale as follows: at 5 minutes 
solvent B was increased to 2.5% over 2.5 min, at 15 min solvent B was increased to 5% 
over 2.5 min, then at 25 minute solvent B was increased to 100% over 3 min to flush the 
column, and then at 30 min solvent B was decreased to 0% over 3 minutes, and the column 
was re-equilibrated at 0% solvent B for 15 min.  Detection of the miharamycins was first 
accomplished by comparison with an authentic standard of 70:30 miharamycin A:B 
mixture, a kind gift provided by Dr. Makoto Ohyama and Dr. Masato Tani of Meiji Seika 
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Kaisha, Ltd. (Tokyo, Japan).  Mass spectrometry was carried out at the Mass Spectrometry 
and Proteomics Facility of the Department of Chemistry and Biochemistry at the 
University of Texas at Austin, Austin, TX.   
3.2.5. Bioassay to Detect Production of Miharamycins 
A disc-diffusion bioassay to detect production of the miharamycins was developed 
based on the published protocols.14,15,21  A loopful of Pseudomonas aeruginosa PA01 
glycerol stock, a kind gift from the laboratory of Dr. Marvin Whiteley of the University of 
Texas at Austin, was streaked on LB agar and grown overnight at 37 °C.  The next day, a 
sterile toothpick was used to pick a single colony of P. aeruginosa and inoculate a 10 mL 
culture of LB broth in a sterile 50 mL conical tube.  This culture was grown overnight in a 
shaking water bath at 220 RPM and 37 °C.  The next day, this culture was used to inoculate 
the sterile, molten assay medium, composed of 0.5% dextrose, 0.5% peptone, 1.5% agar, 
and DI H2O (pH 7.0 prior to sterilization), at a 1:1000 ratio.  After mixing well, 20-25 mL 
plates were made.  After drying, sterile 9 mm Whatman® antibiotic assay discs from Sigma-
Aldrich were aseptically applied to the surface of the plates using flamed forceps.  Culture 
extracts were then applied to the discs, and after drying, the plates were incubated at 37 °C 
overnight.  Zones of inhibition were measured as the width between the edge of the disc 
and the edge of the cleared zone on one side of the disc. 
3.2.6. Quantification of Miharamycins Production Following Putative Precursor Feeding 
Estimation of miharamycins concentration in production medium were made using 
a 2-aminopurine standard curve.  A stock solution of 5 mg/mL 2-aminopurine nitrate salt 
from Sigma-Aldrich was made in DI H2O, and serial dilutions were made in DI H2O.  
Aliquots of serial dilutions were analyzed by HPLC using the same elution methods and 
 137 
apparatus as used for analysis of culture extracts, and peak area integration was performed 
using 32 Karat HPLC Workstation Software.   
 
 
Figure 3.4:  2-amino purine standard curve 
Production cultures of S. miharaensis were prepared and grown as described and fed after 
two days of growth with 5’-guanosine monophosphate (3 mM), L-ornithine (3 mM), or 5’-
guanosine monophosphate and L-ornithine (3 mM each).  Culture samples of 0.5 mL were 
aseptically collected at roughly 24 h time intervals for 150 h, and these samples were 
extracted using the mini-scale protocol described earlier.  The residues were dissolved in 
0.5 mL DI H2O and analyzed by HPLC as described earlier.  The peak areas corresponding 
to miharamycin A and miharamycin B were integrated as described for the 2-aminopurine 
standard curve. 
3.2.7. Interruption of Snv8 
The internal 999 base-pair (bp) fragment of snv8 (“snv8Int”) was amplified using 
genomic DNA isolated from S. novoguineensis as described in Chapter 2 with the 
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following oligonucleotide primers obtained from Sigma-Aldrich: snv8IntFwd: 5'-
TCTAGAGGGCGGGCTCGGACACCTG-3' and snv8IntRev: 5'-
AAGCTTGCGAGCACACCG AGCATG -3'.  These oligonucleotides have engineered 
XbaI and HindIII restriction endonuclease (REN) sites (underlined sequences), 
respectively.  Polymerase chain reaction (PCR) was carried out with KOD HotStart® 
Polymerase from EMDMillipore (Billerica, MA) according to the manufacturer’s 
instructions and using thin-walled PCR tubes.  A Thermocycler Gradient® from Eppendorf 
was used and activation of the polymerase was accomplished with a 2 min incubation at 
95 °C, and then 31 cycles composed of sequential incubations at 95 °C for 20 sec, the 
lowest melting temperature of the primer pair  for 10 sec, and then 70 °C for 10 sec/kbp 
length of DNA target.  A final annealing was carried out at 70 °C for 10 min.  The PCR 
product was purified by agarose gel electrophoresis, and the gel-purified DNA was cloned 
into pCRBlunt vector using E. coli DH5α with T4 DNA ligase.  The recombinant plasmids 
were sequenced at the Core Facilities of the Institute for Cell and Molecular Biology at the 
University of Texas at Austin.  Correctly sequenced plasmid DNA was digested with XbaI 
and HindIII, and the desired DNA product was isolated through agarose gel 
electrophoresis.  The fragment was ligated into pKC1139,22 a kind gift from Dr. Leonard 
Katz (formerly of KOSAN Biosciences, Hayward, CA), digested with the same REN to 
yield plasmid pKCsnv8Int.  Plasmid pKCsnv8Int was then transformed into chemically 
competent E. coli S17-123 for conjugal transfer to S. novoguineensis following a method 
derived from published protocols.12,22,24 
To prepare S. novoguineensis for conjugation, 1 mL of 2-3 day old culture in seed 
medium was spread on a mannitol soya plate, and this plate was incubated at 30 °C for 1 
week to grow a well-sporulated, confluent lawn.  A single colony of E. coli S17-1 
containing pKCsnv8Int was used to make a 5 mL culture in LB broth supplemented with 
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50 µg/mL apramycin in a sterile 50 mL conical tube, and this culture was grown at 37 °C 
overnight.  S. novoguineensis spores were scraped from a confluent sporulating lawn using 
a flamed inoculating loop and deposited in 1 mL sterile LB in a sterile 1.65 mL 
microcentrifuge tube.  This spore suspension was thoroughly vortexed and then incubated 
at 50 °C for 10-15 min.  An aliquot of 1 mL of E. coli S17-1 culture containing plasmid 
pKCsnv8Int was centrifuged in a tabletop centrifuge at 10,000 x g for 1 min, and after 
removing the supernatant, 1 mL sterile LB was added to the pellet, and the pellet was gently 
resuspended.  This suspension was rinsed once more and then resuspended in 1 mL sterile 
LB.  An aliquot of 50 µL of the rinsed, resuspended E. coli culture were added to 1 mL of 
the S. novoguineensis spore solution, and this mixture was thoroughly vortexed.  For each 
replicate conjugation experiment, 200 µL of the mixture were spread on a dehydrated 
mannitol soya plate supplemented with 10 mM MgCl2, and the plate was stored at room 
temperature overnight.  Each plate was overlaid with 2 mL sterile soft R2 agar25 containing 
2.5 mg apramycin and 1.25 mg nalidixic acid, and after the overlay solidified, the plates 
were incubated at room temperature until sporulating colonies appeared (~1 week).  Each 
colony was transferred to a fresh mannitol soya plate containing 100 µg/mL apramycin and 
50 µg/mL nalidixic acid, and the plates were incubated at 40 °C.  Two more spore-to-spore 
transfers were performed using mannitol soya plates containing 100 µg/mL apramycin and 
with incubation at 40 °C. 
To verify interruption of snv8 and assay ability of the exconjugants to produce 
amipurimycin, a loopful of spores of an exconjugant strain were streaked on a mannitol 
soya plate containing 100 µg/mL apramycin, and this plate was incubate at 40 °C for 2-3 
days.  Then, culture tubes containing 10 mL seed medium as described earlier 
supplemented with 100 µg/mL apramycin were inoculated with a single sporulating 
exconjugant colony.  After growth as before at 30 °C, 1 mL of each culture was used for 
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isolation of genomic DNA using the DNeasy Blood and Tissue kit from QIAgen as 
described in Chapter 2, and 1 mL of each culture was used to inoculate 50 mL production 
medium as described earlier supplemented with 2 mM thiamine as described earlier and 
100 µg/mL apramycin.  These cultures were grown and extracted as before.  The remaining 
seed culture volume was used to prepare frozen glycerol stocks as described in Chapter 2. 
PCR analysis of the exconjugant genomic DNA was performed as described earlier 
using the oligonucleotides as primers, snv8Fd: 5'-
TCTAGAATGTACGAGTTCGACCACG-3' and snv8Rv: 5'-
AAGCTTTCATGACGCTGGGCTC-3' according to the KOD HostStart® polymerase 
manual with an annealing temperature of 60 °C and an extension time of 60 sec. 
3.2.8. Cosmid Library Construction 
For the isolation of genomic DNA for S. novoguineensis cosmid library 
preparation, a 0.3 mL portion of 2-3 day old culture grown in seed medium as described 
above was used to inoculate 100 mL of sterile seed medium supplemented with 0.5 % 
glycine.  This culture was grown in a 1 L baffled flask at 30 °C with rotary shaking at 220 
RPM for an additional 2-3 days.  The culture was harvested in sterile 50 mL conical tubes 
by centrifugation at 5,000 x g for 20 min as described earlier.  After removing the 
supernatants, the cell pellets were aseptically resuspended in sterile 10.3% sucrose and 
centrifuged again.  Once more, the supernatants were removed, and the pellets were 
resuspended in 10.3% sucrose.  After removing the supernatant, the pellets were stored at 
-80 °C until use.  Genomic DNA was isolated by phenol:chloroform:isoamyl alcohol 
extraction and isopropanol precipitation according to standard protocols.11,12 
S. novoguineensis genomic DNA isolated as described above was digested with 
Sau3AI under the following conditions: 50 µL DNA, 50 µL NEB buffer 4, 5 µL 100x NEB 
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BSA solution, and 387 µL water.  The reaction was initiated by the addition of 8 µL 
Sau3AI, and after gently vortexing, the reaction was incubated at 37 °C.  Aliquots of 100 
µL were taken every 60 sec and quenched by the addition of 20 µL 6x DNA loading buffer.  
These samples were electrophoresed on a 0.8% agarose gel to gauge the reaction progress 
and extent of digestion; 2-3 min reaction time was deemed optimal.  The digestion reaction 
was repeated and quenched at 2-3 min using 0.5 mL phenol:chloroform:isoamyl alcohol 
(25:24:1) saturated with 10 mM Tris, pH 8.0 and 1 mM EDTA from Sigma-Aldrich.  After 
vortexing, the quenched reaction was centrifuged at 5,000 x g for 10 min, and then the 
upper/aqueous layer was transferred to a new microcentrifuge tube.  An aliquot of 50 µL 3 
M sodium acetate, pH 5.2, was added to the collected aqueous layer, and then 550 µL 
isopropyl alcohol were added, and the tube was thoroughly vortexed.  After centrifugation 
at 16,100 x g for 45 min at 4 °C, the supernatant was removed, 500 µL 70% aqueous 
ethanol were added to the tube, and then it was centrifuged at 16,100 x g for 5 min.  After 
removing the supernatant, the tube was allowed to air-dry for 1 h at room temperature, and 
then dried for 1 min using a Savant SpeedVac.  Finally, the DNA pellet was dissolved in 
15 µL elution buffer (“EB,” 10 mM Tris-HCl, pH 8.5). 
Cosmid vector pOJ446,22 a kind gift from Dr. Leonard Katz (formerly of KOSAN 
Biosciences, Hayward, CA),  was prepared for ligation by digestion with HpaI overnight 
at 37 °C according to the manufacturer’s directions using ~20 µg DNA.  The reaction was 
then treated with calf intestinal alkaline phosphatase (CIAP) from New England Biolabs 
according to the manufacturer’s directions, and then purified using EconoSpin® Mini Spin 
columns and buffers from Epoch Life Science using the QIAgen PCR clean-up protocol,13 
with elution using 50 µL EB.   An aliquot of 20 µL of the spin column eluate (~6 µg DNA) 
from the last step was digested overnight with BamHI from New England Biolabs 
according to the manufacturer’s directions; the reaction was purified using the QIAgen 
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PCR clean up protocol using EconoSpin® Mini Spin columns and buffers from Epoch Life 
Science with elution using 35 µL EB. 
Ligation of the isolated, digested genomic DNA into the digested pOJ446 vector 
was carried out using T4 ligase as per the manufacturer’s directions, except the reaction 
was incubated at 4 °C overnight.  The next day, 1 µL 3 M sodium acetate, pH 5.5, was 
added to the reaction, followed by 11 µL isopropyl alcohol.  The reaction was vortexed 
and centrifuged at 16,100 x g at 4 °C for 45 min, and then the supernatant was removed.  
An aliquot of 20 µL 70% aqueous ethanol was added to the microcentrifuge tube, and after 
centrifugation at 16,100 x g at 4 °C for 5 min, the supernatant was removed.  The tube was 
allowed to air-dry at room temperature for 1 h, followed by drying in a Savant SpeedVac® 
for 1 min.  The resultant pellet was dissolved in 12 µL EB. 
The purified S. novoguineensis-pOJ446 ligation was packaged using the Giga Pack 
XL III kit from Stratagene (now Agilent) following the manufacturer’s directions, and then 
the prepared packaging extract was stored at 4 °C.  The recipient E. coli cells for each 
transfection were freshly prepared as follows. A loopful of E. coli XL-1 Blue MRF’ 
glycerol stock was freshly streaked on an LB agar plate containing 12.5 µg/mL 
tetracycline, and the plate was incubated overnight at 37 °C.  The next day, a singly colony 
was used to inoculate 5 mL LB liquid medium containing 12.5 µg/mL tetracycline, and 
this culture was allowed to grow overnight in a shaking water bath at 37 °C.  The next day, 
the overnight culture was used to inoculate 25 mL fresh LB liquid made 0.2 % (v/v) maltose 
and 10 mM MgSO4 at a 1:100 dilution, without tetracycline, and this new culture was 
grown at 37 °C in a shaking water bath until OD600= 0.5-0.8.  The cells were then treated 
as per the manufacturer’s directions and used for transfection as follows.  To assay the 
optimal transfection conditions, an initial trial was performed for each new packaging 
extract.  Various amounts of the packaging extract were diluted to 130 µL using SM 
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buffer,11 and 200 µL prepared E. coli XL-1 Blue MRF’ cells were added to each dilution.  
The reactions were gently inverted and then incubated at room temperature for 30 min.  A 
total of 1 mL LB was then added to each reaction, and the reactions were incubated at 37 
°C for 45 min.  The reactions were quickly pelleted by centrifugation for 10 sec, and most 
of the supernatant was poured off.  The remaining ~200 µL supernatant was used to 
resuspend the cell pellets, each suspension was spread on one pre-warmed LB agar plate 
containing 50 µg/mL apramycin, and the plates were incubated at 37 °C overnight. 
The next day, each plate from the transfection was flooded with 2 mL LB, and the 
plates were shaken by hand to wash off all of the colonies.  Approximately 1.5 mL bacterial 
suspension was recoverable from each plate; 0.5 mL was used for miniprep isolation of 
DNA, and 125 µL 80% glycerol was added to the remaining 1 mL to make a frozen glycerol 
stock.  Seven cosmid pools were obtained. 
3.2.9. Isolation of Amipurimycin Cluster Cosmid 
Based on analysis of the putative amipurimycin gene cluster from S. 
novoguineensis identified in Chapter 2, peg4680 and peg4707 were tentatively identified 
as the 5’- and 3’-cluster boundaries, respectively.  Oligonucleotide primer pairs 
corresponding to 325 bp and 336 bp fragments, respectively, of these open reading frames 
(ORFs) were obtained from Sigma-Aldrich with the following sequences: 4680f: 5'-
ATGCGGGTCTTCGGAACGATGACCGCC-3'; 4680r: 5'-
AGCAGGGACTCGAACCGGTAGGCGTC-3’; 4707f: 5'-
CCACCGGAGACCTCTTCACCATCGAC-3'; and 4707r: 5'-
AGGAACGCGGTCACTTGTACCAGTCGATG-3'.  PCR was carried out as described 
earlier with an annealing temperature and extension time of 67 °C and 3 sec, respectively, 
for peg4680 and an annealing temperature and extension time of 64 °C and 3 sec, 
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respectively, for peg4707.  The seven cosmid pools collected earlier were screened with 
both probes using PCR, and one pool displaying a strong band for both probes, “NP2,” was 
selected for further screening.  An aliquot of 1 µL of NP2 DNA was transformed into 
chemically competent E. coli XL-1 Blue MRF’ cells, and the transformation mixture was 
plated on LB agar containing 50 µg/mL apramycin and incubated overnight at 37 °C.  A 
total of 150 individual colonies from this transformation were transferred to a gridded 
“master plate” and used to make three sub-pools as follows.  A sterile toothpick was used 
to pick up a single colony, the toothpick was streaked on the gridded plate, and then the 
toothpick was dipped in 5 mL sterile LB containing 50 µg/mL apramycin and then 
discarded.  Every 50 colonies were dipped in the same tube of LB to create three 5 mL 
cultures representing 150 colonies.  After growth overnight in a shaking water bath at 37 
°C, the sub-pool cultures were harvested and the DNA was collected by miniprep with 
elution using 50 µL EB.  These sub-pools were PCR screened with the peg4680 and 
peg4707 probes, and subpool B (“NP2B”), was selected for further screening.  The NP2B  
master plate was used to create five pools of 10 cosmids each using the approach described 
earlier.  NP2B subpool five, corresponding to cosmids 41 through 50, showed strong bands 
for both probes, so each of these cosmids were individually screened.  To do so, ten PCR 
reactions were set up as before but lacking template DNA, then a sterile toothpick was used 
to pick up a single colony, and this toothpick was dipped in the respective PCR reaction; 
this approach was used to supply the template DNA for the remaining reactions.  Finally, 
after screening for both probes, only cosmid 47 (“NP2B47”) showed a band for each probe.  
To verify the identity of the observed bands from the NP2B47 cosmid, these bands were 
excised, purified, and cloned into pCRBlunt as described earlier for sequencing.  The 
resulting cosmid was named pSNVNP2B47, and since it was positive for both probes, it 
was assumed to contain the whole putative amipurimycin biosynthetic gene cluster. 
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Figure 3.5:  Iterative screening approach to isolation of cosmid pSNVNP2B47 
3.2.10. Cloning and Expression of Snv4 and Snv6 
The genes snv4 and snv6 were PCR amplified from cosmid pSNVNP2B47 as 
described earlier with the following oligonucleotide primer pairs with engineered 5’-NdeI 
and 3’-NheI sites (underlined) obtained from Sigma-Aldrich: snv4f: 5'- 
CATATGAGGATCTTCTCCAGTGCCCAG-3' and snv4r: 5'-
GCTAGCTCACGACGTCCTCCCGGTGGGAAC-3'; and snv6f: 5'-
CATATGTCTGACACCCCTGCCCGCAC-3' and snv6r: 5'-
GCTAGCTCACAGACCCCCACCCGTCACGGTC-3'.  The amplified genes were 
isolated by gel electrophoresis and cloned into pCRBlunt sequencing vector as described 
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earlier and sequenced.  Correctly sequenced plasmids were digested with NdeI and NheI 
and cloned into pET28b(+) digested with the same REN to afford transcription of these 
genes as N-terminally His6-tagged constructs.26  The recombinant plasmids containing 
snv4 or snv6 were transformed into chemically competent E. coli BL21-Gold(DE3) and 
plated on LB agar containing 50 µg/mL kanamycin.  For transformants harboring either 
gene, a single colony was picked with a sterile toothpick and used to inoculate 20 mL sterile 
LB broth containing 50 µg/mL kanamycin in a sterile 50 mL conical tube.  These cultures 
were grown overnight in a shaking water bath at 200 RPM and 37 °C overnight.  The next 
day, these cultures were used to inoculate 4 L each of 1 L sterile LB in a 3.2 L Fernbach 
flask at a 1:250 dilution for protein production.  These cultures were grown at 37 °C in an 
Innova® 4330 Refrigerated Incubator-Shaker from New Brunswick Scientific at 220 RPM 
until OD600 ~0.6-1.0.  At that time, snv4 cultures were induced with 0.05 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG), and snv6 cultures were induced with 0.2 mM IPTG.  
At the time of induction, the incubator temperature was lowered to 24 °C, and growth was 
continued for 16-20 h.  To harvest the cell pastes (typically ~5g/L culture), cultures were 
centrifuged at 4,500 x g at 4 °C for 20 min in an Avanti® J-E centrifuge with a JLA 10.5 
fixed-angle rotor.  The pastes were transferred to sterile 50 mL conical tubes and stored at 
-80 °C until use. 
3.2.11. Purification of Snv4 and Snv6 
To purify recombinant Snv4 and Snv6, the cell pastes were first thawed in room 
temperature water.  The lysis, wash, and elution buffers contained imidazole as suggested27 
and were stored at 4 °C.  The buffers for Snv4 purification were composed of 50 mM 
HEPES (pH 8.0), 300 mM NaCl, and 10% glycerol, and the buffers for Snv6 purification 
were composed of 50 mM Tris HCl (pH 8.0), 300 mM NaCl, 0.5 mM 1,4-dithiothreitol 
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(DTT), and 10% glycerol.  Thawed cell pastes were resuspended and transferred to pre-
chilled  250 mL stainless steel Griffin-style beakers from Polar Ware (Kiel, WI) with two 
cell paste volumes of the respective lysis buffer.  Then, 1 mg of chicken egg-white 
lysozyme was added per mL of combined lysis and cell paste volume, and the mixture was 
incubated on ice for 1 h with intermittent stirring.  The cell paste suspensions were then 
sonicated on ice using a Sonicator F550 from Fisher Scientific equipped with a large horn 
using 30 sec bursts at power setting “10” with 1 min cooling in between bursts.  The 
suspensions were sonicated until no longer viscous (typically ~4-5 min total of sonication), 
and then they were centrifuged at 20,000 x g at 4 °C for 40 min in an Avanti® J-E centrifuge 
with a pre-chilled JS 25.50 fixed-angle rotor.  The supernatants were then applied to pre-
chilled, prepacked columns containing ~5.5 mL Ni-NTA resin pre-equilibrated with the 
respective lysis buffer and allowed to gravity flow.  The columns were then washed with 
~100 mL each of the respective wash buffer and eluted with ~15 mL each of the respective 
elution buffer.  After checking fraction purity by SDS-PAGE, pooled fractions were loaded 
into washed Spectra/Por 2 (12-14 kDa molecular weight cutoff) dialysis tubing from 
Spectrum Laboratories (Rancho Dominguez, CA) and dialyzed against 3 L of dialysis 
buffer composed of the respective lysis buffers without imidazole at 4 °C.  The dialyzed 
protein was concentrated to 5-7 mL using Amicon Ultra-15 Centrifugal Filter Units from 
EMDMillipore at 4 °C according to the manufacturer’s instructions.  Finally, the 
concentrations of the purified Snv4 and Snv6 were estimated using the Bradford assay with 
BSA as the standard according to standard protocols, and then the proteins were dispensed 
as 1 mL aliquots into 1.65 mL microcentrifuge tubes, flash frozen in liquid N2, and stored 
at -80 °C until use. 
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3.2.12. In vitro assays using Snv4 and Snv6 
To assay the function of Snv4 as a glycosyltransferase, an in vitro approach was 
taken based on a published study.28  The 0.1 mL reactions were composed of 1 mM of a 
putative sugar donor, α-D-glucose-1-phosphate or UDP-glucuronic acid, 1 mM of a 
putative sugar acceptor, 2-aminopurine or guanine, in the Snv4 dialysis buffer described 
earlier supplemented with 1 mM MgCl2 and were initiated by the addition of Snv4 to 10 
µM.  Reactions were incubated at 37 °C overnight and then filtered through 10 kDa 
molecular weight cutoff Nanosep® centrifugal filters by Pall Laboratory from VWR 
according to the manufacturer’s instructions.  Samples were analyzed by HPLC using the 
same equipment and methods as used earlier for isolation of the miharamycins.  In 
alternative approaches, HPLC purified amipurimycin was reacted with 10 mM UDP in the 
presence of 10 µM Snv4 in the same reaction buffer used earlier or HPLC purified 
amipurimycin was incubated with 10 µM Snv4 in 50 mM or 100 mM potassium phosphate 
buffer (pH 8.0).  These reactions were incubated overnight at 37 °C, filtered, and analyzed 
by HPLC as well.  To assay the function of Snv6, 0.1 mg Snv6 was incubated with 0.5 mM 
NADH or NADPH and 0.5 mM guanine, guanosine, 5’-guanosine monophosphate, 2-
deoxy 5’-guanosine monophosphate, guanosine diphosphate, or 2’-deoxy guanosine 
triphosphate in reaction buffer composed of 50 mM Tris HCl (pH 8.0), 0.5 mM DTT, and 
10% glycerol.  These reactions were incubated at 37 °C for 1.5 h and then filtered and 
analyzed as for the Snv4 reactions. 
3.3. RESULTS AND DISCUSSION 
3.3.1. Isolation of the Miharamycins 
Our studies of the biosynthesis of miharamycins and amipurimycin actually began 
prior to obtaining the putative biosynthetic gene clusters and commenced with 
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development of a reliable method to producing and isolating these compounds.  
Interestingly, despite being reportedly deposited in the Institute of Fermentation Osaka 
(IFO) as IFO-13572,29,30 Kuniko Sato, an IFO curator, revealed the deposit of S. 
novoguineensis  was cancelled by the depositor.  Therefore, we first turned our attention to 
S. miharaensis.  The only available literature in English regarding the growth of S. 
miharaensis and the isolation of miharamycins was a US patent.14  Frustratingly, our 
attempts to replicate the conditions described were met with failure.  Finally, Dr. Masato 
Tani of Meiji Seika Kaisha, Ltd. provided copies of Meiji Seika Kenkyū Nenpō pertaining 
to the isolation and biological activity of the miharamycins,15,21,31 and translation of these 
documents by Dr. Yasushi Ogasawara, a post-doctoral fellow in our lab, revealed the 
correct composition of the growth medium.  However, according to the examples provided, 
the miharamycins were produced in large scale format, e.g., 300 L, using sparged air.14,15  
Because we could not replicate these conditions in our lab, we tried to optimize a small 
scale format to produce miharamycins.  Various culture conditions were used, and a disc-
diffusion bioassay against P. aeruginosa suggested in the literature from Meiji Seika 
Kaisha21 was used to detect production of the miharamycins.  We finally found the 
conditions described in Materials and Methods which reliably resulted in bioactivity by the 
disc-diffusion assay, but analysis by HPLC could not detect the miharamycins.   
3.3.2. Putative Precursor Feeding Studies 
First applied to the industrial production of penicillin G,32,33 precursor feeding has 
been often used to increase yields of bacterial natural products.33-36  We therefore 
undertook a program of putative precursor feeding to both increase production of 
miharamycins and give insight into the biosynthesis of these molecules.  Of the compounds 
fed, L-arginine was first found to almost double the bioactivity of S. miharaensis 
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production culture extracts.  This result was rationalized by considering the biosynthesis 
of arginine is metabolically “expensive” due to the consumption of two equivalents of ATP 
for each molecule of arginine produced.37,38  Gratifyingly, the increased activity seemed to 
be related to increased production of miharamycins, as HPLC analysis was able to detect 
their presence in culture extracts.   At supplementation of L-arginine to concentrations 
above 2 mM, the effects on the production of miharamycin were unpredictable, and at 20 
mM, the production of miharamycins was apparently completely suppressed.  However, 
supplementation with L-ornithine did not seem to have a ceiling to its effect on increasing 
miharamycins production.  This finding is not too surprising, considering L-arginine 
regulation has pleitropic effects intracellularly.38,39   The only other putative precursor 
found to increase miharamycins production was 5’-guanosine monophosphate (GMP), and 
the combination of GMP and L-ornithine qualitatively afforded synergistic increases in 
miharamycins production.  The effect of GMP was somewhat surprising because 
nucleotides reportedly do not readily cross bacterial cell membranes, and it provides 
support for proposed origin of 2-aminopurine, as discussed in Chapter 2.    
In order to validate our method of growth of S. miharaensis for miharamycins 
production, we performed a time-course study of miharamycins production using L-
ornithine and 5’-GMP fed cultures, singly in combination with each other, at a 
concentration of 3 mM.  Generally, concentrations of miharamycin B under each  
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Figure 3.6:  Miharamycins production time course 
condition were higher than concentrations of miharamycin A, and these concentrations 
tended to stay steady during the course of the study.  Notably, higher concentrations of 
miharamycins were obtained in the culture fed both L-ornithine and 5’-GMP, and these 
concentrations fluctuated over a larger range than the cultures fed only L-ornithine and 5’-
GMP.  Interestingly, the first time point at 28 h for the combination culture showed the 
highest concentration of miharamycin A observed during the study at 6.63 µM, but it 
seemed to decrease sharply by the second time point at 50.5 h.  The concentration of 
miharamycin A did increase at later time points, but it never increased as high as was 
observed at 28 h.  Unfortunately, the conclusions from this study can only be taken lightly 
considering the experiment was not replicated.  However, it could reveal that future 
attempts to isolate miharamycin A would benefit not only from feeding both L-ornithine 
and 5’-GMP but also from ending fermentation soon after supplementation. 
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3.3.3. Inhibitor Feeding Studies 
While putative precursor feeding has been used to provide insight in many cases, 
inspired by the work of Gould and co-workers,40,41 we used a set of enzyme inhibitors in 
an effort to identify possible intermediates in the miharamycins biosynthetic pathway.  
These inhibitors included O-(carboxymethyl)-hydroxylamine (also known as 
aminooxyacetic acid), 6-diazo-5-oxo-L-norleucine, 1-aminobenzotriazole, and 
oxythiamine, which are inhibitors of PLP-dependent enzymes,42,43 glutamine-utilizing 
enzymes,44 cytochrome P450 enzymes,45 and thiamine-pyrophosphate-dependent 
enzymes,46 respectively.  These specific inhibitors were used to: 1) try to isolate the 
miharamycins core saccharides by inhibiting installation of the amino functionality at C6 
(aminooxy acetic acid and 6-diazo-5-oxo-L-norleucine); 2) determine the origin of the C8-
C9 fragment (oxythiamine); and 3) determine if the hydroxylated arginine of miharamycin 
A is derived from a cytochrome P450-mediated process (1-aminobenzotriazole). 
 
 
Figure 3.7:  Inhibitor feedings and structures of inhibitors.  A. HPLC analysis of 
inhibitor-fed cultures; B. Structures of inhibitors used: ARG= arginine, AOAA= 
aminooxyacetic acid, DON= 6-diazo-5-oxo-L-norleucine, ABT= 1-aminobenzotriazole, 
and OXY= oxythiamine 
 153 
All inhibitors were fed at 2 mM except 6-diazo-5-oxo-L-norleucine, which was fed 
at 0.5 mM.  Compared to a culture fed L-arginine at 2 mM, the aminooxyacetic acid fed 
culture produced a comparable amount of miharamycin B but considerably less 
miharamycin A; 6-diazo-5-oxo-L-norleucine and 1-aminobenzotriazole fed cultures 
produced less miharamycins in general; and the oxythiamine-fed culture produced almost 
no miharamycins.  Because 6-diazo-5-oxo-L-norleucine and 1-aminobenzotriazole fed 
cultures seemed to have a similar effect, we believe these inhibitors may not have acted 
specifically on the biosynthesis of the miharamycins, making the interpretation of their 
effects less clear.  It should be noted though that 6-diazo-5-oxo-L-norleucine appears to 
potently suppress miharamycins production, as it was only fed at 0.5 mM but attained the 
same level of product suppression as 2 mM 1-aminobenzotriazole.  As discussed in Chapter 
2, we believe 2-amino purine could result from guanine or guanosine, and considering 6-
diazo-5-oxo-L-norleucine suppresses de novo purine biosynthesis through competitive 
inhibition of 2-N-formylglycinamide ribotide (FGAR) amidotransferase,44 the suppression 
of miharamycins production could reflect decreased availability of purines, particularly 
guanosine, which would support our proposal for the origin of 2-aminopurine.  On the other 
hand, aminooxyacetic acid and oxythiamine fed cultures led to more divergent effects on 
the production of the miharamycins.   
Aminooxyacetic acid is a well-known inhibitor of aminotransferases, and it is 
thought to act through the formation of a stable oxime with pyridoxal.42,43  In this light, the 
effect of aminooxyacetic acid on the production of miharamycin A cannot be explained, 
since the difference between miharamycins A and B is a hydroxyl group and not an amine.  
While aminooxyacetic acid is thought to act non-specifically,47 very few reports of its 
activity on enzymes other than those dependent on PLP are available.  However, 
aminooxyacetic acid has been observed to inhibit human FAD-dependent D-aspartate 
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oxidase48 and spinach leaf NAD(P)H-dependent glyoxylate reductase.49  In the former case, 
aminooxyacetic acid was characterized as a potent non-competitive inhibitor with no 
determination of its reversibility or lack thereof, and in the latter, aminooxyacetic acid was 
found to be a reversible inhibitor which preferentially bound the enzyme-glyoxylate 
complex.  Nevertheless, the mechanism of aminooxyacetic acid inhibition of these 
enzymes was not investigated.   Interestingly, aminooxyacetic acid was found to be able to 
form a stable complex with pentobarbital in vivo,50 and though the mechanism was not 
investigated further, the only electrophilic functional group of this barbiturate is an 
amide.51  Thus, it is plausible aminoxyacetic acid could inhibit the requisite enzyme(s) 
necessary for the oxidation of the arginine residue found in miharamycin A, albeit through 
an unknown mechanism. Furthermore, if this is indeed the case, the selective effect of 
aminooxyacetic acid on the production of the miharamycin A could indicate modification 
of arginine is a “tailoring” reaction performed on miharamycin B.   
This line of reasoning is also supported by the YcgI/YcgG homologue found in the 
smh cluster, Smh24.  As discussed in Chapter 2, even though the phosphonate natural 
product argolaphos contains the same hydroxylated arginine,52 the YcgI/YcgG homologue 
from its biosynthetic gene cluster displays only modest similarity and identity to Smh24, 
which suggests their divergent primary sequences are driven by the dissimilarity of their 
substrates.  According to sequence analyses presented in Chapter 2, Smh24 contains a 
putative Rossmann fold, which could be involved in binding a flavin cofactor, supporting 
the role of this enzyme as a putative oxidoreductase.    
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Figure 3.8: A. mechanism of aminooxyacetic acid inhibition of PMP; B. presumed effect 
of feeding aminooxyacetic acid; C.  hypothetical explanation for observed suppression of 
miharamycin A production in the presence of aminooxyacetic acid 
In this light, and given the reactivity of aminooxyaceitc acid as a nucleophile, the selective 
effect of this inhibitor on the production of miharamycin A can be rationalized as follows.  
Flavin-dependent oxidoreductases are well-known for their ability to perform heteroatom 
oxidation reactions, such as N-oxidation.  Usually, hydroxylation is mediated through a 
reactive species, such as peroxy or hydroperoxy flavin.  The former is implicated in 
electrophilic oxygenation reactions, whereas the latter is implicated in nucleophilic 
 156 
oxygenation reactions.53,54  As aminooxyacetic acid is a reactive nucleophile, it could be 
envisioned to more readily react with hydroperoxy flavin, resulting in the formation of an 
alkyl nitrite.  This sequence implies aminooxyacetic acid would be a competitive inhibitor 
preventing oxidation of arginine or miharamycin B to the corresponding compounds 
hydroxyarginine or miharamycin A, respectively.  More work is needed to explore this 
possibility.     
Oxythiamin has been characterized as an inhibitor of TPP-dependent enzymes, 
particularly transketolase.  Although its mechanisms of action are poorly characterized, it 
can be pyrophosphorylated in vivo to generate a non-functional analog which can displace 
TPP.46  As discussed in Chapter 2, the miharamycins are built upon a perhydrofuropyran, 
but unlike the octosyl acid derivatives, we felt the furan portion was derived from a cyclized 
two-carbon branch, especially given the structure of amipurimycin,55 whose C8-C9 
fragment could be viewed as an “open chain” form of the furan ring found in the 
miharamycins. Because transketolase-like enzymes have been implicated in the 
biosynthesis of two-carbon branched sugars like the eurekanate moiety of avilamycin and 
everninomicin,56,57 we felt oxythiamine was a good choice to explore this possibility.  
Instead of recovering intermediates lacking the two-carbon branch, oxythiamine all but 
ablated production of the miharamycins, indicating a TPP-dependent enzyme plays an 
important role in the biosynthesis of the miharamycins or at least is responsible for a step 
prior to and necessary for the attachment of the 2-aminopurine chromophore. The role of a 
transketolase in the biosynthesis of the miharamycins and amipurimycin was substantiated 
by the identification of transketolases in the smh and snv clusters, Smh5a/b and Snv3a/b, 
respectively.  In consideration of the predicted function of Smh5a/b and Snv3a/b in the 
installation of the two-carbon branches, and the effect of oxythiamine on the production of 
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the miharamycins, branching is likely a required step before 2-aminopurine can be 
attached. 
 
 
Figure 3.9:  Presumed effect of oxythiamine feeding on miharamycins production 
Later, assistance from Hisayuki Komaki, a curator from the NITE Biological 
Resource Center (NBRC) in Japan, led to the location of S. novoguineensis in the CBS-
KNAW culture collection in the Netherlands.  Despite the high structural similarity 
between amipurimycin and the miharamycins, the available literature for the growth of S. 
novoguineensis and isolation of amipurimycin described vastly different approaches from 
those described for S. miharaensis and the miharamycins. Early attempts to produce and 
isolate amipurimycin following the published procedure29,30 were unsuccessful, so the 
protocol we developed for the production and isolation of miharamycins was utilized.  
Remarkably, this approach led to the isolation of amipurimycin.  Unlike S. miharaensis, S. 
novoguineensis did not respond to feeding of 5’-GMP.  Prior to identification of the 
amipurimycin biosynthetic gene cluster, which, as discussed in Chapter 2, indicates the 
pendant amino acid cispentacin is derived from glutarate semialdehyde, we believed this 
unusual amino acid could be derived from cyclization of L-lysine or L-norleucine, but 
feeding of these amino acids did not lead to increased production of amipurimycin. 
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3.3.4. In vitro Assays with Snv4 and Snv6 
Then, we sought to determine the early steps of amipurimycin biosynthesis through 
the use of in vitro assays.  The biosyntheses of the hPNAs such as blasticidin S, 
mildiomycin, and gougerotin commence with the condensation of UDP-glucuronic acid 
and cytosine,9 and though the content of the smh and snv clusters identified in Chapter 2 
imply a PKS-based biosynthetic pathway for amipurimycin and the miharamycins, it was 
important to rule out the involvement of a biosynthetic pathway more akin to the known 
hPNAs.  To this end, N-terminally His6-tagged Snv4 was expressed and purified.  Under 
the conditions assayed, Snv4 was not able to condense 2-aminopurine or guanine to UDP-
glucuronic acid.  Alternatively, a reverse glycosylation assay using UDP was not able to 
remove the 2-aminopurine base from HPLC purified amipurimycin.  In consideration of 
the pathway discussed in Chapter 2, wherein the core nucleosides of the miharamycins and 
amipurimycin are activated as monophosphates for transfer to guanine or 2-aminopurine, 
a reverse glycosylation assay in phosphate buffer to remove 2-aminopurine from 
amipurimycin was attempted, as well as a forward glycosylation assay to glycosylate 
guanine or 2-amino purine with the core nucleoside mimic glucose-1-phosphate.  However, 
these attempts were not successful. 
In consideration of the stimulatory effect 5’-GMP had on the production of the 
miharamycins, guanine or its nucleoside or nucleotides were thought to be potential 
precursors to 2-aminopurine through direct reduction of the C6 carbonyl, as discussed in 
Chapter 2.  Therefore, we cloned and expressed Snv6 as an N-terminally His6-tagged 
protein.     
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Figure 3.10:  Summary of Snv4 assays performed. 
Interestingly, the purified protein was a deep brown/orange color, which suggested 
the presence of a chromogenic cofactor.  We discussed in Chapter 2 the possibility Snv6 
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binds a cofactor based on the presence of a putative Rossmann motif58 as well as the 
possibility the protein binds iron due to the presence of a cysteine-rich motif typical of 
iron-sulfur cluster-binding proteins.59  As expected, analysis of recombinant Snv6 by 
HPLC spectroscopic methods by Mr. Geng-Min Lin, a graduate student in the Liu Lab, 
revealed the presence of one equivalent of FAD per molecule and, preliminarily, supported 
the existence of a 4Fe-4S cluster (data not shown).  The ability of Snv6 to reduce guanine, 
guanosine, 5’-GMP, 2-deoxy 5’-GMP, GDP, or 2-deoxy GTP using NADH or NADPH 
was assayed under aerobic conditions and, by Mr. Geng-Min Lin, under anaerobic 
conditions, but no reaction was observed.  It is possible the reaction is more complex, 
requiring additional cofactors or components, or 2-aminopurine is not derived from 
guanine or its derivatives. 
 
 
Figure 3.11:  Hypothetical “direct” reduction of guanine or a derivative thereof by Snv6 
to lead to 2-aminopurine 
 
3.3.5. Genetic Manipulation of S. novoguineensis 
Next, we sought to provide more conclusive evidence of the involvement of the 
smh and snv clusters in the biosynthesis of the miharamycins and amipurimycin through 
gene inactivation experiments.  S. miharaensis was recalcitrant towards attempts to 
introduce DNA, and these attempts were further hindered by the inability of S. miharaensis 
to reliably sporulate.  In fact, lack of sporulation except under very specific conditions was 
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reported to be a defining characteristic of this strain.  Although this phenomenon was not 
explored in S. miharaensis, in consideration of the effect of exogenously supplied arginine 
on miharamycins production, it is notable that defects in sporulation have been linked to 
unstable arginine biosynthesis genes in Streptomyces lividans 66.60   On the other hand, S. 
novoguineensis sporulated abundantly and quite easily on several solid media, which made 
intergeneric conjugation an attractive approach to gene inactivation in this strain, as this 
method can even circumvent active restriction endonuclease systems.12  Furthermore, we 
felt the apparently constitutive production of amipurimycin would be a more convenient 
phenotype.  Single crossover mutations are notable for their ease of introduction,12 so we 
selected this method to interrupt snv8.  This gene was chose for two reasons.  First of all, 
since it is a large gene (3003 bp) a larger fragment could be utilized for the integration 
plasmid, which could improve efficiency of integration.12  Secondly, by interrupting this 
PKS-encoding gene, we could obtain some evidence for its involvement in the production 
of amipurimycin. 
The plasmid pKCsnv8Int was easily introduced into S. novoguineensis through 
intergeneric conjugation via E. coli S17-1, a methylase proficient strain,23,24 which 
indicates S. novoguineensis may not have a high restriction barrier.61  Interestingly, in the 
course of introducing plasmid pKCsnvInt8 into S. novoguineensis, we found this strain 
displays basal resistance to apramycin, but this could be overcome by using a concentration 
of this antibiotic of at least 100 µg/mL in all liquid and solid media.  After three rounds of 
selection, three putative integrants, 94-A, 93-3, and 99-A were recovered.  Because 
integration of the plasmid pKCsnv8Int would result in a ~7.5 kbp insertion in snv8, PCR 
amplification of interrupted snv8 (~10.5 kbp) was expected to be inefficient under 
conditions optimized to amplify the native ~3 kbp gene.  Compared to the wild-type strain 
of S. novoguineensis, this PCR screening failed 94-A, 93-3, and 99-A, indicating the three 
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recovered integrants did indeed harbor an interrupted copy of snv8.  Strain 94-A was 
assayed for its ability to produce amipurimycin compared to the wild-type strain, and no 
amipurimycin was detected.  Therefore, we are confident the snv cluster truly is the 
amipurimycin biosynthetic gene cluster and, because of its high homology to the smh 
cluster we are confident the miharamycins biosynthetic gene cluster has been identified.  
Finally, to further aid in future gene deletion studies through λRED-mediated 
recombineering and heterologous expression, we utilized cosmid library screening to 
isolate cosmid pSNVNP2B47 which appears to contain the entire amipurimycin 
biosynthetic gene cluster. 
 
 
Figure 3.12:  Schematic of snv8 single crossover interruption and PCR screening of 
exconjugants 
3.4. CONCLUSIONS 
While the fine details of the biosynthetic pathways of the miharamycins and 
amipurimycin are currently lacking, our work provides some insight into the biosyntheses 
of these complex PNA.  Specifically, we have developed reliable methods for the 
production and isolation of the miharamycins and amipuimycin, and, most importantly, we 
have provided the first evidence that the clusters identified in Chapter 2 are indeed the 
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correct clusters through single crossover mutation of snv8.  Furthermore, this work has 
established a method for the introduction of DNA into S. novoguineensis and led to the 
isolation of the amipurimycin gene cluster on a single cosmid, a potentially useful tool in 
future investigations into the biosynthesis of amipurimycin. 
Although the predicted activities of recombinant Snv4 and Snv6 were not observed 
under the conditions used, some important conclusions may be drawn.  Namely, in support 
of the PKS model elaborated in Chapter 2 and unlike the biosynthesis of other hPNA, the 
biosyntheses of amipurimycin and miharamycin do not likely involve the condensation of 
2-aminopurine or guanine to UDP-glucuronic acid.  Furthermore, even though 5’-GMP 
was observed to be a strong inducer of miharamycins biosynthesis, which implies it could 
be involved in the biosynthesis of miharamycins and amipurimycin, the inactivity of Snv6 
towards guanine or its derivatives suggests 2-aminopurine may be formed after 
construction of the core nucleoside.  On the other hand, it is very possible the reaction of 
Snv6 is more complex than our conditions, possibly requiring other cofactors or partner 
enzymes, or the function of Snv6 could be sensitive to the presence of a His6-tag.  
Furthermore, if Snv6 does indeed harbor an iron-sulfur cluster, due to the lability of this 
cofactor under aerobic conditions, it would need to be reconstituted anaerobically before 
use.  In all, several avenues to investigate the putative reaction are available.    
The work presented in this chapter dovetails with the analysis provided in Chapter 
2, thereby setting the stage for deeper study of the biosyntheses of the miharamycins and 
amipurimycin, which could be the first members of PKS-derived peptidyl nucleosides and 
offer insight into rare examples of novel enzymatic catalysis. 
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Chapter 4: Investigation Into the Biosynthesis of TDP-2-Deoxy 
Nogalamine  
 
4.1. INTRODUCTION 
Nogalamycin (1) is a structurally unique anthracycline produced by Streptomyces 
nogalater NRRL 3035.  Its high toxicity precludes its use in humans (Figure 4.1).1,2  
Nogalamycin belongs to a small group of anthracycline natural products characterized by 
an algycon extended by two additional heterocycles, rings E and F.3,4  Recent investigations 
into the biosynthesis of nogalamycin have revealed that ring F is actually derived from a 
deoxy amino sugar, nogalamine (2), and ring E is assembled through two bond formation 
between nogalamine and ring D of the algycon.1,5   
 
 
Figure 4.1: Sturctures of nogalamycin and representative extended ring system 
anthracyclines  
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One of these bonds is an O-glycosidic bond between nogalamine and the C1-hydroxyl of 
ring D, but the other is a rarely encountered C-glycosidic linkage between C5’ of 
nogalamine and C2 of ring D.   
 
Glycosylation at ring D of the anthracycline distinguishes nogalamycin and other 
related anthracycline systems such as respinomycin A2 (4) and cororubicin (5) from the 
prototypical, clinically useful anthracyclines daunorubicin (6) and doxorubicin (7) and 
their derivatives (8-9) which bear a  single amino sugar attached to the C7-hydroxyl.1,6,7  
Interestingly, nogalamycin features the permethylated neutral deoxy sugar nogalose (3) at 
its C7-hydroxyl.1   
 
 
Figure 4.2: Structures of clinically relevant anthracyclines. 
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Similar to many other anthracyclines, nogalamycin is a potent DNA intercalator.  Its dually 
glycosylated aglycon affords this natural product a distinct mode of DNA interaction, 
where the appended sugars contribute both minor and major groove interactions to stabilize 
the anthracycline:DNA complex.6,8 Motivated by the wide clinical utility of daunorucin 
and doxorubicin, an extensive semisynthesis program to find less toxic nogalamycin 
derivatives was initiated.  This effort yielded, among other molecules, menogaril, a 7-
methoxy derivative of nogalamycin, which was found to be less toxic than nogalamycin 
but with low activity in clinical trials for a variety of cancers.9-11 While semisynthetic 
efforts to modify nogalamycin mainly focused on derivatives lacking nogalose or other 
ring A substituents, little was done to alter the D-ring or its amino sugar, perhaps due to 
the stability endowed to this portion of the molecule by the additional carbon-carbon bond 
between nogalamine and the aglycon.9,12,13   
Considering that the amino sugars decorating anthracyclines are usually important 
determinants of their potency, it is remarkable that little work has specifically focused the 
biosynthesis of these moieties.3  Nogalamine is an ideal amino sugar to study because its 
biosynthetic pathway has not been definitively established.  Bacterial deoxy sugars have 
been extensively shown to be derived from highly conserved biosynthetic pathways via 
NDP-activated (usually TDP) intermediates,14 and analysis of the nogalamycin 
biosynthetic gene cluster does allow the proposal of a cursory pathway for nogalamine 
biosynthesis (Figure 4.3).5  Namely, following established biosynthetic logic, SnogJ, a 
putative thymidylyl transferase; SnogK, a putative 4’,6’-dehydratase; and SnogH, a 
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putative 2’,3’-dehydratase can be envisioned to perform the first three conserved steps in 
deoxy sugar biosynthesis.   
 
 
Figure 4.3: Pathway supporting a C2’-deoxy sugar pathway for nogalamine 
 
Intriguingly, nogalamine, as found attached to the anthracycline, bears a hydroxyl at C2’ 
which would suggest a pathway that keeps this hydroxyl intact, but the presence of a 2’,3’-
dehydratase and the lack of a 3’,4’-keto isomerase, e.g., Tyl1a,15 suggest that nogalamine 
follows a 2’-deoxy sugar biosynthetic pathway and that the C2’ hydroxyl is installed at 
some point after it is removed, hence the proposed first steps above.1,5  Currently, the 2’ 
hydroxyl of nogalamine is proposed to be installed later in the pathway, perhaps after 
nogalamine is attached to the anthracycline, since noglamycin analogs lacking this 
substituent have been isolated from culture filtrates of S. nogalater.5  There remain some 
significant ambiguities in the next steps.  First, based on the presence of only one putative 
sugar epimerase in the nogalamycin biosynthetic gene cluster, SnogF, TDP-nogalamine 
and TDP-nogalose are likely formed through L-configured intermediates, and their 
pathways, therefore, must share this epimerase.3,5  Second, the nogalamycin gene cluster 
has two sugar 4’-keto reductases, SnogG and SnogC; while SnogG is proposed to be 
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involved in nogalamine biosynthesis, it has not been demonstrated to do so.3  Third, unlike 
most N-methylated amino sugar-containing natural product gene clusters,16,17 the 
nogalamycin gene cluster encodes two N-methyltransferases, SnogA and SnogX.1  The 
function of neither methyltransferase has been demonstrated, and, further, it is not known 
whether both are required for methylation of nogalamine or, if both are required, what their 
order of reaction is.5   
Because anthracyclines with glycosylated D rings are not well-represented amongst 
the anthracyclines in current clinical use, a better understanding of how nogalamine is 
biosynthesized and becomes dually linked to ring D of the aglycon could provide novel 
approaches to overcome the anthracycline class limitations of fatal cardiotoxicity and the 
development of tumor resistance.7,18,19  To address some of these issues, we sought to 
establish the sequence of reactions giving rise to TDP-L-2’-deoxy nogalamine, the likely 
precursor to the amino sugar found in nogalamycin, as well as explore the reaction 
sequence leading to the formation of the nogalamine C2’-aglycon C2 bond.  Herein we 
report the in vitro reconstitution of the TDP-L-2’-deoxy nogalamine biosynthetic pathway 
and demonstrate the functions of SnogF, SnogG, SnogA, and SnogX.  Furthermore, 
evidence to support the feasibility of anthracycline biosynthetic engineering in 
Streptomyces peucetius is provided. 
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4.2. EXPERIMENTAL PROCEDURES 
4.2.1. Chemicals, Reagents, and Materials 
All chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO) 
or Fisher Scientific (Pittsburg, PA) and used without further purification unless otherwise 
noted.  Laboratory consumables such as microcentrifuge tubes, conical tubes, and pipette 
tips were sourced from Fisher Scientific or VWR International (Radnor, PA). 
E.coli DH5α was acquired from Bethesda Research Laboratories (Muskegon, WI), 
pET28b(+) vector DNA was obtained from Novagen (Madison, WI), KOD Hot Start® 
DNA Polymerase Kit was purchased from EMD Chemicals (Madison, WI), restriction 
endonucleases and T4 DNA Ligase Kit were obtained from New England Biolabs 
(Ipswich, MA), and all reagents and apparatus for SDS-PAGE were purchased from Bio-
Rad (Hercules, CA).  1 KB Plus DNA ladder, pCRBlunt vector, and E. coli BL21 (DE3) 
were obtained from Invitrogen (Carlsbad, CA). The Ni-NTA agarose, MiniPrep Kits, and 
QIAquick Gel Extraction Kits were products of QIAgen (Valencia, CA).   
4.2.2. Preparation of TDP-D-glucose 
TDP-D-glucose (11) was enzymatically synthesized from α-D-glucose-1-phosphate 
(10) using a reported method.20  The reaction was quenched by filtration through an 
Amicon® stirred cell and 10 kDa molecular weight cut-off membrane from EMD Millipore 
under N2.  The filtrate was lyophilized to dryness, and the remaining residue was dissolved 
in ~4 mL deionized H2O (diH2O) and loaded onto a column of P2 resin from Bio-Rad 
(Hercules, CA) pre-equilibrated with diH2O.  The column was eluted with diH2O using a 
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peristaltic pump from Pharmacia (Uppsala, Sweden).  Fractions strongly absorbing light at 
267 nm were further analyzed by high performance liquid chromatography (HPLC) using 
a Dionex® CarboPac PA1 analytical column (4 x 250 mm) and a CarboPac PA1 guard 
column (4 x 50 mm) from ThermoFisher Scientific (West Palm Beach, FL) and the detector 
was set at 267 nm.  The binary mobile phase was comprised of diH2O (eluent A) and 0.5 
M aqueous ammonium acetate (eluent B). The elution program was as follows: 5-20%B 
over 15 min, 20-60%B over 20 min, 60-100%B over 2 min, hold 3 min, 100-5%B over 5 
min, using a flow rate of 1 mL/min.  Fractions of >95% purity were pooled and lyophilized 
to yield TDP-glucose. 
4.2.3. Cloning of SnogF, SnogG, SnogA, and SnogX Genes 
Streptomyces nogalater NRRL 3035 was obtained from the NRRL Agricultural 
Research Service Culture Collection (Peoria, IL) and propagated on YM agar (0.3% yeast 
extract, 0.3% malt extract, 0.5% peptone, 1% dextrose, 2% agar) or in tryptic soya broth 
(TSB, pre-mixed powder from Sigma-Aldrich) for liquid cultures, and stored as frozen 
mycelia or spore suspensions in 20% glycerol at -80 °C.  S. nogalater was grown and 
maintained according to standard protocols found in Practical Streptomyces Genetics.21  
Whole genomic DNA was isolated using the DNeasy Blood and Tissue Kit from QIAgen 
(Valencia, CA) according to the manufacturer’s instructions using the recommended pre-
treatment for Gram positive bacteria.  All protocols relating manipulation of recombinant 
DNA were from Molecular Cloning: A Laboratory Manual.22  Oligonucleotides custom-
made by Sigma-Aldrich.  The genes snogF, snogG, snogA, and snogX, were cloned from 
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S. nogalater NRRL 3035 genomic DNA with engineered 5’-NdeI and 3’-NheI sites (in 
bold) using oligonucleotides listed in Table 1. 
Gene Sequence (5’3’) 
 
snogF 
 
Forward: 
CATATGGAGTCACGCACGCTTCTCGTC 
 Reverse: 
TTGCTAGCTCATCCGGCGTACAGGTCGTG 
snogG Forward: 
CATATGACCGCCGGGATACCGCGGAC 
 Reverse: 
GCTAGCTCATAAGGCTGACTCCCGATAGC 
snogA Forward: 
CATATGGTGTACGGCCGGGAACTGGC 
 Reverse: 
ATAATAATAGCTAGCTTACCCGGCCCCGCGCACCCC 
snogX Forward: 
CATATGGTGACGCGTGTGTACGGCAC 
 Reverse: 
AATTAATAATAGCTAGCTCACCCCGCCCGCCCGGACTTC 
 
Table 4.1: Sequence of oligonucleotide primers used to clone genes from S. nogalater 
 
Polymerase chain reaction (PCR) was carried out in 0.2 mL thin-walled mini tubes 
using the following reaction composition with KOD DNA Polymerase Kit reagents: 2.5 
µL 10x buffer, 2.5 µL dNTPs mix, 2.5 µL DMSO, 2 µL MgSO4 solution (1 mM final 
concentration, 0.75 µL of each primer in ddH2O (3 µM final concentration), 1 µL template 
DNA (~12 ng) in QIAgen buffer AE, and 12.5 µL ddH2O. PCR was carried in an Eppendorf 
Thermocycler Gradient® as follows.  After heating the lid of the thermocycler to 105 °C 
and an initial 2 min incubation at 95 °C, 31 cycles were carried out consisting of 95 °C for 
20 s, lowest primer melting temperature for 10 s, and 70 °C for 15 s/kb target length, and 
then 70 °C for 10 min.  PCR products were purified by agarose gel electrophoresis and 
then cloned into pCRBlunt for Sanger sequencing at the Core Facilities of the Institute for 
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Cell and Molecular Biology at the University of Texas at Austin, Austin, TX.  Correctly 
sequenced genes were excised from pCRBlunt, and the gel-purified DNA was ligated 
between their respective sites in pET28b(+) for expression with N-terminal His6-tags. 
4.2.4. Expression and Purification of SnogF, SnogG, SnogA, SnogX, RfbB, TylX3, TylC2, 
and EvaB 
The pET28(+) constructs were used to transform E. coli BL21 (DE3) for 
expression.  The recombinant strains were grown in lysogeny broth (LB) supplemented 
with 30 μg/mL kanamycin.  After growth at 37 °C until OD600 ~0.6, cultures harboring the 
snogA:pET28(+) and snogF:pET28b(+) constructs were induced with 100 μM IPTG and 
allowed to grow at 16 °C for 16 h; the culture harboring the snogX:pET28b(+) construct 
was induced with 200 μM IPTG and allowed to grow at 30 °C for 16 h; and the culture 
harboring the snogG:pET28b(+) construct was induced with 200 μM IPTG and allowed to 
grow at 25 °C for 16 h.  The cultures were harvested by centrifugation at 4500 x g at 4 °C, 
and the cell pellets (typically ~5 g/L) were collected and stored at -80 °C until purification.   
For purification, the cell pellets were thawed in room temperature water and 
resuspended in two volumes of either lysis buffer A, composed of 50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, and 20% glycerol, pH 8.0, (SnogA, SnogF, and SnogX) or 
lysis buffer B, composed of 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 20% 
glycerol, 10 mM L-Arg, 10 mM L-Glu, and 0.5 mM DTT; pH 8.0 (SnogG).  Egg white 
lysozyme was added to a concentration of 1 mg/mL, and the cell suspensions were allowed 
to sit on ice for 30 min with intermittent stirring.  Sonication was performed at maximum 
power with 30 s bursts and one min cooling periods between bursts.  The sonicated 
suspensions were then centrifuged at 20000 x g at 4 °C for 40 min, and the supernatants 
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were applied to pre-packed, lysis buffer-equilibrated columns of 6.5 mL of Ni-NTA resin 
and allowed to flow through.  The columns were then washed with ~100 mL of either wash 
buffer A, which has the same composition of lysis buffer A but has 20 mM imidazole, or 
wash buffer B, which has the same composition of lysis buffer B but has 20 mM imidazole.  
Finally, the proteins were eluted with either elution buffer A, which has the same 
composition of lysis buffer A but has 250 mM imidazole, or elution buffer B, which has 
the same composition as lysis buffer B but has 250 mM imidazole.  After dialysis into 
dialysis buffer A, which is composed of lysis buffer A but with no imidazole, or dialysis 
buffer B, which is composed of lysis buffer B but with no imidazole, the pooled column 
eluates were concentrated to 5-8 mL using an Amicon® stirred cell and 10 kDa molecular 
weight cut-off membrane from EMD Millipore (St. Louis, MO) under N2.  The proteins 
were stored as 1 mL aliquots at -80 °C.   
RfbB, a 4’,6’-dehydratase cloned from Salmonella typhimurium;23 TylX3, a 2’,3’-
dehydratase cloned from Streptomyces fradiae;24 TylC2, a 4’-keto reductase cloned from 
S. fradiae;25 and EvaB, a 4’-aminotransferase cloned from Amycolatopsis orientalis26 were 
expressed and purified as previously reported.  
4.2.5. Enzymatic Assays and HPLC Analyses Thereof 
Assays of the functions of SnogF, SnogG, SnogA, and SnogX were carried out in 
50 mM Tris HCl buffer (pH 8.0) and set up in two steps (Figure 4.4). The first step was 
used to generate TDP-4-keto-6-deoxy glucose (12) and was composed of 5 mM TDP-
glucose and 15 μM RfbB.  After incubation at 37 °C for one hour, the nascent product 12 
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was subjected to the second step of the assay was used to generate 14-16.  The reaction 
mixture from the first step was made 1.5 mM in PLP, 62.5 mM in L-Glu, 5 mM in NADPH, 
20 μM in EvaB, 20 μM in SnogF, 30 μM in SnogG, and the addition of TylX3 to 10 μM 
initiated the second step of the assay.  After incubation at 30 °C for one hour, samples were 
drawn, and after filtration through Amicon® YM-10 centrifugal filters from EMD 
Millipore, the filtrates were analyzed at 267 nm by analytical-scale HPLC using the same 
column and elution program described earlier to check the purity of P2 column fractions.  
Under these conditions, 14 elutes at ~11 min, 15 elutes at ~12 min, and 16 elutes at ~9 min.  
To demonstrate the observed shunt reaction, the second step of the reaction was 
made 5 mM in NADPH, 20 μM in SnogF and 30 μM in SnogG or TylC2.  To analyze the 
sequence of methylations by SnogA and SnogX, one or both of these enzymes was added 
to the second step of the reaction at a concentration of 20 μM along with S-
adenosylmethionine (SAM) at a concentration of 5 mM to generate compounds 17 and 18.  
Using the same HPLC conditions as before, 17 and 18 eluted together at ~7.8 min.  
Resolution of 17 and 18 was achieved by using the same mobile phase as before but 
beginning the HPLC elution program with a gradient from 0% to 30% eluent B.   
To obtain samples for mass spectrometry, eluted peaks of interest were collected 
from repeated injections under analytical conditions, pooled and lyophilized, and the 
resulting residues were dissolved in water.  Mass spectrometry was performed at the Mass 
Spectrometry and Proteomics Facility of the Department of Chemistry and Biochemistry 
at the University of Texas at Austin, Austin, TX.   
HR-MS (ESI-) m/z for (16) calc.’d C16H26N3O13P2- [M-H]-, 530.0946, found 530.0950 
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HR-MS (ESI-) m/z for (17) calc.’d C17H28N3O13P2- [M-H]-, 544.1103, found 544.1087 
HR-MS (ESI-) m/z for (18) calc.’d C18H30N3O13P2- [M-H]-, 558.1259, found 558.1249 
Samples for 1H-NMR were collected from preparative scale (10 mL) reactions 
performed using the same conditions and concentrations of reactants as were used for the 
analytical-scale reactions.  After completion, the reaction was filtered using an Amicon® 
stirred cell and 10 kDa molecular weight cut-off membrane from EMD Millipore. The 
filtrates were purified using HPLC with a Dionex® CarboPac PA1 semi-preparative 
column (9 x 250 mm) and semi-preparative CarboPac PA1 guard column (9 x 50 mm) from 
ThermoFisher Scientific.  The binary mobile phase and elution program used were the 
same as were used for analytical-scale reactions, except a flow rate of 3 mL/min was used.  
Pooled eluted peaks were lyophilized, and the residues were dissolved in D2O.  
1H-NMR 
data were obtained using a Varian® Inova 500 MHz instrument at the Nuclear Magnetic 
Resonance Facility of the Department of Chemistry and Biochemistry at the University of 
Texas at Austin, Austin, TX.    
Compound 16: 1H NMR (D2O, 500 MHz) δ 7.61 (s, 1H, 6-H), 6.21 (m, 1H, 1”-H), 5.18 
(dd, J=5, J=7.5, 1H, 1’-H), 4.46 (m, 1H, 3”-H), 4.05 (m, 3H, 4”-H, 5”-H), 3.69 (m, 1H, 5’-
H), 3.44 (m, 2H, 3’-H, 4’-H), 2.22 (m, 2H, 2”-H), 2.10 (m, 1H, 2’-H), 1.81 (s, 3H, 5-Me), 
1.68 (m, 1H, 2’-H), 1.17 (d, J=6.5, 3H, 5’-Me)  
Compound 20: 1H NMR (D2O, 500 MHz) δ 7.62 (s, 1H, 6-H), 6.22 (t, J=5.5, J=6, 1H, 1”-
H), 5.34 (dd, J=20.5, J=1.5, 1H, 1’-H), 4.43 (m, 1H, 3”-H), 4.39 (m, 1H, 2’-H), 4.03 (m, 
1H, 4”-H), 3.88 (m, 2H, 5”-H), 3.68 (m, 1H, 5’-H), 3.56 (m, 1H, 3’-H), 3.52 (m, 1H, 4’-
H), 2.2-2.3 (m, 2H, 2”-H), 1.18 (d, J=5.5, 3H, 5’-Me) 
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4.2.6. Creation of Plasmids pL234 and pL2W34-5 and Transformation of Streptomyces 
peucetius ATCC 29050 and Streptomyces peucetius WHM1628 
 
Streptomyces peucetius ATCC 29050 and Streptomyces peucetius WHM1628, a 
dnrQ-/dnrS- mutant of S. peucetius ATCC 29050, were kind gifts from the laboratory of 
the late Dr. Richard Hutchinson.  Unless stated otherwise laboratory methods pertaining to 
Streptomyces as well as growth media are described in Practical Streptomyces Genetics.21  
These strains were propagated on R2 or R5 agar plates or in R5 liquid (prepared as 
described for R5 solid medium by Kieser, et al.21 without agar), and stored as frozen 
mycelia suspensions in 20% glycerol at -80 °C.  Oligonucleotides were obtained from 
Sigma-Aldrich.  The genes snoaL2 and snoaW were cloned from S. nogalater genomic 
DNA with engineered ribosomal binding sites (RBS) based on a consensus Streptomyces 
RBS sequence21 using the primers shown in Table 2.  The engineered restriction sites are 
bolded.  The PCR reactions were set up and performed as described earlier. 
 
Gene Sequence (5’3’) 
 
snoaL2 
 
Forward: XbaI 
TCTAGAGGAGGTGCCGCCATGTCAACGACCGCGAAC 
 Reverse: HindIII 
AAGCTTTCACAGTCCGTCCGGCACCACGC 
snoaW Forward: BamHI 
GGATCCAGGAGGTGCCGCCATGACAGTATTGGTAAC 
 Reverse: XbaI 
TCTAGATCACCGGAAGTCCGCTCGGTGGTC 
  
Table 4.2: Sequences of oligonucleotide primers used to clone snoaL2 and snoaW for 
construction of plasmids pL2345 and pL2W34-5.  RBS and spacer are underlined. 
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The snoaL2 and snoaW PCR products were purified by agarose gel electrophoresis, 
and after gel extraction, each was cloned into pCRBlunt.  The pCRBlunt constructs were 
Sanger sequenced at the Core Facilities of the Institute for Cell and Molecular Biology at 
the University of Texas at Austin, Austin, TX.  The correctly sequenced genes were excised 
with the restriction endonucleases indicated in Table 2  and gel purified.   
For the construction of plasmid pL234, digested snoaL2 was cloned into the 
respective sites of the Streptomyces/E. coli shuttle vector pSE34.23  For the construction of 
plasmid pL2W34-5, plasmid pL234 was digested with BamHI and XbaI, and the digested 
snoaW was cloned into these sites.  
4.2.7. Culture Conditions for Anthracyclines Production in S. peucetius ATCC 29050 and 
S. peucetius WHM1628 
 
10 mL cultures of S. peucetius ATCC 29050 and S. peucetius WHM1628 
inoculated with 0.2 mL frozen mycelial suspension were grown in capped culture tubes (25 
x 150 mm) with glass beads at 30 °C with rotary shaking at 200 RPM for 2-3 days.  1 mL 
of each culture was used to inoculate a respective culture of 100 mL R5 liquid medium 
supplemented with 0.5% glycine in 1 L baffled flasks.  These cultures were grown at 30 
°C with rotary shaking at 200 RPM for 2-3 days, and then protoplasts of S. peucetius ATCC 
29050 and S. peucetius WHM1628 were prepared.  Protoplasts were transformed with 3-5 
µg of plasmid DNA using 25% PEG 1000 in P-buffer and plated on R2 agar.  After 
incubating the plates overnight at 30 °C, they were overlaid with 1.25 µg each of 
thiostrepton for selection, using a 50 mg/mL stock solution in DMSO.  The antibiotic-
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treated plates were incubated at 30 °C for 4-5 more days, or until the bright yellow 
transformants appeared.  Pieces of the R2 plates containing S. peucetius ATCC 29050 or 
S. peucetius WHM1628 transformants were cut using a flamed inoculating loop and 
aseptically transferred to culture tubes containing 10 mL liquid R5 medium with 
thiostrepton (50 µg/mL) and glass beads.  These tubes were then capped and grown at 30 
°C with rotary shaking at 200 RPM.  After 3-4 days, 1 mL of these cultures was used to 
inoculate 200 mL of a slight variation of the production medium described by Dekleva, et 
al.24 containing (L-1) 30 g dextrose, 10 g Traders® Protein from ADM (Chicago, IL), 3 g 
NaCl, 3 g CaCO3, 10 mL of the trace elements solution described in Practical Streptomyces 
Genetics21 and thiostrepton (12.5 µg/mL).  These cultures were grown at 30 °C with rotary 
shaking at 220 RPM for 10-12 days. 
4.2.8. Isolation of Anthracyclines from S. peucetius ATCC 29050 and S. peucetius 
WHM1628 
 
To isolate anthracyclines, the cultures were centrifuged at 5000 x g at 4 °C for 30 
min.  The supernatant was removed, adjusted to pH 2.0 using phosphoric acid, and allowed 
to stir with 40 g Diaion™ HP-20 resin (Mitsubishi Chemical; White Plains, NY) at room 
temperature for 2 h.  The cell pellet was collected and allowed to stir with 500 mL methanol 
at room temperature for 2 h as well.  After 2 h, the Diaion™ resin was collected by filtration 
through a Büchner funnel, transferred to a flask and allowed to stir with 500 mL fresh 
methanol overnight at 4 °C; the cell pellet slurry was also filtered, and the filtrate was 
combined with the first resin elution and stored at 4 °C.  The next day, the resin was 
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collected again, transferred back to a flask and eluted once more with 500 mL fresh 
methanol by stirring for an additional 2 h at 4 °C.  The resin was then removed, and the 
filtrate was combined with the earlier elution fractions.  The total eluate (~2 L) was then 
concentrated to dryness through rotary evaportation. 
4.3. RESULTS AND DISCUSSION 
4.3.1. Biosynthetic Study of TDP-nogalamine 
 
 Based on our analysis of the nogalamycin biosynthetic gene cluster, comparison 
with canonical deoxy sugar pathways, and results from our assays, we constructed a 
putative pathway for the biosynthesis of TDP-L-2’-deoxy nogalamine (18, Scheme 1).  
RfbB and TylX3, a 4’,6’-dehydratase and a 2’,3’-dehydratase, respectively, were used in 
the assays in place of the equivalent enzymes from the nogalamycin biosynthetic gene 
cluster due to their ease of expression and purification,20 and their placements in 2’-deoxy 
sugar reaction pathways have been thoroughly investigated.14  
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Figure 4.4:  A. Proposed biosynthetic pathway of TDP-2-deoxy nogalamine; B. 
Observed shunt reaction 
 
The first point of uncertainty in our putative pathway for the biosynthesis of TDP-
2’-deoxy nogalamine is the stereochemical outcome of the predicted 3’-aminotransferase, 
SnogI.  Structures featuring axially5 and equatorially1 placed amino groups have been 
proposed in the literature, but based on the structure of nogalamycin and by analogy to 
other deoxy amino sugar pathways,25,26 we expected the amino group to be installed 
equatorially.  Due to difficulties in expressing snogI and purifying its product, we utilized 
EvaB from the TDP-L-epi-vancosamine pathway, which is known to produce an 
equatorially placed amino group.25  As mentioned before, the nogalamine biosynthetic gene 
cluster encoded two deoxy sugar C4’-keto reductases, SnogC and SnogG.  To provide 
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insight into the most likely enzyme involved in biosynthesis of the amino sugar, we 
performed phylogenetic analysis of SnogC and SnogG.  Because SnogG was found to clade 
with other amino sugar C4’-keto reductases, this enzyme was chosen as the putative TDP-
L-nogalamine 4’-keto reductase instead of SnogC. The assays performed and subsequent 
analyses supported these assertions.   
 
 
Figure 4.5: Phylogenetic relationship of SnogG and SnogC to other known deoxy sugar 
C4’-keto reductases. AknM: aclacinomycin gene cluster from Streptomyces galilaeus 
ATCC 31615; DnmV: daunomycin gene cluster from Streptomyces peucetius ATCC 
29050.  Figure created with TreeView, version 1.6.6, available from 
http://taxonomy.zoology.gla.ac.uk/rod/treeview.html 
 
 When 12 was reacted with TylX3 and EvaB, a new compound, 14, was formed.  
The addition of SnogG and SnogF resulted in formation of 16.  Surprisingly, it was found 
that SnogF and SnogG also accept 12 as a substrate to yield 20, TDP-rhamnose.  This is in 
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accord with the proposal that SnogF acts in both the nogalamine and nogalose pathways 
and indicates that SnogF and SnogG could be substrate-flexible.  Interestingly, SnogC, 
which we propose to be involved in nogalose biosynthesis, has been used in an in vivo 
approach to generate deoxy amino sugars.27 To more closely observe this ostensible shunt 
pathway, 12 was reacted with SnogG and SnogF or with TylC2 and SnogF.  TylC2 is a 4’-
keto reductase from the TDP-L-mycarose pathway previously purified by our 
laboratory28,29 that is expected to generate an equatorially placed alcohol, as predicted for 
SnogG.  The formation of 20 was only seen when 12 was reacted with SnogG and SnogF. 
 
Figure 4.6: Validity of  proposed pathway. Trace A: RfbB, TylX3, EvaB, SnogF, and 
SnogG; Trace B: RfbB, TylX3, EvaB, SnogF; Trace C: RfbB, TylX3, EvaB, SnogG; Trace 
D: RfbB,TylX3, EvaB 
 
 
Mass spectrometry data support the assignments of peak for 16.  The 1H-NMR data 
collected for 16 are in good agreement with those previously published for TDP-L-
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acosamine.30  These data support the roles we predict for SnogF and SnogG—a 3’,5’-
epimerase and a 4’-keto reductase capable of accepting an amino sugar.  Furthermore, 
based on our results, we expect that SnogI results in an equatorially placed amino group.   
1H-NMR data for 20 agree with those published for TDP-L-rhamnose,31-33 supporting our 
predicted role for SnogF but contrary to a previous prediction that SnogF is only a 5’-
epimerase,3 a function seemingly necessary for TDP-L-nogalose biosynthesis.  However, 
it can be appreciated that SnogF is only effectively a 5’-epimerase in the biosynthesis of 
nogalose because there is no 3’ proton available for abstraction since this position is doubly 
substituted.33,34  This observation is in agreement with the apparent substrate flexibility of 
SnogF. 
 
Figure 4.7: Promiscuity of SnogG; Trace A: RfbB, SnogF, TylC2; Trace B: RfbB, SnogF, 
SnogG 
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 Based on the available literature pertaining to nogalamycin, methylation is 
expected to be a post-glycosylation modification requiring two separate N-
methyltransferases, SnogA and SnogX,5 but this is in contrast to the established 
biosyntheses of other N-dimethylated deoxy amino sugars, where methylation occurs prior 
to glycosylation, and dimethylation is accomplished through the iterative action of a single 
methyltransferase.16,25,26   
 
Figure 4.8: N-methyltransferase Assays; Trace A: RfbB, TylX3, EvaB, SnogF, SnogG, 
SnogA; Trace B: RfbB, TylX3, EvaB, SnogF, SnogG, SnogX; Trace C: RfbB, 
TylX3,EvaB, SnogF, SnogG, SnogA, SnogX 
 
Therefore, we predicted that the methylations actually take place at the TDP-deoxy sugar 
stage, but the roles of the methyltransferases and the sequence of methylation are not clear.  
When SnogA was the only methyltransferase present in the second stage of the assays, 
monomethylated compound 17 resulted.  However, when SnogA was replaced with 
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SnogX, only scant product formation was seen.  The addition of SnogA and SnogX 
together in assays results in a mixture of 17 and the dimethylated amino sugar 18, TDP-L-
2’-deoxy nogalamine.   
To more clearly characterize the sequence of activity of SnogA and SnogX, assays 
were performed with SnogA alone, resulting solely in 17, and addition of SnogX after a 
one hour incubation resulted in the formation of 17.  These assignments were supported 
with mass spectrometry data.  Thus, SnogA and SnogX are required to generate 
dimethylated amino sugar 18, TDP-L-2’-deoxy nogalamine, via two sequential 
monomethylations.  Furthermore, SnogA performs the first methylation, and SnogX 
performs the second methylation. 
 
Figure 4.9: Resolution of N-methylated amino sugars; Trace A: 0.5 M NH4OAc gradient 
from 0% to 30% over 15 min; Trace B: 0.5 M NH4OAc gradient from 5% to 20% over 15 
min 
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4.3.2. Anthracycline Bioengineering in Streptomyces peucetius 
 
Studies on the biosynthesis of the E-F ring system of nogalamycin or other extended 
ring systems are complicated by the need for C1-hydroxylated anthracycline aglycons.3,4,35  
Due to the preponderance of reactive positions on an anthracycline aglycon, a 
semisynthetic approach to the installation of a hydroxyl at C1 using a natural product 
anthracycline is not feasible.36  Thus, creating a C1-hydroxylated anthracycline through 
chemical means would involve total synthesis.  Although total synthesis has been used to 
generate many anthracycline analogs, the reaction schemes are lengthy and time 
consuming.37  Alternatively, bioengineering of natural anthracycline production could take 
advantage of the producing organisms’ abilities to generate complex, synthetically 
inaccessible structures.3,4,35  S. nogalater has been reported to be recalcitrant to genetic 
manipulation,38 but since the enzymes responsible for introducing the C1-hydroxyl have 
been identified (SnoaL2 and SnoaW), our approach focused on the introduction of the 
requisite genes into another genetically tractable host.  Through the course of extensive 
study regarding the biosyntheses of daunorubicin and doxorubicin, S. peucetius proved to 
be amenable to transformation.39-42 
Nogalamycin is distinguished from daunorubicin and doxorubicin by the presence 
of a methyl ester at the C10 position, as this substituent is removed in later biosynthetic 
steps of the latter two compounds.39-42  However, ε-rhodomycinone, an early precursor to 
the daunorubicin aglycon, maintains the C10 methyl ester, so for our initial attempts to 
bioengineer the production of C1-hydroxylated anthracyclines, S. peucetius WHM1628, a 
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blocked mutant which accumulates ε-rhodomycinone (21),40 was used as a host.  First, 
snoaL2 was cloned with an artificial Streptomyces ribosomal binding site (RBS) 
downstream from the ermE* promoter of pSE34 to yield plasmid pL234.  However, 
introduction of this plasmid into S. peucetius WHM1628 failed to provide the desired 
hydroxylated compound.  Unexpectedly, during this attempt, Siitonen, et al. showed that 
SnoaL2 requires the quinone reductase SnoaW to perform hydroxylation.43  Thus, snoaW 
was cloned with the same artificial RBS used for pL234 upstream from snoaL2 to yield 
plasmid pL2W34-5.   
Unfortunately, introduction of pL2W34-5 into S. peucetius WHM1628 did not 
provide C1-hydroxylated ε-rhodomycinone either.  Once again, in the midst of this work, 
Siitonen, et al. demonstrated in vivo hydroxylation of nogalamycinone, the nogalamycin 
aglycon, in a heterologous host required prior glycosylation of the C7-hydroxyl.5  With this 
in mind, pL2W34-5 was introduced into S. peucetius ATCC29050 strain.   
 
Figure 4.10: C1 hydroxylation of baumycin A1; A. No reaction with ε-rhodomycinone; 
B. hydroxylated baumycin A1 
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This “wild-type” strain is renowned for its ability to produce daunorubicin, but its major 
product is actually a higher glycoside of daunorubicin, baumycin A1, which is hydrolyzed 
to increase the yield of daunorubicin.44  Gratifyingly, mass spectrometric analysis of a 
culture extract of the transformed S. peucetius ATCC29050 strain revealed the presence of 
C1-hydroxy-baumycin A1 (23).  This compound was not detected in a control culture of 
untransformed S. peucetius ATCC29050.  Thus, pL2W34-5 could be useful in procuring 
C1-hydroxylated anthracyclines. 
4.4. CONCLUSIONS 
Our work has provided the first insights into TDP-nogalamine biosynthesis.  We 
have demonstrated the activities of SnogF, SnogG, SnogA, and SnogX, thereby laying the 
groundwork for future investigations into the biosynthesis of the deoxy sugars decorating 
nogalamycin.  Importantly, we have shown that dimethylation of TDP-nogalamine does 
indeed require both putative N-methyltransferases, SnogA and SnogX, encoded in the 
nogalamycin biosynthetic gene cluster, we have established the sequence of methylations 
performed by SnogA and SnogX, and we have demonstrated that dimethylation can occur 
at the TDP-deoxy sugar stage.  Our results also support the prediction that SnogF is shared 
between the biosynthetic pathways for TDP-nogalamine and TDP-nogalose.  Taken 
together, there is now some evidence that TDP-deoxy sugar biosynthesis in the 
nogalamycin biosynthetic pathway may be amenable to manipulation.  Furthermore, initial 
bioengineering efforts in S. peucetius ATCC29050 have demonstrated the feasibility of 
using this strain to produce C1-hydroxylated anthracyclines.  In all, the groundwork has 
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been laid for further study into the biosynthesis of anthracyclines with extended ring 
systems.  It is hoped future developments in this area could provide strategies to circumvent 
anthracycline toxicity and the development of tumor resistance.  
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